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Abstract 
The focus of these studies was directed  towards the synthesis of novel N-heterocyclic 
compounds and pharmacological evaluation of these compounds for activity at monoamine 
transporters. A series of novel piperidine and pyrrolidine analogues were prepared from 
commercially available starting material with a three and four step synthetic method, 
respectively. A variety of substituents on the aromatic ring were incorporated to achieve a 
diverse library of compounds. The preliminary binding studies of piperidine molecules showed 
strong affinity towards serotonin transporters and moderate affinity towards dopamine 
transporters. The focus of further studies was directed towards utilization of iridium catalysis for 
the development of new synthetic methods for biologically important molecules. This research 
has led to the development of a new synthetic strategy for the construction of nicotine and its 
analogues. In addition, the iridium catalysis was also used for alkylation of amides with primary 
and secondary alcohols under microwave conditions. 
 
Key words: Dopamine, Serotonin, Methamphetamine, Cocaine, Iridium, N-Heterocyclization, 
Catalysis, Microwave, Nicotine, N-Alkylation
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Chapter 1: Design, synthesis and evaluation of novel piperidine derivatives for 
monoamine transporter affinity 
1.1. Abstract 
In an effort to search for potential therapeutic agents for methamphetamine addiction, a novel 
class of compounds was synthesized and evaluated for in vitro dopamine and serotonin 
transporter affinities. These unique 4β-aryl-4α-arylmethoxypiperidine analogues incorporated the 
structure of previously designed dual monoamine transporter selective 3β-aryl-3α-
arylmethoxytropane and serotonin selective meperidine derivatives. 
The short three step methodology was developed for the synthesis of the target compounds. To 
study the effect of substitution of aryl group on dopamine and serotonin affinity, we substituted 
various derivatives with electron-donating, electron-withdrawing and halogen groups on the aryl 
ring. All the compounds were tested for affinity for dopamine and serotonin transporters by 
ability of these compounds to displace natural radiolabeled ligands from the transporters. 
1.2. Introduction 
Psychostimulants 
Cocaine (1) and amphetamines are the most common illicit stimulants among drug abused 
individuals. According to data from the 2012 National Survey on Drug Use and Health 
(NSDUH), over 12 million people (4.7 percent of the population) have tried methamphetamine at 
least once. NSDUH also reports that approximately 1.2 million people used methamphetamine in 
the year leading up to the survey. The number of people who abused methamphetamine for the 
first time in the past year has increased by 62% from 2008 to 2009.1 Since then, there has been 
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little deviation from this level of psychostimulant abuse. The U.S. Department of Justice’s 
National Drug Threat Assessment continues to report that total 82% of state and local agencies in 
the Western states perceive methamphetamine and cocaine as their greatest drug threat (Figure 
1.1).2 
 
Figure 1.1. Illicit drug use profile in USA.2 
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Cocaine and Methamphetamine 
Cocaine (1), (Figure 1.2) (street name: Coke, snow, flake, blow) is a tropane alkaloid that is 
obtained from the leaves of Erythroxylum coca plant. The genus Erythroxylum contains about 
250 species and many of the members produce cocaine.3 The amount of cocaine in the plant is 
less than 1%. It is a weakly alkaline compound (an "alkaloid"), and can therefore combine with 
acidic compounds to form various salts. Cocaine hydrochloride in its purest form is a white, 
crystalline product. 3 
N
H3C
O
O
CH3
O
O
Cocaine
  
(1)
H
N
Methamphetamine
 
(2)  
Figure 1.2. Cocaine (1) and Methamphetamine (2) 
As a psychostimulant, methamphetamine (2) (Figure 1.2) (METH) (street name: Speed, meth, 
chalk, ice, crystal, glass) differs significantly from cocaine. METH is a phenyl-ethyl-amine and a 
member of the amphetamine class of psychostimulants. Methamphetamine can be readily 
synthesized by reduction of commercially available ephedrine or pseudoephedrine found in over 
the counter cold and allergy medicines.4 It is a white, odorless, bitter-tasting powder which 
dissolves in water or alcohol. METH was developed early last century from its parent drug, 
amphetamine, and was used originally as a nasal decongestant and in bronchial inhalers. 
Methamphetamine causes increased activity, decreased appetite and a general sense of well-
being. In high concentration, high levels of methamphetamine get into the brain, making it a 
more potent stimulant drug with long lasting and harmful effects on the central nervous system. 
METH is a Schedule 2 stimulant, which means it is a drug that has been classified for having a 
4 
 
high potential for being abused, and it is available only by prescription. It is prescribed for the 
treatment for narcolepsy and attention deficit hyperactivity disorder but these medical uses are 
limited, and the doses prescribed are much lower than those typically abused. METH can exist in 
two enantiomeric forms, dextrorotatory and levorotatory. The (d)-methamphetamine elicits the 
psychostimulant effects of the drug, while levo form is inactive on central nervous system 
(CNS).3 
Physiological effects of METH 
Methamphetamine causes anorexia, hyperactivity, dilated pupils, flushed skin, excessive 
sweating, restlessness, dry mouth and bruxism, diarrhea, and constipation. In high doses, METH 
can cause convulsions, stroke, heart attack and death.5  Withdrawal symptoms of 
methamphetamine primarily consist of fatigue, depression, and increased appetite. Symptoms 
may last for days with occasional use, and weeks or months with chronic use. The severity is 
dependent on the length of time and the amount of methamphetamine used. Withdrawal 
symptoms may also include anxiety, irritability, headaches, agitation, restlessness, excessive 
sleep, vivid or lucid sleep, deep REM sleep and suicidal ideation.3, 5 
Pharmacological actions of METH 
Important differences exist between the neuropharmacological mechanisms of action of cocaine 
and METH. Cocaine mediates its effects at monoamine transporters. The stimulant and 
reinforcing effects of cocaine are primarily associated with the blockade of dopamine reuptake 
(Figure 1.3).4, 6 
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Cocaine binds to dopamine re-uptake transporters on the pre-synaptic membranes of 
dopaminergic neurones. This binding inhibits the removal of dopamine from the synaptic cleft 
and its subsequent degradation by monoamine oxidase in the nerve terminal. Dopamine remains 
in the synaptic cleft and is free to bind to its receptors on the post synaptic membrane, producing 
further nerve impulses. This increased activation of the dopaminergic reward pathway leads to 
the feelings of euphoria and the ‘high’ associated with cocaine use (Figure 1.3).  
 
Figure 1.3. Mechanism of cocaine action on the dopamine transporter7 
 Alternatively, the mechanism of action of METH appears to be more complex.  METH is a 
neurotransmitter releaser, triggering the release of monoamine neurotransmitters (dopamine, 
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serotonin, and norepinephrine) via the corresponding transporter system in the brain. At high 
doses, METH increases the concentration of dopamine in the synaptic cleft in 4 ways: (1) it can 
bind to the pre-synaptic membrane of dopaminergic neurons and induce the release of dopamine 
from the nerve terminal; (2) It can interact with dopamine containing synaptic vesicles, releasing 
free dopamine into the nerve terminal; (3) It can bind to monoamine oxidase in dopaminergic 
neurons and prevent the degradation of dopamine, leaving free dopamine in the nerve terminal; 
and (4) It can bind to the dopamine re-uptake transporter, causing it to act in reverse and 
transport free dopamine out of the nerve terminal. High-dose amphetamine has a similar effect 
on noradrenergic neurons; it can induce the release of noradrenaline into the synaptic cleft and 
inhibit the noradrenaline re-uptake transporter (Figure 1.4). 
Releasers and uptake inhibitors have dissimilar outcomes at the synapses.6 Although both 
mechanisms increase synaptic neurotransmitter concentrations, releasers produce larger increases 
in extracellular neurotransmitter concentration. Moreover, the increased concentration effects are 
not regulated by neurotransmitter autoreceptor mechanisms. Thus releasers and uptake inhibitors 
produce significantly different cellular responses.4 
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Figure 1.4. Mechanism of METH action8 
It has long been the assumption that disruption of dopaminergic circuitry is the primary 
mechanism of action of METH. Post-mortem studies of METH-users have shown that striatal 
(caudate and putamen) dopamine levels are severely depleted, suggesting that METH can cause 
release of stored dopamine in sufficient amounts to deplete tissue stores of the 
neurotransmitter.6,7 In addition, it has been reported that striatal concentrations of the dopamine 
transporter (DAT) in the post-mortem brains of METH-users are significantly decreased.  In 
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contrast to dopamine, serotonin depletion is not observed to the same extent. However, recent 
positron emission tomography (PET) imaging studies indicate significant loss of the serotonin 
transporter (SERT) in both cerebral cortical and sub-cortical brain regions of chronic METH-
users. Furthermore, the extent of the SERT binding decrease was more severely affected than the 
corresponding DAT binding or that reported for SERT in chronic users of ecstasy i.e. (3, 4-
methylenedioxymethamphetamine (MDMA) a known serotonergic hallucinogen. These results 
are consistent with the behavioral effects associated with METH exposure (e.g., problems in 
cognition and aggression) and could well be explained by a disruption of serotonergic circuitry. 
Treatment of METH dependence 
To date there is no pharmacological therapy for METH-dependence or the adverse side effects 
associated with craving and withdrawal.  A variety of medications have been investigated as 
potential treatment strategies, however, none have been identified as having significant 
promise.10 
Dopamine agonists 
Some modest success with dopamine agonist bupropion (3) has been reported.4, 11 Bupropion was 
reported to reduce METH use among “light “abusers but was not effective against “heavy” 
METH-users.  Alternatively, modafinil (4) showed no clear evidence of efficacy in reducing 
METH use.12 In addition, other clinical trials have shown that the dopamine partial agonist 
aripirizole (5) and GABAergic agent gabapentin (6) exhibited no efficacy toward reduction of 
METH-use (Figure 1.5).13, 14 
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Figure 1.5. Dopamine agonists 
Selective serotonin reuptake inhibitors  
Studies have shown that some selective serotonin uptake inhibitors (SSRIs, e.g., fluoxetine (7), 
paroxetine (8) block the effects of METH in animals, 15, 16 but clinical studies with SSRIs have 
been much less promising.15, 17-19 Recent clinical findings have indicated that treatment of 
chronic METH-users with the SSRI sertaline (9) resulted in sustained METH-craving and an 
elevated likelihood of relapse (Figure 1.6).20 
H
N
Cl
Cl
Sertraline
 
(9)
O
O
O
H
N
F
H
H
O
H
N
CF3
Fluoxetine
 
(7) Paroxetine
 
(8)  
Figure 1.6. Selective serotonin uptake inhibitors (SSRIs) - fluoxetine (7), paroxetine (8), 
Sertraline (9) 
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It is clear from the studies above that new medications are needed for METH–cessation. 
Currently available medications that have application to other abused substances fall short of 
being effective in treating the complex pharmacology of METH addiction.  
Dual acting DAT/SERT approach  
To date there is mounting evidence that in addition to dopaminergic systems, brain serotonergic 
systems also modulate responses in cocaine-induced behaviors and to a greater extent in 
methamphetamine-induced behaviors.21 However, it has become evident that a single 
dopaminergic or serotonergic agent cannot adequately attenuate the behavioral effects associated 
with psychostimulant abuse. The abuse liability of selective dopaminergic agents has diminished 
enthusiasm for an agonist based approach to medication development and clearly SSRIs have not 
been effective in the clinic. However, it has been suggested that the development of an 
appropriately calibrated dual acting DAT/SERT agent may be more effective as a medication 
than a singularly selective transporter agent. For METH addiction, a dual acting DAT/SERT 
agent could be used to attenuate the reinforcing effects while providing protection from the 
psychotic effects associated with METH cessation.21-23 
Based on the pharmacological evidence presented, it is clear that attenuation of dopaminergic 
and serotonergic pathways can affect the behaviors associated with METH abuse and addiction. 
However the question remains: What level of attenuation is required of each monoaminergic 
system to positively modify the behavioral effects of METH abuse? We believe that the proper 
balance of dopaminergic/serotonergic (and noradrenergic) reuptake inhibition can restore the 
monoaminergic tone of METH disrupted neuronal systems and lead to diminished craving, 
psychosis, depression and other symptoms of withdrawal. 
Based on that approach in the past, our laboratory has focused upon the structure activity 
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relationships of meperidine (10) and related molecule. From the SAR of the meperidine 
derivatives and WIN analogues (11), it was found that the 3, 4-dichlorophenyl group is important 
moiety for the molecular recognition at the DAT.24 Moreover, meperidine is more selective for 
the serotonin transporter over the dopamine transporter. Studies on aryl substituted meperidine 
analogues reveled that dopamine transporter affinity of these could be enhanced with 
predominant SERT activity. This effect of aryl substitution on the DAT affinity of meperidine 
analogues is paralleled with the SAR for reported tropane analogues and piperidine analogues. 
However unlike these piperidine and tropane analogues that are DAT selective 3, 4-
dichloromeperidine (12), exhibit high potency at the SERT (Ki = 19nM) and was slightly SERT-
selective (DAT/SERT=6.7) (Figure 1.7).25 
N
H3C
COOEt
X
N
COOCH3
X
Y
 
X=H
 
(10) 
X=F,
 
Cl,
 
I,
 
CH3
   
X=F,
 
Cl,
 
I,
 
CH3
 
(11)   
Y=H
 or X=Y=Cl
NH3C
COOCH3
X
 
X=H,
 
F,
 
Cl,
 
CH3
NH3C
COOR
Cl
Cl
R=Et
R=CH2C6H5(12)
(13a)
(13b)  
Figure 1.7. Meperidine analogues  
Our group explored the structure activity relationships of 3, 4-dichloromeperidine analogues (13) 
at dopamine and serotonin transporters. It was found that chemical modification of the ester 
group generally led to compounds with increased SERT activity. The benzyl ester (13b) was 
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found to be the most potent and most selective ligand of this study.26 
The disubstituted piperazine GBR 12909 (14) is a selective high affinity dopamine transporter 
ligand and a selective dopamine uptake inhibitor. The behavioral studies with GBR 12909 and 
related derivatives have shown potential for the development of an agonist based medicinally 
important molecule for the cocaine addiction. GBR 12909 exhibited slower onset and duration of 
action than cocaine while possessing much higher affinity for the DAT with slower dissolution 
rate. It also shown to antagonize the cocaine induced elevation of extracellular dopamine levels, 
The favorable pharmacological profile of GBR 12909 resulted to in-vivo studies that 
demonstrated its ability to suppress the cocaine self-administration behavior in rhesus monkeys, 
and exhibit non stimulant properties in humans. Although the development of GBR 12909 as 
cocaine medication was halted after phase I, human safety studies identified problematic 
cardiovascular effects. Due to the unique pharmacological profile of GBR 12909, it has served as 
a template for the synthesis of high affinity selective dopamine transporter ligands.  The further 
results showed that the piperazine ring is not necessary for the affinity of GBR 12909 for the 
dopamine transporters. The tropane and piperidine based derivatives of the GBR 12909 have 
been also found to exhibit moderate to high affinity for the DAT with improved selectivity over 
the serotonin transporter (Figure 1.8).27 
13 
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Figure 1.8. GBR 12909 (14) and GBR-benztropine hybrid analogue (15) 
Rice and coworkers have reported the GBR-benztropane analogue (15)  was found to be 
selective for DAT. The pharmacological profile of 15 was found to be more like the GBR 
compounds than benztropine.19  Further, our laboratories have synthesized 3-(2-
(diarylmethoxyethylidene)-8-alkyl-aryl-8-azabicyclo[3.2.1]octane analogues and the dopamine 
transporter affinity was determined. The ethylidene analogues exhibited higher selectivity for 
binding at the DAT over the SERT, with 16 nearly 10-fold more selective than GBR-12909. It 
was evident from studies that 3-ethylidenyl-8-azabicyclo[3.2.1]octane ring system is an 
important structural feature for selective molecular recognition at the DAT. This compound also 
exhibited similar potency as that of corresponding 3α-tropane congeners 15 but were 
significantly more selective for the DAT than 18. The structure-activity relationship studies of 16 
and related tropane analogues, suggest that the high selectivity of 16 resulted from either the 
rigid conformation of 3-ethylidenyltropane ring system or the stereochemical effects imparted by 
unsaturation at C3. (Figure 1.9).28 
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Figure 1.9. 3-ethylidenyl-8-azabicyclo-[3.2.1]octane derivative (16) and Tropane congener (17) 
Our group investigated the effects of unsaturation and stereochemistry at C3 of these tropane-
GBR 12909 hybrid analogues on DAT and SERT binding affinities. For investigation of this 
effect, our group designed and synthesized a series of 3-diarylmethoxymethyl-8-arylalkyl-8-
azabicyclo [3.2.1] oct-2-enes (18). Furthermore, to address the question of stereochemical 
proximity effects of the benzhydryl ether moiety relative to DAT affinity, the 3α- and 3 β-
diarylmethoxymethyl-8-alkylaryl-8-azabicyclo-[3.2.1]-octane derivatives were synthesized (19) 
(Figure 1.10).28 
N
O
X
X
R
N
R
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X
X
3-diarylmethoxymethyl-8-arylalkyl-8-
azabicyclo
 
[3
.2.1]
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Diarylmethoxymethyl-8-alkylaryl-8-azabicyclo
 
[3
.2.1]
 octane
 
(19)
 
Figure 1.10. 3-Diarylmethoxymethyl-8-arylalkyl-8-azabicyclo [3.2.1] oct-2-ene (18) and its 
saturated analogues (19) 
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It was found that diarylmethoxytropane analogues exhibited similar DAT structure activity to 
that of 3α-diarylmethoxyethyl and 3-diarylethylidienyltropane analogues. The results suggested 
that conformational strain imparted by unsaturation at C3 is important for selectivity at the 
dopamine transporter over the serotonin transporter. This is supported by SAR of 3α-isomers in 
this series, which despite the reduced ether length between benzhydryl ether moiety and the 
tropane ring system exhibited similar DAT binding affinity to the 3-
arylmethoxyethylidinyltropanes but were less selective for DAT over SERT. The compounds 
with 3α-stereochemistry were not as well accommodated by transporter constraints for potent 
molecular recognition.27, 28 
Our efforts to develop a novel scaffold for targeting monoamine transporter systems have led to 
the development of several class of DAT and SERT ligands. There have been a number of 
reports that describe 3-aryltropane derivatives exhibiting high affinity and selectivity for the 
DAT.28 Furthermore, we also have reported on a series of piperidine derivatives that exhibit 
affinity and selectivity for SERT. Our group has devised a new pharmacophore by merging these 
two classes of molecules. Furthermore, the arylmethoxy moiety was also included which is 
common in many of the prototypical SSRIs and SNRIs.30, 31 
The designed 3-arylmethoxy-3-aryltropane pharmacophore by merging two pharmacophore 
found active on DAT and SERT. It has showed SERT selectivity and exhibited high affinity for 
the SERT. The monochloro derivative exhibited good affinity for all three transporters. 
However, high lipophilicity of these compounds precluded its progress to further development 
into clinical trials. The 3-arylmethoxy-3-aryltropanes was a unique class of monoamine 
transporter ligands that possess tunable affinity for dopamine and serotonin transporters.32 This 
prompted us a broader examination of the structure-activity relationships of this molecular 
16 
 
scaffold in search of compounds with dual affinity for dopamine and serotonin transporters. It 
was of interest to explore condensed ring systems that would accommodate the pharmacophore 
requirements while reducing the overall molecular weight and lipophilicity inherent to the 
tropane derivatives (Figure 1.11).32 
NR1
X
Pharmacophore
 
1.
O
Y
 
Figure 1.11. Design of Pharmacophore 1 
Recently, In order to devise novel molecular scaffolds targeting monoamine transporters, our 
group has identified the condensed ring system with low molecular weight and lipophilicity, 3-
arylmethoxy-3-arylazetidines as viable targets for the synthesis and biological evaluation at 
monoamine transporters. It was found that the arylazetidines exhibited high affinity for the SERT 
and were generally selective for the SERT over the DAT.  However, it was also clear that the 
DAT affinity can be improved with proper substitution of the 3-aryl group.33 
1.3. Design of new Pharmacophore 
 
In search of a new pharmacophore we decided to merge structural characteristics of 
Pharmacophore 1 and piperidine derivatives (which have been found to be active at SERT). 
Given the similar structural characteristics of these two classes of molecules it was of interest to 
explore the possibility of merging the two pharmacophores to develop a class of monoamine 
17 
 
transporter ligands that would have a unique profile of multiple transporter affinities. The new 
pharmacophore 2 was designed (Figure 1.12). 
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NR1
X
Y
X
Y
SERT
 selective
meperidine
Pharmacophore
 
1. N
R
O
O
Y
Pharmacophore
 
2.
 
Figure 1.12. Design of Pharmacophore 2 
1.4. Objectives 
Based on the pharmacological evidence presented, it is clear that attenuation of dopaminergic 
and serotonergic pathways can affect the behaviors associated with METH abuse and addiction. 
We believe that the proper balance of dopaminergic/serotonergic (and noradrenergic) reuptake 
inhibition can restore the monoaminergic tone of METH disrupted neuronal systems and lead to 
diminished craving, psychosis, depression and other symptoms of withdrawal.  
Based on the above hypothesis, the objective of this study is to explore dual DAT/SERT 
inhibitor for treatment of METH addiction. The focus of this study will be to design a SAR for 
the novel set of aryl piperidine derivatives. The developed SAR will be utilized to optimize 
potency and alter selectivity at the various transporters. The results of this project will provide 
the foundation for future studies aimed at the development of new medications for 
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methamphetamine addiction. 
The designed pharmacophore analogues will be prepared from commercially available starting 
material 1-Boc-4-piperidone. Further, the method will be standardized for the synthesis of final 
target molecules by optimizing various conditions. After standardization of the synthetic method, 
a variety of electron withdrawing and electron releasing substituents will be introduced on the 
aromatic ring to produce a library of derivatives for biological evaluation.  
Biological evaluation will consist of in initial in vitro screening at DAT and SERT to determine 
the binding affinity. In-Vitro binding affinity for monoamine transporters will be determined by 
ability of compounds to displace the radilabeled ligand from rat caudate-putmen tissue. The 
binding affinity for the DAT will be determined by inhibition of [3H] WIN35,428 (20) and at 
SERT by inhibition of [3H]Citalopram (21) (Figure 1.13).32 
N
O
O
F
WIN
 
35,428
 
(20)
O
N
F
N
Citalopram
 
(21)  
Figure 1.13. Radiolabelled ligands for the transporters for the binding studies. 
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1.5. Results and Discussion  
Synthesis of target compounds 
The commercially available 1-(Boc)-4-piperidone (21) was used for the synthesis of the target 
molecules. The 4-aryl moiety was introduced with a preformed aryl lithium reagent by addition 
to the ketone of 1-(Boc) 4-piperidone. A variety of substituents were installed on the aryl moiety 
to furnish intermediates 24a-24d (Scheme 1.1.). 32 
N
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-78oC
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23a-d
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d=CF3
R1
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Scheme 1.1. Synthesis of intermediates 24a-24d 
The alcohols 24a-24d were reacted with variety of substituted benzyl bromides (25a-25i) in the 
presence of sodium hydride to yield compounds 26aa-26di with 70-90% yield (Scheme 1.2.). 
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Scheme 1.2. Synthesis of intermediates 26aa-26di 
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Removal of the N-Boc group was attempted using trifluoroacetic acid but only a trace amount of 
deprotected product was observed after the overnight reaction. An alternate method using 
hydrochloric acid and methanol was attempted which gave rapid deprotection within 2 hours and 
a quantitative yield of product as the hydrochloride salts 27aa-27di (Scheme 1.3.). The final 
compounds were then screened for binding affinity at monoamine transporters. 
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Scheme 1.3. Synthesis of final compounds 27aa-27di 
In-vitro screening of final compounds 
The binding affinities of all the compounds listed in Table 1.1 were determined for DAT and 
SERT. 
N
H
O
R2
.HCl
R1
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Cmpda Code R1 R2 DAT Ki 
(nM)b 
SERT Ki 
(nM)b 
DAT/SERT 
27aa TAV-12 H H 403 ± 100 145 ± 16 2.77 
27ab TAV-09 H 4-F 1810 ± 1110 17.0 ± 0.90 106 
27ac TAV-52 H 4-CH3 3108 ± 376 2.5 ± 0.20 1243.2 
27ad TAV-18 H 4-CF3 10,000 ± 1960 2.6 ± 2.4 3846.1 
27ae TAV-19 H 3,4-Cl2 976 ± 316 15.8 ± 17.2 61.7 
27af TAV-51 H 2-F 502 ± 340 567 ± 453 0.0015 
27ag TAV-53 H 3-F 536 ± 139 85.3 ± 24.7 65.2 
27ah TAV-54 H 3,5-F2 1705 ± 785 40.5 ± 11.1 42 
27ba TAV-13 F H 1494 ± 326 30.8 ± 2.90 48.5 
27bb TAV-07 F 4-F 3970 ± 356 44.5 ± 44.7 89.2 
27bc TAV-67 F 4-CH3 4693  ± 1552 2.1 ± 0.90 2234 
27bd TAV-15 F 4-CF3 8134 ± 54 433 ± 21.2 18.7 
27be TAV-46 F 3,4-Cl2 4110 ± 687 8.9 ± 10.6 461.7 
27bf TAV-68 F 2-F 1471 ± 663 327 ± 105 4.5 
27bg TAV-72 F 3-F 1470 ±130 79.9 ± 28.1 18.4 
27bh TAV-71 F 3,5-F2 2836 ± 826 53.3 ± 14.1 53.2 
27bi TAV-45 F 4-Cl 2368 ± 789 1.3 ± 1.4 1821 
27ca TAV-25 Cl H 1039 ± 476 133 ± 108 7.8 
27cb TAV-29 Cl 4-F 1960 ± 155 8.3 ± 4.5 236 
27cc TAV-34 Cl 4-CH3 2171 ± 458 1.5 ± 0.70 1447.3 
27cd TAV-28 Cl 4-CF3 5667 ± 2397 0.50 ± 0.50 11334 
27ce TAV-26 Cl 3,4-Cl2 2277± 1191 0.60 ± 0.6 3795 
27cf TAV-61 Cl 2-F 2035 ± 1006 193 ± 126 10.5 
27cg TAV-72 Cl 3-F 2520 ± 471 35.7 ± 33.8 70.6 
27ch TAV-63 Cl 3,5-F2 2835 ± 828 56.8 ± 39.9 49.9 
27ci TAV-64 Cl 4-Cl 26%  @ 100 µM 199 ± 126 - 
27da TAV-37 CF3 H 1938 ± 139 135 ± 82 14.35 
27db TAV-40 CF3 F 2170 ± 263 35.8 ± 11.3 60.6 
27dd TAV-39 CF3 4-CF3 5686 ± 35 3.7 ± 2.6 1536.7 
27de TAV-38 CF3 3,4-Cl2 9183 ± 1472 7.5 ± 2.5 1224.4 
 aAll compounds were tested as the HCl salts. bAll values are the mean ± SEM of three experiments preformed in 
triplicate. 
Table 1.1. Preliminary binding studies. 
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Structure-activity relationship studies 
The preliminary binding studies show that the binding affinity varies with the type of substituent 
present on the aromatic ring.  It was found that all the compounds showed strong affinity towards 
serotonin transporters. Transporter affinities of the 4-arylmethoxy-4-arylpiperidines were 
generally selective for the SERT over the DAT with exception of 27af which displayed slight 
selectivity for the dopamine transporter over the serotonin transporter (DAT/SERT = 0.0015). 
Most notably, compounds 27cd (Ki = 0.05 nM) and 27ce (Ki = 0.06 nM) were the most potent 
ligands of the series at the serotonin transporter.  The binding affinity of 27cd and 27ce exceeded 
the potency of the radiolabeled ligand citalopram, (Ki = 2 nM) used for obtaining this data. In 
general, the compounds with 4-trifluromethyl, 4-methyl and 3, 4-dichloro groups on the aromatic 
ring of the benzyloxy group ring showed highest potency at the serotonin transporter. Therefore, 
it can be concluded that these groups are important substituents on the aryl ring of these 
piperidine analogues for molecular recognition at serotonin transporters. 
The compound 27aa (Ki = 403 nM) was most potent ligands of the series at the dopamine 
transporter. However, it is noteworthy that 27aa also exhibited nearly equal affinity for both 
DAT and SERT (DAT/SERT = 2.77). This confirms that the 4-aryl-4 arylmethoxypiperidines are 
viable targets for the development of selective serotonin transporter ligands with variable DAT 
affinity. 
1.6. Conclusion 
A series of 4-aryl-4-arylmethoxypiperidine analogues were synthesized and evaluated as 
dopamine and serotonin transporter ligands. The in vitro affinity (Ki) for the dopamine 
transporter and the serotonin transporter of this series was determined by inhibition of [3WIN]-
35,428 and [3H]citalopram, respectively, in rat caudate putamen tissue. The results of this study 
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clearly demonstrate that 4-aryl-4-arylmethoxypiperidines are selective ligands for the serotonin 
transporter over the dopamine transporter. The preliminary binding studies show that the 4-aryl-
4-arylmethoxypiperidines exhibit high affinity for SERT and modest to low affinity for DAT.  
The analogue TAV-28 (27cd) showed highest affinity towards SERT transporters. Overall, this 
investigation suggested that the 4-trifluromethyl, 4-methyl and 3, 4-dichloro group on the 
aromatic ring of the benzyloxy group ring is a key structural feature for molecular recognition at 
the serotonin transporter as well as differentiation between the serotonin transporter and the 
dopamine transporter. 
1.7. Experimental  
All chemicals were purchased from Aldrich Chemical Company and used as received unless 
otherwise noted. Anhydrous Ethyl ether (Et2O), Dimethylformamide (DMF), Methanol (MeOH), 
Dichloromethane (DCM) was purchased from Mallinckrodt Baker. Inc. Thin layer 
chromatography (TLC) 20×20 cm aluminium plates pre-coated with silica gel purchased from 
EMD Millipore USA and used to monitor reactions via visualization with short-wave UV light. 
1H NMR (400 MHz) and 13C NMR (100 MHz) spectra were recorded on a Varian 400 MHz 
NMR spectrometer at ambient temperature in CDCl3. 1H NMR chemical shifts are reported as δ 
values (ppm) relative to tetramethylsilane. 13C NMR chemical shifts are reported as δ values 
(ppm) relative to CDCl3 (77.0 ppm). Atlantic Microlab, Inc., Norcross, GA performed all CHN 
microanalyses. 
General procedure A. Synthesis of tertiary alcohols (24a-24d) 
In a clean, dry round-bottom flask was added substituted benzenes (2 equiv.) (23a-23d) in dry 
ethyl ether (20 ml). The solution of n-butyl lithium (2 equiv.) was added to the solution dropwise 
at -78 °C. The solution of 1-(Boc) 4-piperidone (1 equiv.) (22) in diethyl ether was added to the 
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solution at -78 °C. The solution was warmed to room temperature and stirred for 2h. The 
reaction mixture was diluted with ammonium chloride solution. The reaction mixture was 
extracted with ethyl ether (3×30 ml). The organic extract was washed with brine solution (30 ml) 
and dried over sodium sulphate. The solvent was evaporated under reduced pressure. The crude 
mixture was purified using column chromatography to obtain compounds 24a-24d. 
Tert-butyl-4-hydroxy-4-phenylpiperidine-1-carboxylate (24a) 
N
O O
OH
 
General procedure A: This compound was obtained as a white solid (2 g, 75%). 
1H NMR (400 MHz, CDCl3): δ 7.25-7.48 (m, 5H), 3.98 (s, 1H), 3.24 (s, 2H), 2.00 (d, J =11.6 
Hz, 2H), 1.74 (d, J=11.2 Hz, 2H), 1.44-1.59 (m, 11H).  
13C NMR (100 MHz, CDCl3): δ 28.6, 34.8, 39.4, 76.3, 79.6, 127.9, 128.8, 129.5, 144.1, 155.1. 
Tert-butyl-4-(4-fluorophenyl-4-hydroxypiperidine-1-carboxylate (24b) 
N
O O
OH
F
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General procedure A: This compound was obtained as a white solid (2.4 g, 82%). 
1H NMR (400 MHz, CDCl3): δ 7.25-7.43 (m, 2H), 7.03-7.05 (t, J=8.8 Hz, 2H), 3.95 (s, 1H), 
3.20 (s, 2H), 1.88 (d, J=11.6 Hz, 2H), 1.63 (d, J=11.2 Hz, 2H), 1.42-1.61 (m, 11H). 
13C NMR (100 MHz, CDCl3): δ 28.6, 34.8, 39.4, 76.3, 79.6, 125.4, 129.5, 143.2, 144.1, 155.1. 
Tert-butyl-4-(4-chlorophenyl)-4-hydroxypiperidine-1-carboxylate (24c) 
N
O O
OH
Cl
 
General procedure A: This compound was obtained as a white solid (2.3g, 78%). 
1H NMR (400 MHz, CDCl3): δ 7.32-7.45 (m, 4H), 3.98 (s, 1H), 3.18 (s, 2H), 1.88 (d, J=10.8Hz 
2H), 1.64 (d, J=11.6Hz, 2H), 1.40-1.59 (m, 11H). 
13C NMR (100 MHz, CDCl3): δ 28.4, 34.5, 39.5, 75.8, 79.7, 128.6, 128.9, 133.6, 143.3 155.1. 
Tert-butyl-4-hydroxy-4-(4-(trifluoromethyl)phenyl)piperidine-1-carboxylate (24d) 
N
O O
OH
F3C
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General procedure A: This compound was obtained as a white solid (1.8 g, 72%). 
1H NMR (400 MHz, CDCl3): δ 7.66 (d, J=8.0Hz, 2H), 7.60 (d, J=8.0Hz, 2H), 4.01 (s, 1H), 3.14 
(s, 2H), 2.00 (s, 2H), 1.74 (s, 2H), 1.44-1.63 (m, 11H). 
13C NMR (100 MHz, CDCl3): δ 28.6, 35.7, 40.1, 76.1, 79.7, 125.7, 125.8, 126.8, 128.6, 129.3, 
155.1,  
General procedure B. Benzylation of alcohols (26aa-26di) 
The solution of alcohols (24a-24d, 1 equiv.) was stirred in dimethylformamide at 0 °C. To the 
solution was added sodium hydride at 0 °C. The benzyl bromide (25a-25i, 1.1 equiv.) was added 
to the solution and the reaction was stirred for 2 h. The reaction was quenched with water and 
extracted with ethyl acetate (3×20 ml). The organic solvent was washed with brine solution and 
dried over sodium sulphate. The crude product was purified using column chromatography to 
obtain compounds 26aa-26di. 
N-(tert-Butoxycarbonyl)-4-(phenylmethoxy)-4-phenyl-piperidine (26aa, TAV-08) 
N
O O
O
 
General procedure B: This compound was obtained as a colorless liquid (300 mg, 80%). 
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1H NMR (100 MHz, CDCl3): δ 7.40-7.43 (m, 3H), 7.25-7.34 (m, 5H), 7.08 (t, J=8.8Hz, 2H), 
4.08 (s, 4H), 3.26 (s, 2H), 2.13 (d, J=6.0Hz, 2H), 1.88 (s, 2H), 1.46 (s, 9H).  
13C NMR (400 MHz, CDCl3): δ 28.6, 34.8, 39.4, 63.4, 76.3, 79.6, 125.4, 126.0, 127.4, 127.9, 
128.8, 129.5, 143.2, 144.1, 155.1. 
N-(tert-Butoxycarbonyl)-4-[(4-fluorophenyl)methoxy]-4-phenyl-piperidine (26ab, TAV-08) 
N
O O
O
F
 
General procedure B: This compound was obtained as a colorless liquid (315 mg, 79%). 
1H NMR (400 MHz, CDCl3): δ 7.36-7.43 (m, 6H), 7.28-7.32 (m, 2H), 7.02-7.11 (m, 1H), 4.05 
(s, 4H), 3.24 (s, 2H), 2.13 (d, J=12.4Hz, 2H), 1.93 (s, 2H), 1.47 (s, 9H). 
 13C NMR (100 MHz, CDCl3): δ 28.6, 34.8, 39.4, 62.8, 76.4, 79.6, 126.0, 126.6, 128.0, 128.9, 
129.2, 132.5, 139.4, 144.0, 155.1. 
N-(tert-Butoxycarbonyl)-4-[(4-methylphenyl)methoxy]-4-phenyl-piperidine (26ac, TAV-47) 
28 
 
N
O O
O
CH3
 
General procedure B: This compound was obtained as a colorless liquid (271mg, 68%). 
1H NMR (400 MHz, CDCl3): δ 7.49 (d, J=12.0Hz, 2H), 7.41 (t, J=8.0Hz, 2H), 7.30 (t, J=8.0, 
1H), 7.22 (d, J=8.0 Hz, 2H), 7.17 (d, J=8.0 Hz, 2H), 4.10 (s, 4H), 3.20 (s, 2H), 2.37 (s, 3H), 2.17 
(d, J=10.8Hz, 2H), 1.95 (s, 2H), 1.51 (s, 9H). 
 13C NMR (100 MHz, CDCl3): δ 155.2, 144.8, 137.2, 136.0, 129.3, 128.8, 127.8, 126.2, 79.6, 
76.0, 64.2, 39.5, 34.6, 28.7, 21.4. 
N-(tert-Butoxycarbonyl)-4-[(4-trifluoromethylphenyl)methoxy]-4-phenyl-piperidine (26ad, 
TAV-16) 
N
O O
O
CF3
 
General procedure B: This compound was obtained as a colorless liquid (350 mg, 89%). 
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 1H NMR (400 MHz, CDCl3): δ 7.58 (d, J=8.0Hz, 2H), 7.36-7.45 (m, 6H), 7.29-7.32 (m, 1H), 
4.17 (s, 2H), 4.03 (s, 2H), 3.26 (s, 2H), 2.15 (d, J=12.0Hz, 2H), 1.95 (s, 2H), 1.47 (s, 9H). 
 13C NMR (100 MHz, CDCl3): δ 28.6, 34.8, 39.4, 63.4, 76.3, 79.6, 125.4, 126.0, 127.4, 127.9, 
128.8, 129.5, 129.8, 143.2, 144.1, 155.1 
N-(tert-Butoxycarbonyl)-4-[(4-chlorophenyl)methoxy]-4-phenyl-piperidine (26ae, TAV-17) 
N
O O
O
Cl
Cl
 
General procedure B: This compound was obtained as a colorless liquid (310 mg, 80%). 
1H NMR (400 MHz, CDCl3): δ 7.36-7.43 (m, 5H), 7.28-7.32 (m, 2H), 7.02-7.11 (m, 1H), 4.05 
(s, 4H), 3.24 (s, 2H), 2.13 (d, J=12.4Hz, 2H), 1.93 (s, 2H), 1.47 (s, 9H). 
 13C NMR (100 MHz, CDCl3): δ 28.6, 34.8, 39.4, 62.8, 76.4, 79.6, 126.0, 126.6, 128.0, 128.8, 
128.9, 129.2, 130.4, 131.2, 144.0, 155.1, 161.5. 
N-(tert-Butoxycarbonyl)-4-[(2-fluorophenyl)methoxy]-4-phenyl-piperidine (26af, TAV-48) 
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N
O O
O F
 
General procedure B: This compound was obtained as a colorless liquid (280 mg, 72%). 
1H NMR (400 MHz, CDCl3): δ 7.45-7.50 (m, 3H), 7.37 (t, J=7.2 Hz, 2H), 7.21-7.31 (m, 2H), 
7.13 (t, J=7.2 Hz, 1H), 6.71 (t, J=8.4Hz, 1H), 4.18 (s, 2H), 4.02 (s, 2H), 3.29 (s, 2H), 2.15 (d, 
J=13.2Hz, 2H), 1.93 (s, 2H),  1.51 (s, 9H). 
13C NMR (100 MHz, CDCl3):  δ 161.9, 159.5, 155.1, 144.3, 129.9, 129.2, 128.8, 127.8, 126.1, 
124.3, 115.4, 79.5, 76.3, 58.1, 39.5, 34.8, 28.7. 
N-(tert-Butoxycarbonyl)-4-[(3-fluorophenyl)methoxy]-4-phenyl-piperidine (26ag, TAV-49) 
N
O O
O
F
 
General procedure B: This compound was obtained as a colorless liquid (300 mg, 82%). 
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1H NMR (400 MHz, CDCl3): δ 7.45 (d, J=7.6 Hz, 2H), 7.38 (t, J=8.0Hz, 2H), 7.23-7.31 (m, 
2H), 7.06 (t, J=7.6 Hz, 2H), 6.94 (t, J=8.0Hz, 1H), 4.11 (s, 4H), 3.29 (s, 2H), 2.15 (d, J=12.4Hz, 
2H) 1.94 (s, 2H), 1.50 (s, 9H). 
13C NMR (100 MHz, CDCl3): δ 164.3, 161.9, 155.1, 144.3, 141.8, 130.0, 128.8, 127.9, 126.1, 
122.8, 114.2, 79.6, 76.2, 63.4, 40.3, 34.5, 28.7. 
N-(tert-Butoxycarbonyl)-4-[(3,5-difluorophenyl)methoxy]-4-phenyl-piperidine (26ah, TAV-
50) 
N
O O
O
F
F
 
General procedure B: This compound was obtained as a colorless liquid (284 mg, 72%). 
1H NMR (400 MHz, CDCl3): δ 7.28-7.43 (m, 5H), 6.82 (d, J=6.4Hz, 2H), 6.65-6.70 (m, 1H), 
4.09 (s, 4H), 3.25 (s, 2H), 2.13-2.16 (m, 2H), 1.94 (s, 2H), 1.45-1.48 (s, 9H). 
 13C NMR (100 MHz, CDCl3): δ 28.6, 34.4, 39.5, 63.0, 76.4, 79.7, 109.8, 126.0, 128.0, 128.9, 
143.0, 143.9, 155.1, 162.0, 164.5. 
N-(tert-Butoxycarbonyl)-4-benzyloxy-4-(4-fluorophenyl)-piperidine (26ba, TAV-11) 
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N
O O
O
F
 
General procedure B: This compound was obtained as a colorless liquid (290 mg, 80%). 
1H NMR (400 MHz, CDCl3): δ 7.40-7.43 (m, 2H), 7.25-7.34 (m, 5H), 7.08 (t, J=8.8Hz, 2H), 
4.08 (s, 4H), 3.26 (s, 2H), 2.13 (d, J=6.0Hz, 2H), 1.88 (s, 2H), 1.46 (s, 9H).  
13C NMR (100 MHz, CDCl3): δ 28.6, 34.8, 39.4, 63.4, 76.3, 79.6, 125.4, 126.0, 127.4, 127.9, 
129.5, 129.8, 143.2, 144.1, 155.1. 
N-(tert-Butoxycarbonyl)-4-[(4-fluorophenyl)methoxy]-4-(4-fluorophenyl-piperidine ( 26bb, 
TAV-06) 
N
O O
O
F
F
 
General procedure B: This compound was obtained as a colorless liquid (275mg, 68%). 
1H NMR (400 MHz, CDCl3): δ 7.36-7.40 (m, 2H), 7.21-7.26 (m, 2H), 7.00-7.04 (m, 4H), 6.88-
6.93 (m, 1H), 4.06 (s, 4H), 3.24 (s, 2H), 2.12 (d, J=13.2Hz, 2H), 1.87 (s, 2H), 1.46 (s, 9H). 
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13C NMR (100 MHz, CDCl3): δ 28.6, 34.8, 39.4, 63.4, 75.8, 79.6, 114.0, 114.4, 115.7, 122.7, 
127.9, 129.9, 140.1, 141.5, 163.6. 
N-(tert-Butoxycarbonyl)-4-[(4-methylphenyl)methoxy]-4-(4-fluorophenyl)-piperidine (26bc, 
TAV-65) 
N
O O
O
F
CH3
 
General procedure B: This compound was obtained as a colorless liquid (280 mg, 72%). 
1H NMR (400 MHz, CDCl3): 7.42-7.46 (m, 2H), 7.22 (d, J=8.0Hz, 2H), 7.16 (d, J=8.0Hz, 2H), 
7.05-7.09 (m, 2H), 4.07 (s, 4H), 3.29 (s, 2H), 2.35 (s, 3H), 2.13 (d, J=12.0Hz, 2H), 1.90 (s, 2H), 
1.51 (s, 9H). 
 13C NMR (100 MHz, CDCl3): 21.3, 28.7, 34.7, 39.5, 64.1, 75.6, 79.6, 115.4, 127.9, 129.3, 
135.8, 137.3, 140.6, 155.1, 161.1, 163.5. 
N-(tert-Butoxycarbonyl)-4-[(4-trifluoromethylphenyl)methoxy]-4-(4-fluorophenyl)-
piperidine (26bd, TAV-14) 
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N
O O
O
F
CF3
 
General procedure B: This compound was obtained as a colorless liquid (285 mg, 71%). 
1H NMR (400 MHz, CDCl3): δ 7.57 (d, J=8.4Hz, 2H), 7.38-7.42 (m, 4H), 7.03 (t, J= 7.2Hz, 
2H), 4.01 (s, 2H), 4.02 (s, 2H), 3.24 (s, 2H), 2.13 (d, J=12.4Hz, 2H), 1.91 (s, 2H), 1.47 (s, 9H). 
 13C NMR (100 MHz, CDCl3): δ 28.5, 34.6, 40.2, 63.3, 76.0, 79.6, 115.7, 125.4, 127.2, 129.8, 
140.0, 142.9, 155.1, 161.1, 163.6. 
N-(tert-Butoxycarbonyl)-4-[(3,4-dichlorophenyl)methoxy]-4-(4-fluorophenyl-piperidine 
(26be, TAV-42) 
N
O O
O
F
Cl
Cl
 
General procedure B: This compound was obtained as a colorless liquid (285 mg, 78%). 
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1H NMR (400 MHz, CDCl3): δ 7.32-7.38 (m, 4H), 7.00-7.08 (m, 3H), 4.01 (s, 4H), 3.21 (s, 2H), 
2.09 (d, J=12.0Hz, 2H), 1.87 (s, 2H), 1.45 (s, 9H). 
 13C NMR (100 MHz, CDCl3): δ 163.6, 161.1, 155.0, 139.1, 132.5, 131.3, 130.4, 129.1, 127.8, 
126.6, 115.5, 79.7, 76.0, 62.8, 39.5, 35.8, 28.6. 
N-(tert-Butoxycarbonyl)-4-[(2-fluorophenyl)methoxy]-4-(4-fluorophenyl)-piperidine (26bf, 
TAV-66) 
N
O O
O
F
F
 
General procedure B: This compound was obtained as a colorless liquid (310 mg, 84%). 
1H NMR (400 MHz, CDCl3): δ 7.39-7.45 (m, 3H) 7.21-7.25 (m, 1H), 6.96-7.14 (m, 4H), 4.13 
(s, 2H) 4.02 (s, 2H) 3.25 (s, 2H) 2.11-2.14 (d, J=12.0Hz, 2H) 1.88 (t, 2H) 1.47 (s, 9H). 
13C NMR (100 MHz, CDCl3): δ 28.6, 34.8, 39.3, 58.0, 75.9, 79.6, 115.2, 124.3, 125.8, 127.8, 
128.3, 129.9, 140.3, 141.5, 155.1, 159.4, 163.6. 
N-(tert-Butoxycarbonyl)-4-[(3-fluorophenyl)methoxy]-4-(4-fluorophenyl)-piperidine (26bg, 
TAV-70) 
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N
O O
O
F
F
 
General procedure B: This compound was obtained as a colorless liquid (275mg, 68%). 
1H NMR (400 MHz, CDCl3): δ 7.36-7.40 (m, 2H), 7.21-7.26 (m, 2H), 7.00-7.04 (m, 4H), 6.88-
6.93 (m, 1H), 4.06 (s, 4H), 3.24 (s, 2H), 2.12 (d, J=13.2Hz, 2H), 1.87 (s, 2H), 1.46 (s, 9H). 
13C NMR (100 MHz, CDCl3): δ 28.6, 34.8, 39.4, 63.4, 75.8, 79.6, 114.0, 114.4, 115.7, 122.7, 
127.9, 129.9, 140.1, 141.5, 155.1, 161.1, 163.6. 
N-(tert-Butoxycarbonyl)-4-[(3,5-difluorophenyl)methoxy]-4-(4-fluorophenyl)-piperidine 
(26bh, TAV-69) 
N
O O
O
F
F
F
 
General procedure B: This compound was obtained as a colorless liquid (268 mg, 64%). 
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1H NMR (400 MHz, CDCl3): δ 7.33-7.37 (m, 2H), 6.99 (t, J=8.4Hz, 2H), 6.75-6.80 (m, 2H), 
6.59-6.64 (m, 1H), 4.03 (s, 4H), 3.20 (s, 2H), 2.07-2.10 (d, J=12.0Hz, 2H), 1.86 (s, 2H), 1.44 (s, 
9H). 
13C NMR (100 MHz, CDCl3): δ 28.5, 34.4, 39.3, 62.9, 76.0, 79.6, 102.3, 109.5, 115.5, 127.7, 
139.8, 142.9, 155.0, 162.0, 164.4. 
N-(tert-Butoxycarbonyl)-4-[(4-chlorophenyl)methoxy]-4-(4-fluorophenyl)-piperidine (26bi, 
TAV-43) 
N
O O
O
F
Cl
 
General procedure B: This compound was obtained as a colorless liquid (274mg, 68%). 
1H NMR (400 MHz, CDCl3): δ 7.36-7.39 (m, 2H), 7.18-7.26 (m, 4H), 7.02 (d, J=9.6Hz, 2H), 
4.03 (s, 4H), 3.23 (s, 2H), 2.10 (d, J=12.8Hz, 2H), 1.87 (s, 2H), 1.46 (s, 9H).  
13C NMR (100 MHz, CDCl3): δ 28.6, 35.7, 40.2, 63.4, 75.8, 79.6, 115.4, 127.6, 128.6, 128.8, 
133.2, 140.1, 155.0, 161.1, 163.5.   
N-(tert-Butoxycarbonyl)-4-(phenylmethoxy)-4-(4-chlorophenyl)-piperidine (26ca, TAV-16) 
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N
O O
O
Cl
 
General procedure B: This compound was obtained as a colorless liquid (280mg, 72%). 
1H NMR (400 MHz, CDCl3): δ 7.25-7.40 (m, 9H), 4.09 (s, 4H), 3.26 (s, 2H), 2.10 (s, 2H), 1.88 
(s, 2H), 1.47 (s, 9H). 
 13C NMR (100 MHz, CDCl3): δ 28.7, 34.5, 39.4, 64.3, 72.3, 75.8, 79.7, 127.5, 127.7, 128.0, 
128.6, 128.9, 133.6, 138.7, 143.3, 155.1. 
N-(tert-Butoxycarbonyl)-4-[(4-fluorophenyl)methoxy]-4-(4-chlorophenyl)-piperidine (26cb, 
TAV-26) 
N
O O
O
Cl
F
 
General procedure B: This compound was obtained as a colorless liquid (268 mg, 65%). 
1H NMR (400 MHz, CDCl3): δ 7.36-7.39 (m, 2H), 7.18-7.26 (m, 4H), 7.02 (d, J=9.6Hz, 2H), 
4.03 (s, 4H), 3.23 (s, 2H), 2.10 (d, J=12.8Hz, 2H), 1.87 (s, 2H), 1.46 (s, 9H).  
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13C NMR (100 MHz, CDCl3): δ 28.6, 35.7, 40.2, 63.4, 75.8, 79.6, 115.4, 127.6, 128.6, 128.8, 
133.2, 137.3, 140.1, 155.0, 161.1.  
N-(tert-Butoxycarbonyl)-4-[(4-methylphenyl)methoxy]-4-(4-chlorophenyl)-piperidine (26cc, 
TAV-33) 
N
O O
O
Cl
CH3
 
General procedure B: This compound was obtained as a colorless liquid (238 mg, 64%). 
1H NMR (400 MHz, CDCl3): 7.42-7.46 (m, 2H), 7.22 (d, J=8.0Hz, 2H), 7.16 (d, J=8.0Hz, 2H), 
7.05-7.09 (m, 2H), 4.07 (s, 4H), 3.29 (s, 2H), 2.35 (s, 3H), 2.13 (d, J=12.0Hz, 2H), 1.90 (s, 2H), 
1.51 (s, 9H). 
 13C NMR (100 MHz, CDCl3): 21.3, 28.7, 34.7, 39.5, 64.1, 75.6, 79.6, 115.4, 127.9, 129.3, 
135.8, 137.3, 140.6, 155.1, 161.1, 163.5. 
N-(tert-Butoxycarbonyl)-4-[(4-trifluromethylphenyl)methoxy]-4-(4-chlorophenyl)-
piperidine (26cd, TAV-24) 
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N
O O
O
Cl
CF3
 
General procedure B: This compound was obtained as a colorless liquid (275mg, 68%). 
1H NMR (400 MHz, CDCl3): δ 7.57 (d, J=8.0Hz, 2H), 7.32-7.41 (m, 6H), 4.15 (s, 2H), 4.05 (s, 
2H), 3.24 (s, 2H), 2.13 (d, J=13.2Hz, 2H), 1.90 (s, 2H), 1.47 (s, 9H). 
 13C NMR (100 MHz, CDCl3): δ 28.6, 34.8, 39.4, 63.5, 76.1, 79.7, 123.0, 125.4, 127.5, 129.0, 
129.6, 129.9, 133.8, 142.3, 142.8, 155.1. 
N-(tert-Butoxycarbonyl)-4-[(3,4-dichlorophenyl)methoxy]-4-(4-chlorophenyl)-piperidine 
(26ce, TAV-23) 
N
O O
O
Cl
Cl
Cl
 
General procedure B: This compound was obtained as a colorless liquid (310mg, 82%). 
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1H NMR (400 MHz, CDCl3): δ 7.34-7.39 (m, 5H), 7.25 (s, 1H), 7.08 (dd, J=2.0Hz, 8.0Hz, 1H), 
4.03 (s, 4H), 3.21(s, 2H), 2.09 (d, J=12.0Hz, 2H), 1.88 (s, 2H), 1.46 (s, 9H). 
13C NMR (100 MHz, CDCl3): δ 28.6, 34.4, 39.3, 62.9, 76.1, 79.8, 126.6, 127.5, 129.0, 129.2, 
130.5, 131.5, 132.6, 133.8, 138.9, 142.6, 155.1. 
N-(tert-Butoxycarbonyl)-4-[(2-fluorophenyl)methoxy]-4-(4-chlorophenyl)-piperidine (26cf, 
TAV-57) 
N
O O
O
Cl
F
 
General procedure B: This compound was obtained as a colorless liquid (285mg, 74%). 
1H NMR (400 MHz, CDCl3) : δ 7.32-7.45 (m, 5H), 7.21-7.25 (m, 1H) 7.12 (t, J= 7.2Hz, 1H), 
7.00 (t, J=8.8Hz, 1H), 4.14 (s, 2H), 4.02 (s, 2H), 3.24 (s, 2H), 2.12 (m, 2H), 1.87 (m, 2H), 1.47 
(s,  9H). 
 13C NMR (100 MHz, CDCl3): δ 28.6, 34.7, 39.4, 58.2, 76.0, 79.7, 115.2, 124.3, 125.7, 128.9, 
129.3, 129.9, 133.6, 141.4, 143.0, 155.1, 159.4. 
N-(tert-Butoxycarbonyl)-4-[(3-fluorophenyl)methoxy]-4-(4-chlorophenyl)-piperidine (26cg, 
TAV-58) 
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N
O O
O
Cl
F
 
General procedure B: This compound was obtained as a colorless liquid (278mg, 72%). 
1H NMR (400 MHz, CDCl3): δ 7.36-7.21 (m, 5H), 7.00-703 (m, 2H), 6.89-6.94 (m, 1H), 4.72-
4.75 (m, 4H), 3.23 (s, 2H), 2.08-2.12 (m, 2H), 1.87 (s, 2H), 1.46 (s, 9H). 
 13C NMR (100 MHz, CDCl3): δ 28.6, 34.5, 39.4, 63.5, 75.9, 79.7, 114.2, 122.7, 127.6, 129.0, 
130.0, 133.7, 141.3, 142.9, 155.1, 161.9, 164.3. 
N-(tert-Butoxycarbonyl)-4-[(3,5-fluorophenyl)methoxy]-4-(4-chlorophenyl)-piperidine 
(26ch, TAV-59) 
N
O O
O
Cl
F
F
 
General procedure B: This compound was obtained as a colorless liquid (280 mg, 75%). 
1H NMR (400 MHz, CDCl3): δ 7.28-7.33 (m, 4H), 6.80 (d, J=7.2Hz, 2H), 6.64 (t, J=8.8Hz, 
1H), 4.05 (s, 2H), 3.20 (s, 2H), 2.11 (d, J=12.0Hz, 2H), 1.87 (s, 2H), 1.45 (s, 9H). 
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13C NMR (100 MHz, CDCl3): δ 28.5, 34.4, 39.3, 62.9, 76.0, 79.6, 102.3, 109.5, 115.5, 127.7, 
139.8, 142.9, 155.0, 162.0, 164.4. 
N-(tert-Butoxycarbonyl)-4-[(4-chlorophenyl)methoxy]-4-(4-chlorophenyl)-piperidine (26ci, 
TAV-60) 
N
O O
O
Cl
Cl
 
General procedure B: This compound was obtained as a colorless liquid (264 mg, 63%). 
1H NMR (400 MHz, CDCl3): δ 7.32-7.37 (m, 4H), 7.29 (d, J=8.8Hz, 2H), 7.20 (d, J=8.0Hz, 
2H), 4.05 (s, 4H), 3.23 (s, 2H), 2.10 (d, J=12.0Hz, 2H), 1.88 (s, 2H), 1.47 (s, 9H). 
 13C NMR (100 MHz, CDCl3): δ 28.6, 34.8, 39.4, 63.6, 75.9, 79.8, 127.6, 128.7, 128.8, 129.0, 
133.4, 133.7, 137.1, 143.0, 155.1. 
N-(tert-Butoxycarbonyl)-4-(phenylmethoxy)-4-(4-trifluoromethyl)-phenyl-piperidine (26da, 
TAV-32) 
N
O O
O
F3C
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General procedure B: This compound was obtained as a colorless liquid (280mg, 75%). 
1H NMR (400 MHz, CDCl3): δ 7.65 (d, J=8.0Hz, 2H), 7.59 (d, J=8.0Hz, 2H), 7.28-7.37 (m, 
5H), 4.14 (s, 4H), 3.30 (s, 2H), 2.16 (d, J=8.8Hz, 2H), 1.94 (s, 2H), 1.51 (s, 9H). 
13C NMR (100 MHz, CDCl3): δ 28.6, 22.8, 35.7, 40.1, 64.5, 76.1, 79.7, 125.7, 125.8, 125.8, 
126.6, 127.5, 127.7, 128.6, 138.5, 148.9, 155.1.  
N-(tert-Butoxycarbonyl)-4-[(4-fluorophenyl)methoxy]-4-(4-trifluoromethylphenyl)-
piperidine (26db, TAV-36) 
N
O O
O
F3C
F
 
General procedure B: This compound was obtained as a colorless liquid (265 mg, 70%). 
1H NMR (400 MHz, CDCl3): δ 7.62 (d, J=8.4Hz, 2H), 7.55 (m, J=8.4Hz, 2H), 7.25 (m, 2H), 
6.98 (t, J=8.4Hz, 2H), 4.06 (s, 4H), 3.25 (s, 2H), 2.12 (d, J=12.8Hz, 2H), 1.90 (s, 2H), 1.47 (s, 
9H). 
13C NMR (100 MHz, CDCl3): δ 28.5, 35.6, 40.1, 63.8, 76.1, 79.7, 115.5, 125.7, 126.5, 129.1, 
130.1, 134.2, 148.7, 155.0, 161.1, 163.6. 
N-(tert-Butoxycarbonyl)-4-[(4-methylphenyl)methoxy]-4-(4-trifluoromethylphenyl)-
piperidine (26dc, TAV-41) 
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N
O O
O
F3C
CH3
 
General procedure B: This compound was obtained as a colorless liquid (285 mg, 75%). 
1H NMR (400 MHz, CDCl3): δ 7.66 (d, J=8.4Hz, 2H), 5.60 (d, J=8.4Hz, 2H), 7.22 (d, J=8.0Hz, 
2H), 7.17 (d, J=8.0Hz, 2H), 4.10 (s, 4H), 3.30 (s, 2H), 2.36 (s, 3H), 2.15 (d, J=12.0Hz, 2H), 1.93 
(s, 2H), 1.50 (s, 9H). 
13C NMR (100 MHz, CDCl3): δ 155.1, 149.0, 137.5, 135.4, 130.1, 129.8, 129.3, 127.7, 126.6, 
125.8, 79.7, 76.0, 64.4, 40.1, 35.9, 28.6, 21.3 
N-(tert-Butoxycarbonyl)-4-[(4-trifluoromethylphenyl)methoxy]-4-(4-trifluoromethylphenyl-
piperidine (26dd, TAV-35) 
N
O O
O
F3C
CF3
 
General procedure B: This compound was obtained as a colorless liquid (268mg, 64%). 
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1H NMR (400 MHz, CDCl3): δ 7.63 (d, J=8.4Hz, 2H), 7.55-7.58 (m, 4H), 7.42 (d, J=8.0Hz, 
2H), 4.18 (s, 2H), 4.06 (s, 2H), 3.26 (s, 2H), 2.15 (d, J=8.8Hz, 2H), 1.94 (s, 2H), 1.47 (s, 9H). 
13C NMR (100 MHz, CDCl3): δ 28.5, 34.6, 36.3, 63.6, 76.3, 79.8, 125.4, 125.5, 125.8, 126.4, 
127.3, 129.6, 129.9, 130.2, 142.6, 148.6, 155.0. 
N-(tert-Butoxycarbonyl)-4-[(3,4-dichlorophenyl)methoxy]-4-(4-trifluoromethylphenyl)-
piperidine (26de, TAV-33) 
N
O O
O
F3C
Cl
Cl
 
General procedure B: This compound was obtained as a colorless liquid (314 mg, 82%). 
1H NMR (400 MHz, CDCl3): δ 7.60 (d, J=8.0Hz, 2H), 7.52 (d, J=8.0Hz, 2H), 7.32-7.36 (m, 
2H),7.07-7.10 (d, J=8.0Hz, 1H),  4.04 (s, 4H), 3.21 (s, 2H), 2.09-2.13 (d, J =13.2Hz, 2H), 1.90 
(s, 2H), 1.45 (s, 9H). 
13C NMR (100 MHz, CDCl3): δ 28.6, 34.5, 38.4, 63.0, 76.4, 79.8, 125.7, 125.8, 125.9, 126.4, 
126.5, 129.1, 130.5, 131.4, 132.6, 138.3, 155.0, 160.3. 
N-(tert-Butoxycarbonyl)-4-[(2-fluorophenyl)methoxy]-4-(4-trifluoromethyphenyl)-
piperidine (26df, TAV-73) 
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N
O O
O
F3C
F
 
General procedure B: This compound was obtained as a colorless liquid (264mg, 69%). 
1H NMR (400 MHz, CDCl3): δ 7.64 (d, J=8.4Hz, 2H), 7.58 (d, J=8.0Hz, 2H), 7.46 (t, J=7.6Hz, 
1H), 7.23-7.29 (m, 1H), 7.15 (t, J=7 .6Hz, 1H), 6.99 (t, J=9.2Hz, 1H), 4.17 (s, 4H), 3.27 (s, 2H), 
2.15 (d, J=12.0Hz, 2H), 1.92 (s, 2H), 1.48 (s, 9H). 
 13C NMR (100 MHz, CDCl3): δ 161.9, 159.5, 155.1, 148.6, 130.2, 129.9, 126.5, 125.8, 125.5, 
124.3, 115.5, 102.8, 79.7, 75.9, 63.5, 39.4, 34.5, 28.6. 
N-(tert-Butoxycarbonyl)-4-[(3,5-difluorophenyl)methoxy]-4-(4-trifluoromethyphenyl)-
piperidine (26dh, TAV-73) 
N
O O
O
F3C
F
F
 
General procedure B: This compound was obtained as a colorless liquid (285 mg, 78%). 
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1H NMR (400 MHz, CDCl3): δ 7.61 (d, J=8.0Hz, 2H), 7.53 (d, J=8.0Hz, 2H), 6.81 (d, J=6.4Hz, 
2H), 6.63 (t, J=9.2Hz, 1H), 4.09 (s, 4H), 3.23 (s, 2H), 2.13 (d, J=12.0Hz, 2H), 1.92 (s, 2H), 1.45 
(s, 9H). 
 13C NMR (100 MHz, CDCl3): δ 164.4, 161.9, 155.0, 148.2, 142.6, 130.3, 126.4, 125.8, 109.6, 
102.7, 79.7, 76.4, 63.1, 39.3, 34.7, 28.5. 
N-(tert-Butoxycarbonyl)-4-[(4-chlorophenyl)methoxy]-4-(4-trifluoromethyphenyl)-
piperidine (26di, TAV-75) 
N
O O
O
F3C
Cl
 
General procedure B: This compound was obtained as a colorless liquid (270 mg, 65%). 
1H NMR (400 MHz, CDCl3): δ 7.64 (d, J=8.4Hz, 2H), 7.55 (d, J=8.0Hz, 2H), 7.30 (d, J=8.4Hz, 
2H), 7.23 (d, J=8.4Hz, 2H), 4.08 (s, 4H), 3.25 (s, 2H), 2.14 (d, J=12.0Hz, 2H), 1.92 (s, 2H), 1.48 
(s, 9H).  
13C NMR (100 MHz, CDCl3):  155.1, 148.6, 142.4, 137.0, 133.5, 130.2, 129.9, 128.8, 126.5, 
125.8, 79.8, 76.2, 63.7, 39.3, 34.4, 28.6. 
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General procedure C. Synthesis of hydrochloride salts (27aa-27di) 
To the solution of 23aa-23di in methanol (10 ml) was added to concentrated HCl (2ml) and 
stirred for 1h. The solvent was evaporated under reduced pressure. To the crude product was 
added water (20 ml) at 0 °C. The solid formed was filtered and dried under vacuum to get the 
hydrochloride salt of compounds 24aa-24di. 
4-(Benzyloxy)-4-phenyl-piperidinium chloride (27aa, TAV-12) 
N
H
O
.HCl
 
General procedure C: This compound was obtained as a white solid (200 mg, 95%). 
1H NMR (400 MHz, CDCl3): δ 7.48 (d, J=8.4Hz, 2H), 7.34 (t, J=7.6Hz, 3H), 7.30-7.34 (m, 
4H), 7.27-7.28 (m, 1H), 4.11 (s, 2H), 3.16 (t, J=12.0Hz, 2H), 2.93 (d, J=12.0Hz, 2H), 2.15 (d, 
J=11.6Hz, 2H), 1.93 (t, J=12.0Hz, 2H), 1.72 (s, NH) 
13C NMR (100 MHz, CDCl3):  δ 36.5, 42.5, 63.9, 76.4, 126.2, 127.4, 127.5, 127.6, 128.5, 128.6, 
139.3, 145.4. 
 Anal. Calcd for C18H22ClNO. 2/3H2O:  C, 68.48; H, 7.45; N, 4.44 Found: C, 68.22; H, 7.47; N, 
4.47.  
4-(4-Fluorobenzyloxy)-4-phenyl-piperidinium chloride (27ab, TAV-09) 
50 
 
N
H
O
.HCl
F
 
General procedure C: This compound was obtained as a white solid (194 mg, 94%). 
1H NMR (400 MHz, CDCl3): δ 7.40-7.42 (m, 2H), 7.23-7.40 (m, 2H), 6.97-7.01 (m, 4H), 4.03 
(s, 2H), 3.14 (t, J=11.6Hz, 2H), 2.93 (d, J= 9.6Hz, 2H), 2.10 (d, J=13.2Hz, 2H), 1.86-1.93 (m, 
2H), 1.62 (s, NH) 
13C NMR (100 MHz, CDCl3): δ 36.5, 42.5, 63.1, 76.1, 115.2, 115.5, 127.9, 129.2, 134.8, 141.2, 
161.1, 163.5.  
Anal. Calcd for C18H21ClF2NO. H2O:  C, 60.54; H, 6.16; N, 4.05 Found: C, 60.42; H, 6.20; N, 
3.91. 
4-(4-Methylbenzyloxy)-4-phenyl-piperidinium chloride (27ac, TAV-52) 
N
H
O
.HCl
CH3
 
General procedure C: This compound was obtained as a white solid (172 mg, 78%).  
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1H NMR (400 MHz, CDCl3): δ 7.41-7.45 (m, 3H), 7.19 (d, J=8.0Hz, 2H), 7.13 (d, J=7.6Hz, 
2H), 7.03-7.07 (m, 2H), 4.03 (s, 2H), 3.15 (t, J=11.2Hz, 2H), 2.92-2.95 (m, 2H), 2.33 (s, 3H), 
2.12 (d, J=13.2Hz, 2H), 1.85-1.92 (m, 2H), 1.70 (s, NH). 
13C NMR (100 MHz, CDCl3): δ 21.3, 36.6, 42.4, 63.7, 75.9, 115.2, 115.5, 127.7, 127.9, 128.0, 
129.2, 136.1, 137.2. 
Anal. Calcd for C18H21ClF2NO. 2.1/4H2O:  C, 63.68; H, 8.02; N, 3.91 Found: C, 63.68; H, 8.02; 
N, 3.91. 
4-(4-Trifluoromethylbenzyloxy)-4-phenyl-piperidinium chloride (27ad, TAV-18) 
N
H
O
.HCl
CF3
 
General procedure C: This compound was obtained as a white solid (165 mg, 87%).  
1H NMR (400 MHz, CDCl3): δ 7.57 (d, J=8.4Hz, 2H), 7.45 (t, J=8.4Hz, 4H), 7.37 (t, J= 7.6Hz, 
2H), 7.279 (t, J=7.6Hz, 1H), 4.16 (s, 2H), 3.15 (t, J=11.6Hz, 2H), 2.95 (s, J=12.0Hz, 2H), 2.15 
(d, J=12.0Hz, 2H), 1.92-2.00 (m, 2H) 1.64 (s, NH). 
13C NMR (100 MHz, CDCl3): δ 36.4, 42.5, 63.1, 76.7, 125.4, 125.8, 126.1, 127.4, 127.6, 128.7, 
129.4, 143.5, 145.1. 
Anal. Calcd for C19H21ClF3NO. H2O:  C, 58.54; H, 5.95; N, 3.59 Found: C, 58.55; H, 5.43; N, 
3.55.  
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4-(3,4-Dichlorobenzyloxy)-4-phenyl-piperidinium chloride (27ae, TAV-19) 
N
H
O
.HCl
Cl
Cl
 
General procedure C: This compound was obtained as a white solid (210 mg, 96%).  
1H NMR (400 MHz, CDCl3): δ 7.44-7.35 (m, 6H), 7.29 (t, J=7.2Hz, 1H), 7.11 (dd, J=1.6Hz, 
8.4Hz, 1H), 4.04 (s, 2H), 3.14 (t, J=12.0Hz, 2H), 2.95 (m, 2H), 2.15 (d, J=11.6Hz, 2H), 1.94 (t, 
J=12.0Hz, 2H), 1.71 (s, NH) 
13C NMR (100 MHz, CDCl3): δ 36.3, 42.5, 62.6, 76.7, 126.1, 126.6, 127.7, 128.7, 129.3, 130.4, 
131.2, 132.5, 139.6, 144.9.  
Anal. Calcd for C18H20Cl3NO:  C, 57.31; H, 5.48; N, 3.71 Found: C, 57.71; H, 5.57; N, 3.82 
4-(2-Fluorobenzyloxy)-4-phenyl-piperidinium chloride (27af, TAV-51) 
N
H
O
.HCl
F
 
General procedure C: This compound was obtained as a white solid (175 mg, 80%).  
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1H NMR (400 MHz, CDCl3): δ 7.46-7.52 (m, 3H), 7.37 (t, J=7.6Hz, 2H), 7.22-7.30 (m, 2H), 
7.14 (t, J=8.4Hz, 1H), 6.99 (t, J=9.2Hz, 1H), 4.16 (s, 2H), 3.15 (t, J=12.0Hz, 2H), 2.95 (d, 
J=12.4Hz, 2H), 2.15 (d, J=12.4Hz, 2H), 1.94 (t, J=12.0Hz, 2H), 1.80 (s, NH). 
13C NMR (100 MHz, CDCl3):  δ 161.8, 159.4, 145.2, 129.8, 129.0, 128.7, 127.5, 126.1, 124.2, 
115.1, 76.6, 57.7, 42.4, 36.4. 
Anal. Calcd for C18H21ClFNO:  C, 64.47; H, 6.576; N, 4.18 Found: C, 64.51; H, 6.77; N, 4.25. 
4-(3-Fluorobenzyloxy)-4-phenyl-piperidinium chloride (27ag, TAV-53) 
N
H
O
.HCl
F
 
General procedure C: This compound was obtained as a white solid (182 mg, 84%).  
1H NMR (400 MHz, CDCl3) : δ 7.46 (d, J= 7.2Hz, 2H), 7.37 (t, J=8.0Hz, 2H), 7.24-7.30 (m, 
2H), 7.07 (t, J= 8.4Hz, 2H), 6.91-6.96 (m, 1H), 4.01 (s, 2H), 3.13-3.20 (m, 2H), 2.94-2.98 (m, 
2H), 2.14 (d, J=12.0Hz, 2H), 1.92-1.99 (m, 2H), 1.81 (s, NH). 
 13C NMR (100 MHz, CDCl3): δ 36.3, 42.4, 63.1, 76.5, 114.1, 114.2, 122.7, 126.1, 128.7, 142.0, 
142.0, 145.1, 161.9, 164.0. 
Anal. Calcd for C18H21ClFNO. 3/4H2O:  C, 67.18; H, 6.58; N, 4.35 Found: C, 64.47; H, 6.76; N, 
4.18. 
4-(3,5-Difluorobenzyloxy)-4-phenyl-piperidinium chloride (27ah, TAV-54) 
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N
H
O
.HCl
F
F
 
General procedure C: This compound was obtained as a white solid (180 mg, 84%).  
1H NMR (400 MHz, CDCl3): δ 7.63 (d, J=8.4Hz, 2H), 7.56 (d, J=8.0Hz, 2H), 7.24-7.30 (m, 
2H), 7.03-7.07 (m, 2H), 6.91-6.96 (m, 1H), 4.09 (s, 4H), 3.26 (s, 2H), 2.15 (d, J=12.0Hz, 2H), 
1.93 (s, 2H), 1.48 (s, NH).  
13C NMR (100 MHz, CDCl3): δ 164.3, 161.9, 155.1, 148.6, 125.8, 122.7, 114.2, 114.5, 79.8, 
76.2, 63.6, 39.3, 35.7, 28.5. 
Anal. Calcd for C18H20ClF2NO. H2O:   C, 60.42; H, 6.20; N, 3.91. Found: C, 60.48; H, 6.18; N, 
3.87. 
4-Benzyloxy-4-(4-fluorophenyl)-piperidinium chloride (27ba, TAV-13) 
N
H
O
.HCl
F
 
General procedure C: This compound was obtained as a white solid (196 mg, 96%). 
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1H NMR (400 MHz, CDCl3): δ 7.46 (d, J=8.8Hz, 1H), 7.34-7.39 (m, 2H), 7.23-7.31 (m, 5H), 
6.99 (t, J=8.4Hz, 1H), 4.06 (s, 2H), 3.16 (t, J=12.0Hz, 2H), 2.93 (d, J=12.0Hz, 2H), 2.15 (d, 
J=11.6Hz, 2H), 1.94 (t, J=12.0Hz, 2H), 1.66 (s, NH) 
13C NMR (100 MHz, CDCl3):  δ 36.5, 42.5, 63.9, 76.4, 126.2, 127.4, 127.5, 127.6, 128.5, 128.6, 
139.3, 145.4. 
Anal. Calcd for C18H21ClFNO. 3/4H2O:  C, 67.18; H, 6.58; N, 4.35 Found: C, 66.25; H, 6.64; N, 
4.29. 
4-(4-Fluorobenzyloxy)-4-(4-fluorophenyl)-piperidinium chloride (27bb, TAV-07) 
N
H
O
.HCl
F
F
 
General procedure C: This compound was obtained as a white solid (205 mg, 95%).  
1H NMR (400 MHz, CDCl3): δ 7.40-7.43 (m, 2H), 7.23-7.26 (m, 2H), 6.97-7.01 (m, 4H), 4.03 
(s, 3H), 3.14 (t, J=11.6Hz, 2H), 2.92 (d, J=12.0Hz, 2H), 2.10 (d, J=12.0Hz, 2H), 1.86-1.93 (m, 
2H), 1.64 (s, NH). 
 13C NMR (100 MHz, CDCl3): δ 36.5, 42.5, 63.1, 76.1, 115.3, 115.5, 127.8, 129.2, 134.8, 141.2, 
161.1, 163.4. 
 Anal. Calcd for C18H21ClF2NO. H2O:  C, 60.54; H, 6.16; N, 4.05 Found: C, 60.42; H, 6.20; N, 
3.91. 
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4-(4-Methylbenzyloxy)-4-(4-fluorophenyl)-piperidinium chloride (27bc, TAV-67) 
N
H
O
.HCl
F
CH3
 
General procedure C: This compound was obtained as a white solid (172 mg, 78%).  
1H NMR (400 MHz, CDCl3): δ 7.41-7.45 (m, 2H), 7.19 (d, J=8.0Hz, 2H), 7.13 (d, J=7.6Hz, 
2H), 7.03-7.07 (m, 2H), 4.03 (s, 2H), 3.15 (t, J=11.2Hz, 2H), 2.92-2.95 (m, 2H), 2.33 (s, 3H), 
2.12 (d, J=13.2Hz, 2H), 1.85-1.92 (m, 2H), 1.70 (s, NH). 
13C NMR (100 MHz, CDCl3): δ 21.3, 36.6, 42.4, 63.7, 75.9, 115.2, 115.5, 127.7, 127.9, 128.0, 
129.2, 136.1, 137.2. 
Anal. Calcd for C19H23ClFNO. H2O:  C, 64.49; H, 7.12; N, 3.96 Found: C, 62.61; H, 7.09; N, 
3.99. 
4-(4-Trifluoromethylbenzyloxy)-4-(4-fluorophenyl)-piperidinium chloride (27bd, TAV-15) 
N
H
O
HCl
F
CF3
 
General procedure C: This compound was obtained as a white solid (185 mg, 90%).  
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1H NMR (400 MHz, CDCl3): δ 7.57 (d, J=12.0Hz, 2H), 7.39-7.43 (m, 4H), 7.05 (t, J=8.8Hz, 
2H), 4.14 (s, 2H), 3.14 (t, J=12.0Hz, 2H), 2.95 (d, J=11.2Hz, 2H), 2.14 (d, J=12.0Hz,  2H), 1.89-
1.96 (m, 2H), 1.77 (s, NH)  
 13C NMR (100 MHz, CDCl3): δ 36.4, 42.4, 63.1, 76.3, 115.4, 115.6, 125.3, 127.4, 127.8, 140.8, 
143.2, 161.0, 163.5. 
 Anal. Calcd for C19H20ClF4NO. 3/4H2O:  C, 56.58; H, 5.37; N, 3.47 Found: C, 56.61; H, 5.31; 
N, 3.56. 
4-(4-Fluorobenzyloxy)-4-(3,4-dichlorophenyl)-piperidinium chloride (27be, TAV-46) 
N
H
O
.HCl
Cl
Cl
F
 
General procedure C: This compound was obtained as a white solid (210 mg, 96%).  
1H NMR (400 MHz, CDCl3): δ 7.44-7.35 (m, 5H), 7.29 (t, J=7.2Hz, 1H), 7.11 (dd, J=1.6Hz, 
8.4Hz, 1H), 4.04 (s, 2H), 3.14 (t, J=12.0Hz, 2H), 2.95 (d, J=12.0Hz, 2H), 1.86-1.94 (m, 2H), 
1.42 (s, NH).  
13C NMR (100 MHz, CDCl3): δ 36.3, 42.5, 62.6, 76.7, 126.1, 126.6, 127.7, 128.7, 129.3, 130.4, 
131.2, 132.5, 139.6, 144.9. 
Anal. Calcd for C18H20Cl2FNO. H2O:  C, 55.33; H, 4.90; N, 3.58 Found: C, 55.09; H, 4.75; N, 
3.63. 
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4-(2-Fluoromethylbenzyloxy)-4-(4-fluorophenyl)-piperidinium chloride (27bf, TAV-68) 
N
H
O
.HCl
F
F
 
General procedure C: This compound was obtained as a white solid (175 mg, 80%).  
1H NMR (400 MHz, CDCl3): δ 7.46-7.52 (m, 2H), 7.37 (t, J=7.6Hz, 2H), 7.22-7.30 (m, 2H), 
7.14 (t, J=8.4Hz, 1H), 6.99 (t, J=9.2Hz, 1H), 4.16 (s, 2H), 3.15 (t, J=12.0Hz, 2H), 2.95 (d, 
J=12.4Hz, 2H), 2.15 (d, J=12.4Hz, 2H), 1.94 (t, J=12.0Hz, 2H), 1.80 (s, NH). 
13C NMR (100 MHz, CDCl3):  δ 161.8, 159.4, 145.2, 129.8, 129.0, 128.7, 127.5, 126.1, 124.2, 
115.1, 76.6, 57.7, 42.4, 36.4. 
Anal. Calcd for C18H21ClF2NO:  C, 67.18; H, 6.58; N, 4.35 Found: C, 66.92; H, 6.60; N, 4.36. 
4-(3-Fluoromethylbenzyloxy)-4-(4-fluorophenyl)-piperidinium chloride (27bg, TAV-72) 
N
H
O
.HCl
F
F
 
General procedure C: This compound was obtained as a white solid (182 mg, 84%).  
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1H NMR (400 MHz, CDCl3) : δ 7.46 (d, J=7.2Hz, 2H), 7.37 (t, J=8.0Hz, 2H), 7.24-7.30 (m, 
2H), 7.07 (t, J=8.4Hz, 2H), 4.01 (s, 2H), 3.13-3.20 (m, 2H), 2.94-2.98 (m, 2H), 2.14 (d, 
J=12.0Hz, 2H), 1.92-1.99 (m, 2H), 1.81 (s, NH). 
 13C NMR (100 MHz, CDCl3): δ 36.3, 42.4, 63.1, 76.5, 114.1, 114.2, 122.7, 126.1, 128.7, 142.0, 
142.0, 145.1, 161.9, 164. 
Anal. Calcd for C18H21ClF2NO:  C, 63.62; H, 5.93; N, 4.12 Found: C, 63.42; H, 5.90; N, 4.10. 
4-(3, 4-Difluorobenzyloxy)-4-(4-fluorophenyl)-piperidinium chloride (27bh, TAV-71) 
N
H
O
.HCl
F
F
F
 
General procedure C: This compound was obtained as a white solid (180 mg, 84%).  
1H NMR (400 MHz, CDCl3): δ 7.63 (d, J=8.4Hz, 2H), 7.56 (d, J=8.0Hz, 2H), 7.24-7.30 (m, 
1H), 7.03-7.07 (m, 2H), 6.91-6.96 (m, 1H), 4.09 (s, 4H), 3.26 (s, 2H), 2.15 (d, J=12.0Hz, 2H), 
1.93 (s, 2H), 1.48 (s, 2H).  
13C NMR (100 MHz, CDCl3): δ 164.3, 161.9, 155.1, 126.5, 125.8, 122.7, 114.2, 114.5, 79.8, 
76.2, 63.6, 39.3, 35.7. 
Anal. Calcd for C18H19ClF3NO. H2O:  C, 57.53; H, 5.63; N, 3.73 Found: C, 57.71; H, 5.64; N, 
3.67. 
4-(3, 4-Chlorobenzyloxy)-4-(4-fluorophenyl)-piperidinium chloride (27bi, TAV-45) 
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N
H
O
.HCl
F
Cl
 
General procedure C: This compound was obtained as a white solid (200 mg, 95%).  
1H NMR (400 MHz, CDCl3): δ 7.40-7.43 (m, 2H), 7.23-7.26 (m, 2H), 6.97-7.01 (m, 4H), 4.03 
(s, 3H), 3.14 (t, J=11.6Hz, 2H), 2.92 (d, J=12.0Hz, 2H), 2.10 (d, J=12.0Hz, 2H), 1.86-1.93 (m, 
2H), 1.64 (s, NH). 
 13C NMR (100 MHz, CDCl3): δ 36.5, 42.5, 63.1, 76.1, 115.3, 115.5, 127.8, 129.2, 134.8, 141.2, 
161.1, 163.4. 
Anal. Calcd for C18H20Cl2FNO. H2O:  C, 62.19; H, 5.81; N, 3.74 Found: C, 62.17; H, 5.87; N, 
3.70. 
4-Benzyloxy-4-(4-chlorophenyl)-piperidinium chloride (27ca, TAV-25) 
N
H
O
.HCl
Cl
 
General procedure C: This compound was obtained as a white solid (295 mg, 87%).  
1H NMR (400 MHz, CDCl3): δ 7.25-7.42 (m, 9H), 4.09 (s, 2H), 4.05 (s, 2H), 3.15 (t, J=11.6Hz, 
2H), 2.93 (d, J=12.0Hz, 2H), 2.12 (d, J=12.8Hz, 2H), 1.85-1.93 (m, 2H), 1.71 (s, NH). 
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 13C NMR (100 MHz, CDCl3): δ 36.48, 42.46, 63.9, 76.1, 127.5, 127.6, 127.7, 128.5, 128.8, 
133.3, 139.0, 144.2. 
Anal. Calcd for C18H21Cl2NO. 3/4H2O:  C, 63.91; H, 6.26; N, 4.14 Found: C, 63.26; H, 6.05; N, 
4.10. 
4-(4-Fluorobenzyloxy)-4-(4-chlorophenyl)-piperidinium chloride (27cb, TAV-29) 
N
H
O
.HCl
Cl
F
 
General procedure C: This compound was obtained as a white solid (185 mg, 82%).  
1H NMR (400 MHz, CDCl3): δ 7.32-7.39 (m, 4H), 7.23-7.27 (m, 2H), 6.97-7.03 (m, 2H), 4.04 
(s, 2H), 3.10-3.16 (m, 2H), 2.92-2.96 (m, 2H), 2.10 (d, J=8.0Hz, 2H), 1.85-1.92 (m, 2H), 1.62 (s, 
NH). 
13C NMR (100 MHz, CDCl3): δ 36.4, 42.4, 63.3, 76.2, 115.4, 127.6, 129.2, 133.3, 134.7, 144.0, 
161.1, 163.5.  
Anal. Calcd for C19H20ClFNO. 2/3H2O:  C, 58.72; H, 5.84; N, 3.80 Found: C, 58.70; H, 5.61; N, 
3.93. 
4-(4-Methylbenzyloxy)-4-(4-chlorophenyl)-piperidinium chloride (27cc, TAV-34) 
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N
H
O
.HCl
Cl
CH3
 
General procedure C: This compound was obtained as a white solid (172 mg, 78%).  
1H NMR (400 MHz, CDCl3): δ 7.41-7.45 (m, 2H), 7.19 (d, J=8.0Hz, 2H), 7.13 (d, J=7.6Hz, 
2H), 7.03-7.07 (m, 2H), 4.03 (s, 2H), 3.15 (t, J=11.2Hz, 2H), 2.92-2.95 (m, 2H), 2.33 (s, 3H), 
2.12 (d, J=13.2Hz, 2H), 1.85-1.92 (m, 2H), 1.70 (s, 1H). 
13C NMR (100 MHz, CDCl3): δ 21.3, 36.6, 42.4, 63.7, 75.9, 115.2, 115.5, 127.7, 127.9, 128.0, 
129.2, 136.1, 137.2. 
Anal. Calcd for C19H23Cl2NO. 1/3H2O:  C, 63.70; H, 6.66; N, 3.91 Found: C, 63.59; H, 6.31; N, 
3.98. 
4-(4-Trifluoromehylbenzyloxy)-4-(4-chlorophenyl)-piperidinium chloride (27cd, TAV-28) 
N
H
O
.HCl
Cl
CF3
 
General procedure C: This compound was obtained as a white solid (198 mg, 90%).  
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1H NMR (400 MHz, CDCl3): δ 7.57 (d, J=8.0Hz, 2H), 7.31-7.43 (m, 6H), 4.14 (s, 2H), 3.14 (t, 
J=11.4Hz, 2H), 2.94 (d, J=12.0Hz, 2H), 2.10 (d, J=11.6Hz, 2H), 1.87-1.94 (m, 2H), 1.67 (s, 
NH). 
13C NMR (100 MHz, CDCl3): 36.3, 42.4, 63.1, 125.4, 127.4, 127.6, 128.9, 129.8, 133.5, 137.3, 
143.1, 143.7,  
Anal. Calcd for C19H20Cl2F3NO. 3/4H2O:  C, 54.36; H, 5.16; N, 3.34 Found: C, 54.30; H, 5.14; 
N, 3.38. 
4-(3,4-Dichlorobenzyloxy)-4-(4-chlorophenyl)-piperidinium chloride (27ce, TAV-26) 
N
H
O
.HCl
Cl
Cl
Cl
 
General procedure C: This compound was obtained as a white solid (165 mg, 76%).  
1H NMR (400 MHz, CDCl3): δ 7.32-7.40 (m, 5H), 7.10 (d, J=8.0Hz, 2H), 4.08-3.14 (t, 
J=12.4Hz, 2H), 2.93-2.96 (m, 2H), 2.07-2.11 (d, J=13.2Hz, 2H), 1.90-1.94 (m, 2H), 1.68 (s, 
NH). 
 13C NMR (100 MHz, CDCl3):  δ 36.2, 42.4, 62.6, 76.4, 126.6, 127.5, 128.9, 129.2, 130.4, 
131.3, 132.6, 133.5, 139.3, 143.5. 
Anal. Calcd for C18H19Cl4NO:  C, 53.10; H, 4.70; N, 3.44 Found: C, 53.02; H, 4.95; N, 3.42. 
4-(2-Fluorobenzyloxy)-4-(4-chlorophenyl)-piperidinium chloride (27cf, TAV-61) 
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N
H
O
.HCl
F
Cl
 
General procedure C: This compound was obtained as a white solid (175 mg, 80%).  
1H NMR (400 MHz, CDCl3): δ 7.46-7.52 (m, 2H), 7.37 (t, J=7.6Hz, 2H), 7.22-7.30 (m, 2H), 
7.14 (t, J=8.4Hz, 1H), 6.99 (t, J=9.2Hz, 1H), 4.16 (s, 2H), 3.15 (t, J=12.0Hz, 2H), 2.95 (d, 
J=12.4Hz, 2H), 2.15 (d, J=12.4Hz, 2H), 1.94 (t, J=12.0Hz, 2H), 1.80 (s, NH). 
13C NMR (100 MHz, CDCl3):  δ 161.8, 159.4, 145.2, 129.8, 129.0, 128.7, 127.5, 126.1, 124.2, 
115.1, 76.6, 57.7, 42.4, 36.4. 
Anal. Calcd for C18H20Cl2FNO:  C, 60.68; H, 5.66; N, 3.93 Found: C, 60.57; H, 5.81; N, 3.89. 
4-(3-Fluoromethylbenzyloxy)-4-(4-chlorophenyl)-piperidinium chloride (27cg, TAV-72) 
N
H
O
.HCl
F
Cl
 
General procedure C: This compound was obtained as a white solid (182 mg, 84%).  
1H NMR (400 MHz, CDCl3) : δ 7.46 (d, J= 7.2Hz, 2H), 7.37 (t, J=8.0Hz, 2H), 7.24-7.30 (m, 
2H), 7.07 (t, J= 8.4Hz, 2H), 4.01 (s, 2H), 3.13-3.20 (m, 2H), 2.94-2.98 (m, 2H), 2.14 (d, 
J=12.0Hz, 2H), 1.92-1.99 (m, 2H), 1.81 (s, 2H). 
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 13C NMR (100 MHz, CDCl3): δ 36.3, 42.4, 63.1, 76.5, 114.1, 114.2, 122.7, 126.1, 128.7, 142.0, 
142.0, 145.1, 161.9, 164. 
Anal. Calcd for C18H21Cl2FNO. H2O:  C, 60.54; H, 6.16; N, 4.05 Found: C, 60.42; H, 6.20; N, 
3.91. 
4-(3, 4-Difluorobenzyloxy)-4-(4-chlorophenyl)-piperidinium chloride (27ch, TAV-63) 
N
H
O
.HCl
F
F
Cl
 
General procedure C: This compound was obtained as a white solid (180 mg, 84%).  
1H NMR (400 MHz, CDCl3): δ 7.63 (d, J=8.4Hz, 2H), 7.56 (d, J=8.0Hz, 2H), 7.24-7.30 (m, 
1H), 7.03-7.07 (m, 2H), 6.91-6.96 (m, 1H), 4.09 (s, 4H), 3.26 (s, 2H), 2.15 (d, J=12.0Hz, 2H), 
1.93 (s, 2H), 1.48 (s, NH).  
13C NMR (100 MHz, CDCl3): δ 164.3, 161.9, 155.1, 148.6, 126.5, 122.7, 114.2, 114.5, 79.8, 
76.2, 63.6, 39.3, 35.7. 
Anal. Calcd for C18H19Cl2 F2NO:  C, 57.77; H, 5.12; N, 3.74 Found: C, 57.96; H, 5.15; N, 3.64. 
4-(4-Chlorobenzyloxy)-4-(4-chlorophenyl)-piperidinium chloride (27ci, TAV-64) 
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N
H
O
.HCl
Cl
Cl
 
General procedure C: This compound was obtained as a white solid (200 mg, 95%).  
1H NMR (400 MHz, CDCl3): δ 7.40-7.43 (m, 2H), 7.23-7.26 (m, 2H), 6.97-7.01 (m, 4H), 4.03 
(s, 3H), 3.14 (t, J=11.6Hz, 2H), 2.92 (d, J=12.0Hz, 2H), 2.10 (d, J=12.0Hz, 2H), 1.86-1.93 (m, 
2H), 1.64 (s, NH). 
 13C NMR (100 MHz, CDCl3): δ 36.5, 42.5, 63.1, 76.1, 115.3, 115.5, 127.8, 129.2, 134.8, 141.2, 
161.1, 163.4. 
Anal. Calcd for C18H20Cl3NO. 3/4H2O:  C, 63.20; H, 5.93; N, 3.17 Found: C, 63.17; H, 6.13; N, 
3.06. 
4-Benzyloxy-4-(4-trifluromethylphenyl)-piperidinium chloride (27da, TAV-37) 
N
H
O
.HCl
F3C
 
General procedure C: This compound was obtained as a white solid (170 mg, 78%).  
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1H NMR (100 MHz, CDCl3): δ 7.58-7.65 (m, 4H), 7.25-7.36 (m, 5H), 4.12 (s, 2H), 3.20 (t, 
J=12.0Hz, 2H), 2.96 (d, J=11.6Hz, 2H), 2.14 (d, J=12.4Hz, 2H), 1.90-1.97 (m, 2H), 1.70 (s, 
NH). 
13C NMR (100 MHz, CDCl3): δ 36.4, 42.3, 64.1, 76.4, 125.6, 126.5, 127.6 128.6, 129.5, 129.8, 
138.8, 149.8, 161.1 
Anal. Calcd for C19H21ClF3NO:  C, 61.37; H, 5.69; N, 3.77 Found: C, 61.10; H, 5.72; N, 3.73. 
4-(4-Fluorobenzyloxy)-4-(4-trifluoromethylphenyl)-piperidinium chloride (27db, TAV-40) 
N
H
O
.HCl
F
F3C
 
General procedure C: This compound was obtained as a white solid (175mg, 84%).  
1H NMR (400 MHz, CDCl3): δ 7.64 (d, J=8.4Hz, 2H), 7.57 (d, J=8.4Hz, 2H), 7.25-7.29 (m, 
2H), 7.01 (t, J=8.8Hz, 2H), 4.06 (s, 2H), 3.13-3.19 (t, J=12.0Hz, 2H), 2.96 (s, J=12.0Hz, 2H), 
2.13 (d, J=12.0Hz, 2H), 1.93 (t, J=12.4Hz, 2H) 1.72 (s, NH). 
13C NMR (100 MHz, CDCl3): δ 163.6, 161.1, 149.6, 134.5, 129.2, 126.5, 125.7, 115.5, 115.3, 
76.5, 63.4, 42.3, 36.3. 
Anal. Calcd for C19H20ClF4NO:  C, 58.54; H, 5.17; N, 3.59 Found: C, 58.25; H, 5.23; N, 3.66. 
4-(4-Trifluoromethylbenzyloxy)-4-(4-trifluoromethylphenyl)-piperidinium chloride (27dd, 
TAV-39) 
68 
 
N
H
O
HCl
F3C
CF3
 
General procedure C: This compound was obtained as a white solid (200mg, 92%).  
1H NMR (400 MHz, CDCl3): δ 7.55-7.63 (m, 6H), 7.43 (d, J=8.0Hz, 2H), 4.16 (s, 2H), 3.15 (t, 
J=12.0Hz, 2H), 2.98 (d, J=11.6Hz, 2H), 2.14 (d, J=12.4Hz, 2H), 1.95 (t, J=12.0Hz, 2H), 1.80 (s, 
NH). 
13C NMR (100 MHz, CDCl3): δ 36.3, 42.3, 63.3, 76.7, 123.4, 125.4, 125.6, 125.8, 126.4, 127.4, 
129.9, 130.0, 142.9, 149.3. 
Anal. Calcd for C20H20ClF6NO:  C, 54.62; H, 4.58; N, 3.18 Found: C, 54.52; H, 4.57; N, 3.12.  
4-(3, 4-Dichlorobenzyloxy)-4-(4-trifluoromethylphenyl)-piperidinium chloride (27de, TAV-
38) 
N
H
O
.HCl
F3C
Cl
Cl
 
General procedure C: This compound was obtained as a white solid (182 mg, 81%).  
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1H NMR (400 MHz, CDCl3): δ 7.58-7.64 (m, 3H), 7.21 (d, J=8.4Hz, 2H), 7.15 (d, J=8.0Hz, 
2H), 4.07 (s, 2H), 3.15 (m, 2H), 2.96 (d, J=12.0Hz, 2H), 2.34 (s, 3H), 2.113 (d, J=12.0Hz, 2H), 
1.88-1.96 (m, 2H), 1.64 (s, NH). 
13C NMR (100 MHz, CDCl3): δ 21.3, 36.4, 42.3, 64.0, 76.3, 125.6, 126.6, 127.7, 128.6, 129.3, 
129.5, 129.8, 133.3, 135.8, 137.3, 149.9 
Anal. Calcd for C19H19Cl3F3NO:  C, 51.78; H, 4.45; N, 3.81 Found: C, 51.59; H, 4.53; N, 2.91.  
1.8. References 
 
1. Substance Abuse and Mental Health Services Administration, Results from the 2012 
National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series 
H-46, HHS Publication No. (SMA) 13-4795. Rockville, MD: Substance Abuse and Mental 
Health Services Administration, 2013. 
2. http://wyoming.methproject.org/documents/Meth%20Impact%20%20National%20Statistics
%20Final.pdf. 
3. Elkashef, A.; Vocci, F.; Hanson, G.; White, J.; Wickes, W.; Tiihonen, J. Pharmacotherapy 
of methamphetamine addiction: An Update. Subst. Abuse 2008, 29, 31-49 
4. Nichols, D. E. Medicinal chemistry and structure-activity relationships. In Amphetamine 
and its analogs: Psychopharmacology, toxicology and abuse. Cho, A.K. and Segal, D. S. 
(Eds). Academic Press, San Diego, 1994, pp. 3-41. 
5. Negus, S. S.; Mello, N. K.; Blough, B. E.; Baumann, M. H.; Rothman, R. B. Monoamine 
releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as a 
70 
 
candidate agonist medication for cocaine dependence. J. Pharmacol. Exp. Ther. 2007, 320, 
627-36. 
6. Howell, L.L.; Carroll, F.I.; Votaw, J. R.; Goodman, M.M.;  Kimmel, H. L. Effects of 
combined dopamine and serotonin transporter inhibitors on cocaine self-administration. J. 
Pharmacol. Exp. Ther. 2007, 320, 757-65. 
7. http://www.cnsforum.com/educationalresources/imagebank/substance_abuse/mao_cocaine. 
8. http://chekhovsgun.blogspot.com/2010/05/psychosis-among-substance-users.html. 
9. Runyon, S. P.; Carroll, F. I. Dopamine transporter ligands: Recent developments and 
therapeutic potential. Curr. Top. Med. Chem. 2006, 6, 1825. 
10. Runyon, S. P.; Carroll, F. I. In Dopamine Transporters: Chemistry Biology and 
Pharmacology; Trudell, M. L., Izenwasser, S., Eds.; John Wiley & Sons, Inc.: Hoboken, 
2008, pp. 125-170. 
11. Shoptaw, S.; Heinzerling, K.; Rotheram-Fuller, E.; Steward, T.; Swanson, A.N.; DeLa 
Garza, R.; Newton, T.; Ling, W.  Randomized, placebo-controlled trial of bupropion for the 
treatment of methamphetamine dependence. Drug Alcohol Depend. 2008, 96, 222-32. 
12. Shearer, J.; Drake, S.; Rodgers, C.; Slade, T.; vanBeek, I.; Lewis, J.; Brady, D.; McKetin, 
R.; Mattic, R. P.; Woodak, A.  A double-blind, placebo controlled trial of modafinil for 
methamphetamine dependence. Addiction 2009, 104, 224-233 
13. Newton, T.F.; Reid, M.S.; DeLaGraza, R.; Mahoney, J. J.; Abad, A.; Condos, R.; Palamar, 
J.; Halkitis, P.N.; Mojisak, J.; Anderson, A.; Li, S. H.; Elkashef, A. Evaluation of the 
subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent 
volunteers. Int. J. Neuropsychopharmacol. 2008, 11, 1037-45. 
71 
 
14. Urschel, H.C.; Hanselka, L.L.; Baron, M. A controlled trial of flumazenil, gabapentin and 
hydroxyzine in the treatment of methamphetamine dependence. CPDD 70th annual meeting, 
Puerto Rico, June 2008: 56 
15. Takamatsu, Y.; Yamamoto, H.; Ogai, Y.; Hagino, Y.; Markou, A.; Ikeda, K. Fluoxetine as a 
Potential pharmacotherapy for methamphetamine dependence studies in mice. Ann. N.Y. 
Acad. Sci. 2006,1074, 295–302. 
16. Munzar, P.; Baumann, M.H.; Shoaib, M.; Goldberg, S.R. effects of dopamine and serotonin-
releasing agents on methamphetamine discrimination and self-administration in rats.  
Psychopharmacology 1999, 141, 287-96. 
17. Batki, S.L.; Moon, J.; Bradley, M.; Hersh, D.; Smolar, S.; Mengis, M.; Delucchi, K.;  Sexe, 
D.; Bennett, S.; Lefkowitz, E.; Chu, W.;  Morello, L.; Jacob, P. III; Jones, R.T. Fluoxetine in 
methamphetamine dependence. A controlled preliminary analysis. CPDD 61st Annual 
Meeting, Acapulco, 1999, Abstr. 235. 
18. Batki, S.L.; Moon, J.; Delucchi, K.;  Bradley, M.; Hersh, D.; Smolar, S.; Mengis, M.; 
Lefkowitz, E.; Sexe, D.; Morello, L.; Everhart, T.; Jacob, P. III; Jones, R.T. 3rd  
Methamphetamine quantitative urine concentrations during a controlled trial of fluoxetine 
treatment. Ann. NY Acad. Sci. 2000, 909, 260-3. 
19. Piaseki, M.P.; Steinagel, G.M.; Thienhaus, O.J.; Kohlenberg, B. S.; An exploratory study: 
the use of paroxetine for methamphetamine craving. J. Psychoactive Drugs, 2002, 34, 301 
20. Zorick, T.; Sugar, C.A.; Helleman, G.; Shoptaw, S.; London, E.D. Poor response to 
sertraline in methamphetamine dependence is associated with sustained craving for 
methamphetamine. Drug Alcohol Depend. 2011, 118, 500-3. 
72 
 
21. Rothman, R. B.; Partilla, J. S.; Baumann, M. H.; Dersch, C. M.; Carroll, F. I.; Rice, K. C. 
Neurochemical neutralization of methamphetamine with high-affinity nonselective 
inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant 
abuse. Synapse, 2000, 35, 222-227. 
22. Vocci, F. J.; Appel, N. M. Approaches to the development of medications for the treatment 
of methamphetamine dependence. Addiction, 2007, 102 (Supp. 1), 96-106. 
23. Baumann, M. H.; Clark, R. D.; Woolverton, W. L.; Wee, S.; Blough, B. E.; Rothman, R. B. 
In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of 
mesolimbic dopamine transmission in the rat. J. Pharmacol. Exp. Ther. 2011, 337, 218-25 
24. Lomenzo, S. A.; Rhoden, J.;  Izenwasser, S.; Wade, D.;  Kopajtic, T.; Katz, J. L.; Trudell, M. 
L. Synthesis and biological evaluation of meperidine analogues at monoamine transporters.  
J. Med. Chem. 2005, 48, 1336. 
25. Rhoden, J.; Bouvet, M.; Izenwasser, S.; Wade, D.; Lomenzo, S. A.; Trudell, M. L. 
Structure-Activity studies of 3’,4’-dichloromeperidine analogues at dopamine and serotonin 
transporters. Bioorg. Med. Chem. 2005, 13, 5623-29.  
26. Gu, X.; Izenwasser, S.; Wade, D.; Housman, A.; Gulasey, G.; Savoie, C. D.; Mobley, D. L.; 
Lomenzo, S. A.; Trudell, M. L. Synthesis and structure-activity studies of benzyl ester 
meperidine and normeperidine derivatives as selective Serotonin transporter ligands. 
Bioorg. Med. Chem. 2010, 18, 8356-8365. 
27. Zhang, S.; Izenwasser, S.; Wade, D.; Xu, L.; Trudell, M. L. Synthesis of  Dopamine 
Transporter Selective 3-(Diarylmethoxymethyl)-8-alkylaryl-8-azabicyclo[3.2.1]octane 
Derivatives. Bioorg. Med. Chem. 2006, 14, 7943. 
73 
 
28. Chen, Z.; Skolnick, P. Triple uptake inhibitors: Therapeutic potential and beyond. Exp. 
Opin. Invest. Drugs 2007, 16, 1365-77. 
29. Skolnick, P.; Kreiter, P.; Tizzano, J.; Popik, P.; Czobor, P.; Lippa, A. Preclinical and clinical 
pharmacology of DOV216,303, a triple uptake inhibitor.  CNS Drug Rev. 2006, 12, 123. 
30. Kaur, H.; Izenwasser, S.; Verma, A.; Wade, D.; Housman, A.; Gulasey, G.; Trudell, M. L. 
Synthesis And Monoamine Transporter Affinity Of 3-Aryl-3-Arylmethoxtropane 
Derivatives.  73rd Cpdd Meeting, Hollywood, Fl, 2011. Abstr. 64 
31.  Lomenzo, S. A.; Izenwasser, S.; Gerdes, R. M.; Katz, J. L.; Kopajtic, T.; Trudell, M. L. 
Synthesis, dopamine and serotonin binding affinities of novel analogues of meperidine.  
Bioorg. Med. Chem. Lett. 1999, 9, 3273-3276. 
32. Kaur, H.; Izenwasser, S.; Verma, A.; Wade, D.; Housman, A.; Stevens, E. D.; Mobley, D. 
L.; Trudell, M. L. Synthesis and Monoamine Transporter Affinity of 3α-Arylmethoxy-3β-
arylnortropanes. Bioorg. Med. Chem. Lett. 2009, 19, 6865. 
33. Thaxton, A.; Izenwasser, S.; Wade, D.; Wade, D.; Stevens, E. D.; Mobley, D. L.; Jaber, V.; 
Lomenzo, S. A.; Trudell, M. L. 3-Aryl-3-arylmethoxyazetidines. A new class of high 
affinity ligands for monoamine transporters. Bioorg. Med. Chem. Lett. 2013, 23, 4404-4407. 
 
 
 
 
 
 
 
74 
 
Chapter 2: Design, synthesis and pharmacological evaluation of 3-aryl-3-aryl 
pyrrolidines as monoamine transporter ligands 
2.1. Abstract 
We have designed a novel pyrrolidine pharmacophore by combining structural features of 
previously active pharmacophore (i.e. piperidine and azetidine pharmacophore). The target 
compounds were prepared via a four step procedure from 1-Boc-pyrolidin-3-ol. 
2.2. Introduction 
The dual acting affinity of piperidine1,2 and azetidine3 series on monoamine transporters 
prompted an investigation to explore the pharmacophore by replacing azetidine or piperidine ring 
with pyrrolidine ring.1-4 
O
N
H
X
YO
N
H
X Y
O
N
H
X Y
Azetidine
 
pharmacophore Pharmacophore
 
3 Piperidine
 
pharmacophore
 
Figure 2.1. Design of pyrrolidine pharmacophore. 
A novel pyrrolidine pharmacophore (Pharmacophore 3) was designed with aryl and 
arylmethoxy substitution on 3 position of ring. A variety of substituents on the aromatic ring 
would provide a potent and selective dual acting agent at monoamine transporter.5-7  
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2.3. Results and discussion 
 Synthesis of target compounds 
The commercially available 1-Boc-pyrrolidin-3-ol was used for the synthesis of the target 
molecules. The substrate was oxidized using Dess–Martin periodinane to furnish corresponding 
ketone in excellent yields (Scheme 2.1).8 
N
O O
HO
N
O O
O
Dess-Martin
 reagent
 
Methanol
2h,
 
90%
(1) (2)  
Scheme 2.1. Synthesis of Boc-pyrollidin-3-one 
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BuLi,
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65-75%
R1 :
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 c=Cl
(2) 3a
-3c 4a
-4c
R1
R1
 
Scheme 2.2. Synthesis of tert-alcohol using aryl lithium reagent. 
The ketone was further reacted with a pre-formed aryl lithium reagent that was synthesized in-
situ using n-Butyl lithium and substituted bromobenzenes to produce tertiary alcohol in moderate 
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to good yields. A variety of substituents were installed on the aryl moiety to furnish 
intermediates 4a-4c (Scheme 2.2). 
R1 :
 a=H,
 
b=F,
 c=Cl
R2
 : a= H,
 
b=4-F,
 c=4-Cl,
 
d=3,4-Cl2
, e=4-CF3
,f=4-CH3
, g=3,5-F2
, h=2-F,
              
i=3-Cl
N
O O
HO
Br
R2
NaH,
 
DMF
0oC-RT
65-75%
N
O O
O
R2
4a-4c 5a
-5i 6aa-6ci
R1 R1
 
Scheme 2.3. Alkylation of alcohol using substituted benzyl bromides. 
The alcohols 4a-4c were alkylated using variety of substituted benzyl bromides.  The alkylation 
was performed using sodium hydride and dimethylformamide to furnish intermediates 6aa-6ci in 
excellent yields (Scheme 2.3). 
R1 :
 a=H,
 
b=F,
 c=Cl
R2
 : a= H,
 
b=4-F,
 c=4-Cl,
 
d=3,4-Cl2
, e=4-CF3
,f=4-CH3
, g=3,5-F2
, h=2-F,
              
       
i=3-Cl
N
O O
O
HCl.
 
MeOH
N
H
O
85-95%
R2 R2
6aa-6ci 7aa
-7ci
R1 R1
.HCl
 
Scheme 2.4. Deprotection of Boc-group  
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Removal of the N-Boc group was performed using hydrochloric acid in methanol to give 
quantitative yield of the pyrrolidines as the hydrochloride salts 7aa-7ci (Table 2.1, Scheme 2.4.). 
Cmpda code R1 R2 
7aa TAV-91 H H 
7ab TAV-85 H 4-F 
7ac TAV-103 H 4-CH3 
7ad TAV-84 H 3,4-Cl2 
7ae TAV-130 H 2-F 
7af TAV-104 H 3,5-F2 
7ag TAV-87 H 4-Cl 
7ah TAV-132 H 3-Cl 
7ba TAV-94 4-F H 
7bb TAV-100 4-F 4-F 
7bc TAV-108 4-F 4-CH3 
7bd TAV-106 4-F 3, 4-Cl2 
7ca TAV-114 4-Cl H 
7cb TAV-124 4-Cl 4-F 
7cf TAV-122 4-Cl 4-CH3 
7cd TAV-120 4-Cl 3,4-Cl2 
7cg TAV-126 4-Cl 3,5-F2 
7cc TAV-116 4-Cl 4-Cl 
7ci TAV-136 4-Cl 3-Cl 
aAll compounds were synthesized as the HCl salts. 
Table 2.1. Final pyrrolidine derivatives. 
All the compounds will be tested as hydrochloride salts. Binding affinities for the dopamine, 
serotonin and norepinephrine transporters will be determined by the ability of the drug to 
displace the radiolabeled ligands [3H] WIN35,428, [3H] Citalopram, and [3H] nisoxetine 
respectively, from the monoamine transporters in rat brain tissue using previously reported 
assays. 
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All the compounds synthesized in this study are in the process of biological evaluation. The 
potency and efficacy that is determined for these compounds will provide the direction for 
further studies with these novel tropane derivatives. All the biological studies will be reported in 
due course. 
2.5. Conclusion 
We have synthesized 3-aryl-3-arylmethoxy pyrrolidines using 1-Boc-3-pyrrolidinol using a 4 
step synthesis methods. All the final compounds were synthesized with 15-45% of overall yields. 
We will perform the screening of these compounds on monoamine transporters and study the 
structure activity relationship in future.  
2.6. Experimental  
 
All chemicals were purchased from Aldrich Chemical Company and used as received unless 
otherwise noted. Anhydrous Ethyl ether (Et2O), Dimethylformamide (DMF), Methanol (MeOH), 
Dichloromethane (DCM) was purchased from Mallinckrodt Baker. Inc. Thin layer 
chromatography (TLC) 20×20 cm aluminium plates precoated with silica gel purchased from 
EMD Millipore USA and used to monitor reactions via visualization with short-wave UV light. 
1H NMR (400 MHz) and 13C NMR (400 MHz) spectra were recorded on a Varian 400 MHz 
NMR spectrometer at ambient temperature in CDCl3. 1H NMR chemical shifts are reported as δ 
values (ppm) relative to tetramethylsilane. 13C NMR chemical shifts are reported as δ values 
(ppm) relative to CDCl3 (77.0 ppm). Atlantic Microlab, Inc., Norcross, GA performed all CHN 
microanalyses. 
Synthesis of tert-butyl 3-oxopyrrolidine-1-carboxylate 
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To a clean dry flask was added tert-butyl-3-hydroxypyrrolidine-1-carboxylate (10.7 mmol, 1 
equiv.) in dry methanol (20 ml). To the reaction mixture was then added Dess–Martin 
periodinane (16.1 mmol, 1.5 equiv.) in portions. The reaction mixture was stirred for 3 h at room 
temperature. After the completion of reaction, the solvent was evaporated under reduced pressure 
and the crude mixture was diluted with water and extract with ethyl ether (3×20ml). The organic 
extract was dried over anhydrous sodium sulphate and the solvent was evaporated under reduced 
pressure to get final product as white solid. (Yield : 1.85g, 90%) 
1H NMR (400 MHz, CDCl3): 4.32 (d, J = 12.8, 2H), 4.12 (s, 2H), 2.71 (d, J = 12.4, 2H), 1.40 
(s, 9H) 
13C NMR (100 MHz, CDCl3): 28.7, 27.5, 37.0, 56.7, 79.5, 159.0, 192.5 
General procedure A. Synthesis of tertiary alcohols (4a-4c) 
In a clean, dry round-bottom flask was added substituted benzenes (2 equiv.) (3a-3c) in dry ethyl 
ether (20 ml). The solution of n-Butyl lithium (2.1 equiv.) was added to the solution dropwise at 
0ºC. The solution of 1-(Boc) 4-pyrrolidinone (1 equiv.) (2) in diethyl ether was added to the 
solution at -78ºC. The solution was warmed to room temperature and stirred for 2h. The reaction 
mixture was diluted with ammonium chloride solution. The reaction mixture was extracted with 
ethyl ether (3×30 ml). The organic extract was washed with brine solution (30 ml) and dried over 
sodium sulphate. The solvent was evaporated under reduced pressure. The crude mixture was 
purified using column chromatography to obtain compounds 4a-4c. 
Tert-butyl-3-hydroxy-3-phenylpyrrolidine-1-carboxylate 
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OH
N
O
O
 
General procedure A: This compound was obtained as a colorless liquid (2.2 g, 70%). 
1H NMR (400 MHz, CDCl3): 7.47 (d, J = 7.6Hz, 2H), 7.36 (t, J = 8.0Hz, 2H), 7.28 (t, J= 
7.2Hz, 1H), 3.52-3.67 (m, 4H), 3.12 (brs, 1H), 2.12-2.23 (m, 2H), 1.42 (s, 9H). 
13C NMR (100 MHz, CDCl3): 28.7, 44.4, 44.8, 64.5, 77.9, 79.7, 126.7, 126.8, 128.6, 128.9, 
155.0 
Tert-butyl-3-(4-fluorophenyl)-3-hydroxypyrrolidine-1-carboxylate 
OH
N
O
O
F
 
General procedure A: This compound was obtained as a colorless liquid (1.8g, 55%). 
1H NMR (400 MHz, CDCl3): 7.42-7.45 (m, 2H), 7.06-7.12 (m, 2H), 3.42-3.65 (m, 4H), 3.18 
(brs, 1H), 2.15-2.21 (m, 2H), 1.41 (s, 9H). 
13C NMR (100 MHz, CDCl3): 28.7, 44.4, 44.8, 65.9, 75.3, 79.6, 115.6, 127.7, 128.7, 136.1, 
154.8. 
Tert-butyl-3-(4-chlorophenyl)-3-hydroxypyrrolidine-1-carboxylate 
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General procedure A: This compound was obtained as a colorless liquid (2.1g, 62%). 
1H NMR (400 MHz, CDCl3): 7.30 (m, 2H), 7.42 (m, 2H), 3.30-3.92 (m, 4H), 3.12 (brs, 1H), 
2.15-2.30 (m, 2H), 1.39 (s, 9H)  
13C NMR (100 MHz, CDCl3): 28.7, 44.4, 44.8, 66.0, 76.3, 79.6, 128.3, 129.0, 134.2, 138.4, 
154.7. 
General procedure B. Benzylation of alcohols (6aa-6ch) 
The solution of compounds 4a-4c was stirred in dimethylformamide at 00C. To the solution was 
added sodium hydride (2.2 equiv.)  at 00C. Variety of benzyl bromides (1.2 equiv.) (5a-5h) was 
added to the solution and the reaction was stirred for 2 h. The reaction was quenched with water 
and extracted with ethyl acetate (3×20 ml). The organic solvent was washed with brine solution 
and dried over sodium sulphate. The crude product was purified using column chromatography 
to obtain compounds 6aa-6ch. 
N-(tert-Butoxycarbonyl)-3-(phenylmethoxy)-3-phenyl-pyrrolidine (6aa, TAV-82) 
O
N
O
O
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General procedure B: This compound was obtained as a colorless liquid (280 mg, 75%). 
1H NMR (400 MHz, CDCl3): 7.24-7.7.48 (m, 10H), 3.93-4.26 (m, 3H), 3.52-3.73 (m, 3H), 
2.51-2.52 (m, 1H), 2.12-2.27 (m, 1H), 1.49 (d, J=11.2Hz, 9H). 
13C NMR (100 MHz, CDCl3): 28.7, 34.0, 36.5, 44.2, 44.6, 54.8, 56.9, 66.0, 79.8, 85.0, 86.2, 
126.8, 127.6, 127.7, 128.5, 128.6, 128.9, 138.9, 140.6, 154.8. 
N-(tert-Butoxycarbonyl)-3-[(4-fluorophenyl)methoxy]-3-phenyl-pyrrolidine (6ab, TAV-83) 
O
N
F
O
O
 
General procedure B: This compound was obtained as a colorless liquid (270 mg, 65%). 
1H NMR (400 MHz, CDCl3): 7.34-7.45 (m, 5H), 7.16-7.20 (m, 2H), 6.94-6.97 (m, 2H), 3.91-
4.20 (m, 3H), 3.51-3.63 (m, 3H), 2.48-2.52 (m, 1H), 2.17-2.27 (m, 1H), 1.49 (d, J=11.2Hz, 9H). 
13C NMR (100 MHz, CDCl3): 28.7, 33.9, 36.5, 44.4, 44.8, 53.8, 55.9, 65.3, 79.6, 85.0, 86.0, 
115.5, 126.8, 128.9, 129.3, 134.4, 140.0, 154.8, 161.2, 163.6. 
N-(tert-Butoxycarbonyl)-3-[(4-methylphenyl)methoxy]-3-phenyl-pyrrolidine (6ac, TAV-
101) 
O
N
O
O
CH3
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General procedure B: This compound was obtained as a colorless liquid (285 mg, 75%). 
1H NMR (400 MHz, CDCl3): 7.35-7.49 (m, 5H), 7.14 (m, 4H), 3.94-4.22 (m, 3H), 3.56-3.74 
(m, 3H), 2.51-2.54 (m, 1H), 2.34 (s, 3H) 2.23-2.26 (m, 1H), 1.52 (d, J=11.6Hz, 9H). 
13C NMR (100 MHz, CDCl3): 21.3, 38.8, 33.9, 36.5, 44.5, 44.9, 54.0, 56.1, 65.9, 79.5, 84.9, 
85.8, 126.8, 127.8, 128.3, 128.8, 129.2, 135.7, 137.3, 140.3, 155.0. 
N-(tert-Butoxycarbonyl)-3-[(3,4-dichlorophenyl)methoxy]-3-phenyl-pyrrolidine (6ad, TAV-
82) 
O
N
Cl Cl
O
O
 
General procedure B: This compound was obtained as a colorless liquid (255 mg, 55%). 
1H NMR (400 MHz, CDCl3): 7.30-7.41 (m, 6H), 7.00-7.05 (m, 1H), 3.88-4.18 (m, 3H), 3.52-
3.69 (m, 3H), 2.46-2.51 (m, 1H), 2.18-2.28 (m, 1H), 1.47 (d, J=9.2Hz, 9H). 
13C NMR (100 MHz, CDCl3): 28.7, 33.9, 36.4, 44.4, 44.8, 53.7, 55.9, 64.5, 79.7, 85.3, 86.2, 
126.7, 126.8, 128.6, 128.9, 129.3, 130.4, 131.3, 132.5, 139.0, 139.6, 155.0. 
N-(tert-Butoxycarbonyl)-3-[(3-fluorophenyl)methoxy]-3-phenyl-pyrrolidine (6ae, TAV-129) 
O
N
O
O
F
 
General procedure B: This compound was obtained as a colorless liquid (270 mg, 70%). 
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1H NMR (400 MHz, CDCl3): 7.31-7.46 (m, 6H), 7.21-7.22 (m, 1H), 7.07-7.12 (m, 1H), 6.94-
6.99 (m, 1H), 4.28 (t, J=12.4Hz, 1H), 4.146 (t, J=12.0Hz, 1H), 3.96 (d, J=12.4Hz, 1H), 3.51-
3.65 (m, 3H), 2.50-2.51 (m, ,1H), 2.20-2.25 (m, 1H), 1.48 (d, J=13.2Hz, 9H). 
13C NMR (100 MHz, CDCl3): 28.7, 33.9, 35.9, 44.4, 44.8, 54.4, 56.1, 59.6, 79.5, 85.1, 86.0, 
115.1, 115.3, 124.2, 124.3, 126.7, 128.4, 128.8, 129.3, 129.9, 139.8, 155.6 
N-(tert-Butoxycarbonyl)-3-[(3,5-difluorophenyl)methoxy]-3-phenyl-pyrrolidine (7af, TAV-
102) 
O
N
O
O
F
F
 
General procedure B: This compound was obtained as a colorless liquid (250 mg, 55%). 
1H NMR (400 MHz, CDCl3): 7.25-7.41 (m, 5H), 6.61-6.74 (m, 3H), 4.04-4.21 (m, 2H), 3.68 (d, 
J=11.2Hz, 1H), 3.52-3.69 (m, 3H), 2.47-2.51 (m, 1H), 2.18-2.28 (m, 1H), 1.48 (d, J=8.0Hz, 
9H). 
13C NMR (100 MHz, CDCl3): 28.6, 33.9, 36.5, 44.4, 44.8, 53.6, 55.8, 64.7, 79.7, 85.3, 86.2, 
115.7, 126.6, 128.5, 129.3, 132.5, 135.5, 138.9, 154.7, 163.9. 
N-(tert-Butoxycarbonyl)-3-[(4-chlorophenyl)methoxy]-3-phenyl-pyrrolidine (6ag, TAV-86) 
O
N
Cl
O
O
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General procedure B: This compound was obtained as a colorless liquid (275 mg, 65%). 
1H NMR (400 MHz, CDCl3): 7.32-7.44 (m, 5H), 7.24-7.27 (m, 2H), 7.13-7.16 (m, 2H), 4.06-
4.21 (m, 2H), 3.90 (d, J=11.6Hz, 1H), 3.51-3.71 (m, 3H), 2.47-2.51 (m, 1H), 2.17-2.25 (m, 1H), 
1.48 (d, J=11.2Hz, 9H). 
13C NMR (100 MHz, CDCl3): 28.7, 34.0, 36.5, 44.4, 44.9, 53.8, 55.9, 65.2, 79.6, 85.1, 86.0, 
126.7, 126.8, 128.4, 128.5, 128.6, 133.3, 133.4, 137.2, 137.3, 139.9, 140.0, 154.8 
N-(tert-Butoxycarbonyl)-3-[(3-chlorophenyl)methoxy]-3-phenyl-pyrrolidine (6ah, TAV-
131) 
O
N
O
O
Cl
 
General procedure B: This compound was obtained as a colorless liquid (250 mg, 50%). 
1H NMR (400 MHz, CDCl3): 7.33-7.42 (m, 5H), 7.19-7.26 (m, 3H), 7.07-7.10 (m, 1H), 3.91-
4.21 (m, 3H), 3.52-3.70 (m, 3H), 2.49-2.51 (m, 1H), 2.18-2.21 (m, 1H), 1.49 (d, J=9.4Hz, 9H). 
13C NMR (100 MHz, CDCl3): 28.7, 33.9, 36.4, 44.4, 44.9, 53.8, 56.0, 65.1, 79.6, 85.1, 86.1, 
125.5, 126.8, 127.5, 127.7, 128.5, 128.9, 129.7, 134.3, 139.8, 140.7, 154.8 
N-(tert-Butoxycarbonyl)-3-phenylmethoxy-3-(4-fluorophenyl)-pyrrolidine (6ba, TAV-93) 
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O
N
O
O
F
 
General procedure B: This compound was obtained as a colorless liquid (280 mg, 68%). 
1H NMR (400 MHz, CDCl3): 7.42-7.45 (m, 2H), 7.22-7.33 (m, 4H), 7.06-7.12 (m, 2H), 3.92-
4.24 (m, 3H), 3.51-3.68 (m, 3H), 2.49-2.53 (m, 1H), 2.16-2.22 (m, 1H), 1.50 (d, J=9.6Hz, 9H). 
13C NMR (100 MHz, CDCl3): 28.7, 34.0, 36.4, 44.4, 44.8, 54.1, 56.1, 65.9, 79.6, 84.5, 85.4, 
115.6, 127.6, 127.7, 128.7, 136.1, 138.6, 154.8, 161.4, 163.9. 
N-(tert-Butoxycarbonyl)-3-[(4-fluorophenyl)methoxy]-3-(4-fluorophenyl)-pyrrolidine (6bb, 
TAV-99) 
O
N
O
O
F F
 
General procedure B: This compound was obtained as a colorless liquid (265 mg, 62%). 
1H NMR (400 MHz, CDCl3): 7.38-7.43 (m, 2H), 7.14-7.18 (m, 2H), 7.06-7.11 (m, 2H), 6.94- 
7.00 (m, 2H),  3.87-4.18 (m, 3H), 3.49-3.67 (m, 3H), 2.45-2.50 (m, 1H), 2.14-2.24 (m, 1H), 1.47 
(d, J=9.6Hz, 9H). 
13C NMR (100 MHz, CDCl3): 28.7, 34.0, 36.6, 44.4, 44.8, 53.9, 56.0, 65.3, 79.7, 84.5, 85.4, 
115.3, 115.8, 128.6, 129.4, 134.2, 136.0, 154.9, 161.4, 163.9. 
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N-(tert-Butoxycarbonyl)-3-[(4-methylphenyl)methoxy]-3-(4-fluorophenyl)-pyrrolidine (6bc, 
TAV-107) 
O
N
O
O
F CH3
 
General procedure B: This compound was obtained as a colorless liquid (282 mg, 78%). 
1H NMR (400 MHz, CDCl3): 7.41-7.45 (m, 2H), 7.06-7.12 (m, 6H), 4.04-4.20 (m, 2H), 3.93 (d, 
J=11.6Hz, 1H), 3.51-3.65 (m, 3H), 2.48-2.52 (m, 1H), 2.32 (s, 3H), 2.15-2.21 (m, 1H), 1.50 (d, 
J=10.0Hz, 9H). 
13C NMR (100 MHz, CDCl3): 21.3, 28.7, 34.04, 36.4, 44.4, 44.8, 54.2, 56.1, 65.8, 79.6, 84.4, 
85.3, 115.6, 127.7, 128.6, 129.2, 136.2, 137.3, 154.8, 161.4, 163.9. 
N-(tert-Butoxycarbonyl)-3-[(3,4-dichlorophenyl)methoxy]-3-(4-fluorophenyl)-pyrrolidine 
(6bd, TAV-105) 
O
N
O
O
F ClC
l
 
General procedure B: This compound was obtained as a colorless liquid (278 mg, 72%). 
1H NMR (400 MHz, CDCl3): 7.25-7.39 (m, 4H), 6.99-7.09 (m, 3H), 4.00-4.16 (m, 2H), 3.87 (d, 
J=11.6Hz, 1H), 3.50-3.64 (m, 3H), 2.44-2.49 (m, 1H), 2.15-2.24 (m, 1H), 1.46 (d, J=8.4Hz, 
9H). 
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13C NMR (100 MHz, CDCl3): 28.7, 34.0, 36.4, 44.4, 44.8, 53.8, 55.9, 64.5, 79.7, 84.7, 85.7, 
115.7, 126.6, 128.5, 130.5, 131.4, 132.5, 135.5, 138.9, 154.7, 161.5, 163.9. 
N-(tert-Butoxycarbonyl)-3-[(2-fluorophenyl)methoxy]-3-(4-fluorophenyl)-pyrrolidine (6be, 
TAV-111) 
O
N
O
O
F
F
 
General procedure B: This compound was obtained as a colorless liquid (280mg, 84%). 
1H NMR (400 MHz, CDCl3): 7.31-7.43 (m, 3H), 7.21-7.25 (m, 1H), 6.93-7.11 (m, 4H), 3.88-
4.27 (m, 3H), 3.46-3.65 (m, 3H), 2.49-2.52 (m, 1H), 2.16-2.27 (m, 1H), 1.45-1.47 (d, J=9.6Hz, 
9H). 
13C NMR (100 MHz, CDCl3): 28.7, 33.9, 35.9, 44.4, 44.8, 54.5, 56.1, 59.6, 79.6, 84.6, 85.5, 
115.8, 124.2, 124.3, 125.5, 128.5, 129.3, 129.9, 135.8, 154.7, 161.4, 163.9. 
N-(tert-Butoxycarbonyl)-3-[(3,5-difluorophenyl)methoxy]-3-(4-fluorophenyl)-pyrrolidine 
(6bf, TAV-109) 
O
N
O
O
F
F
F
 
General procedure B: This compound was obtained as a colorless liquid (264 mg, 62%). 
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1H NMR (400 MHz, CDCl3): 7.34-7.39 (m, 2H), 7.02-7.07 (m, 2H), 6.59-6.71 (m, 3H), 4.00-
4.18 (m, 2H), 3.88 (d, J=11.6Hz, 1H), 3.51-3.59 (m, 3H), 2.43-2.48 (m, 1H), 2.14-2.20 (m, 1H), 
1.44 (d, J=6.4Hz, 9H). 
13C NMR (100 MHz, CDCl3): 28.6, 34.0, 36.4, 44.3, 44.8, 53.8, 55.8, 64.6, 79.7, 84.8, 85.7, 
102.7, 109.8, 115.7, 128.5, 135.5, 142.7, 154.7, 161.8, 164.3. 
N-(tert-Butoxycarbonyl)-3-[(4-chlorophenyl)methoxy]-3-(4-fluorophenyl)-pyrrolidine (6bg, 
TAV-95) 
O
N
O
O
F Cl
 
General procedure B: This compound was obtained as a colorless liquid (270 mg, 68%). 
1H NMR (400 MHz, CDCl3): 7.37-7.40 (m, 2H), 7.21-7.24 (m, 2H), 7.12 (d, J=8.0Hz, 2H), 
7.03- 7.08 (m, 2H),  3.87-4.17 (m, 3H), 3.50-3.64 (m, 3H), 2.45-2.48 (m, 1H), 2.13-2.23 (m, 1H), 
1.46 (d, J=9.6Hz, 9H). 
13C NMR (100 MHz, CDCl3): 28.7, 34.0, 36.4, 44.4, 44.8, 54.0, 55.9, 65.1, 79.6, 84.6, 85.5, 
115.8, 128.6, 128.9, 133.4, 135.8, 137.1, 154.9, 161.4, 163.9 
N-(tert-Butoxycarbonyl)-3-phenylmethoxy-3-(4-chlorophenyl)-pyrrolidine (6ca, TAV-113) 
O
N
O
O
Cl
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General procedure B: This compound was obtained as a colorless liquid (284 mg, 86%). 
1H NMR (400 MHz, CDCl3): 7.21-7.38 (m, 9H), 4.04-4.23 (m, 2H), 3.91(d, J=11.6Hz, 1H), 
3.52-3.68 (m, 3H), 2.47-2.48 (m, 1H), 2.15-2.18 (m, 1H), 1.49 (d, J=9.6Hz, 9H). 
13C NMR (100 MHz, CDCl3): 28.7, 34.1, 36.5, 44.4, 44.8, 54.0, 55.9, 66.0, 79.6, 84.5, 85.4, 
127.6, 127.6, 128.2, 128.3, 128.5, 129.0, 134.2, 138.4, 138.9, 154.7. 
N-(tert-Butoxycarbonyl)-3-[(4-fluorophenyl)methoxy]-3-(4-chlorophenyl)-pyrrolidine (6cb, 
TAV-123) 
O
N
O
O
Cl F
 
General procedure B: This compound was obtained as a colorless liquid (272 mg, 64%). 
1H NMR (400 MHz, CDCl3): 7.36-7.37 (m, 4H), 7.15-7.18 (m, 2H), 6.94-6.99 (m, 2H), 4.01-
4.18 (m, 2H),  3.87 (d, J=11.6Hz, 1H), 3.50-3.61 (m, 3H), 2.46-2.49 (m, 1H), 2.13-2.20 (m, 
1H),1.45 (d, J=9.6Hz, 9H). 
13C NMR (100 MHz, CDCl3): 28.7, 34.0, 36.6, 44.4, 44.8, 53.8, 55.8, 65.4, 79.7, 84.5, 85.5, 
115.5, 128.2, 129.1, 129.4, 134.2, 138.6, 154.7, 161.2, 163.6. 
N-(tert-Butoxycarbonyl)-3-[(4-methylphenyl)methoxy]-3-(4-chlorophenyl)-pyrrolidine (6cc, 
TAV-121) 
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O
N
O
O
Cl CH3
 
General procedure B: This compound was obtained as a colorless liquid (265 mg, 60%). 
1H NMR (400 MHz, CDCl3): 7.39-7.29 (m, 4H), 7.12 (d, J=0.8Hz, 4H), 4.03-4.20 (m, 2H), 
3.90 (d, J=11.6Hz, 1H), 3.49-3.68 (m, 3H), 2.48-2.50 (m, 1H), 2.33 (s, 3H), 2.16-2.21 (m, 1H), 
1.48 (d, J=10.4Hz, 9H). 
13C NMR (400 MHz, CDCl3): 21.3, 28.7, 34.0, 36.6, 44.4, 44.8, 53.9, 56.0, 66.0, 79.6, 84.4, 
85.4, 128.3, 129.0, 129.2, 129.3, 134.2, 135.4, 137.6, 139.0, 154.8 
N-(tert-Butoxycarbonyl)-3-[(3,4-dichlorophenyl)methoxy]-3-(4-chlorophenyl)-pyrrolidine 
(6cd, TAV-119) 
O
N
O
O
Cl Cl
Cl
 
General procedure B: This compound was obtained as a colorless liquid (285 mg, 84%). 
1H NMR (400 MHz, CDCl3): 7.25-7.36 (m, 6H), 6.99-7.03 (m, 1H), 3.99-4.16 (m, 2H), 3.84 (d, 
J=11.6Hz, 1H), 3.50-3.64 (m, 3H), 2.44-2.47 (m, 1H), 2.13 (s, 1H), 1.46(d, J=8.4Hz, 9H). 
13C NMR (100 MHz, CDCl3): 28.7, 34.0, 36.4, 44.3, 44.7, 53.7, 55.7, 64.6, 79.8, 84.8, 85.7, 
126.6, 128.1, 129.1, 129.3, 130.4, 131.5, 132.6, 134.5, 138.3, 138.7, 154.7. 
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N-(tert-Butoxycarbonyl)-3-[(3,5-difluorophenyl)methoxy]-3-(4-chlorophenyl)-pyrrolidine 
(6ce, TAV-133) 
O
N
O
O
Cl
F
 
General procedure B: This compound was obtained as a colorless liquid (260 mg, 61%). 
1H NMR (400 MHz, CDCl3): 7.33 (m, 4H), 6.60-6.72 (m, 4H), 3.85-4.19 (m, 3H), 3.51-3.63 
(m, 3H), 2.46-2.47 (m, 1H), 2.14-2.20 (m, 1H), 1.45 (d, J=6.0Hz, 9H). 
13C NMR (100 MHz, CDCl3): 28.6, 34.0, 36.5, 44.3, 44.8, 53.6, 55.7, 64.8, 79.8, 84.8, 85.7, 
102.8, 109.8, 127.7, 127.8, 128.1, 129.1, 134.4, 138.2, 142.7, 154.6, 161.9 
N-(tert-Butoxycarbonyl)-3-[(3,5-difluorophenyl)methoxy]-3-(4-chlorophenyl)-pyrrolidine 
(6cf, TAV-125) 
O
N
O
O
Cl
F
F
 
General procedure B: This compound was obtained as a colorless liquid (270 mg, 65%). 
1H NMR (400 MHz, CDCl3): 7.31-7.37 (m, 4H), 7.19-7.21 (m, 1H), 7.05-7.10 (m, 1H), 6.93-
6.97 (m, 1H), 4.21 (t, J=11.2Hz, 1H), 4.10-4.16 (t, J=11.2Hz, 1H), 3.90 (d, J=11.6Hz, 1H), 
3.48-3.64 (m, 3H), 2.47-2.50 (m, 1H), 2.10-2.19 (m, 1H), 1.45 (d, J=8.0Hz, 9H). 
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13C NMR (100 MHz, CDCl3): 28.7, 33.9, 35.9, 44.3, 44.7, 54.4, 55.9, 59.7, 79.7, 84.6, 85.5, 
115.4, 124.2, 128.2, 129.0, 129.3, 129.9, 134.2, 138.5, 154.7. 
N-(tert-Butoxycarbonyl)-3-[(4-chlorophenyl)methoxy]-3-(4-chlorophenyl)-pyrrolidine (6cg, 
TAV-115) 
O
N
O
O
Cl Cl
 
General procedure B: This compound was obtained as a colorless liquid (275 mg, 72%). 
1H NMR (400 MHz, CDCl3): 7.34 (d, J=3.6Hz, 4H), 7.23-7.26 (m, 2H), 7.12-7.14 (m, 2H), 
4.00-4.18 (m, 2H),  3.86 (d, J=12.0Hz, 1H), 3.48-3.65 (m, 3H), 2.44-2.47 (m, 1H), 2.13-2.19 (m, 
1H), 1.46 (d, J=9.6Hz, 9H). 
13C NMR (100 MHz, CDCl3): 28.7, 34.1, 36.5, 44.4, 44.8, 53.8, 55.8, 65.3, 79.7, 84.6, 85.6, 
125.5, 127.4, 128.1, 128.2, 129.1, 134.4, 138.4, 142.6, 154.7 
N-(tert-Butoxycarbonyl)-3-[(3-chlorophenyl)methoxy]-3-(4-chlorophenyl)-pyrrolidine (6ch, 
TAV-135) 
O
N
O
O
Cl
Cl
 
General procedure B: This compound was obtained as a colorless liquid (290 mg, 81%). 
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1H NMR (400 MHz, CDCl3): 7.31-7.32 (m, 4H), 7.15-7.17 (m, 3H), 7.03-705 (m, 1H), 3.98-
4.16 (m, 2H), 3.86 (d, J=11.2Hz, 1H), 3.49-3.62 (m, 3H), 2.42-2.45 (m, 1H), 2.14-2.17 (m, 1H), 
1.44 (d, J=8.0Hz, 9H). 
13C NMR (100 MHz, CDCl3): 28.7, 33.9, 36.3, 44.3, 44.7, 53.9, 55.8, 65.2, 79.7, 84.6, 85.6, 
125.4, 127.5, 127.7, 127.8, 128.2, 129.1, 129.8, 134.3, 138.4, 140.5, 154. 
General procedure C. Synthesis of hydrochloride salts (7aa-7eh) 
To the solution of 6aa-6ch in methanol  (15ml)was added to conc. HCl (2 ml) and stirred for 1h. 
The solvent was evaporated under reduced pressure. To the crude product was added water 
(20ml) at 00C. The solid formed was filtered and dried under vaccum to get hydrochloride salt of 
compounds 7aa-7ch. 
3-(Benzyloxy)-3-phenylpyrrolidine hydrochloride (7aa, TAV-91) 
O
N
H
.HCl
 
General procedure C: This compound was obtained as a white solid (182 mg, 81%).  
1H NMR (400 MHz, CDCl3): 7.23-7.41 (m, 10H), 4.10-4.20 (m, 2H), 3.43 (d, J=12.0Hz, 1H), 
3.26-3.30 (m, 1H), 3.10 (s, 1H), 2.91-2.94 (m, 1H), 2.37-2.48 (m, 2H), 2.10-2.18 (m, 1H) 
13C NMR (100 MHz, CDCl3): 36.1, 46.2, 58.2, 65.8, 88.0, 127.5, 127.7, 128.5, 128.6, 128.8, 
133.6, 138.8, 140.1. 
Anal. Calcd for C17H20ClNO:  C, 70.46; H, 6.96; N, 4.83 Found: C, 69.80; H, 6.79; N, 4.87. 
3-(4-Fluorobenzyloxy)-3-phenylpyrrolidine hydrochloride (7ab, TAV-85) 
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O
N
H
F
.HCl
 
General procedure C: This compound was obtained as a white solid (190 mg, 88%).  
1H NMR (400 MHz, CDCl3): 7.33-7.39 (m, 5H), 7.17-7.20 (m, 2H), 6.96-7.00 (m, 2H), 4.05-
4.14 (m, 2H), 3.41 (dd, J=1.2Hz, 12.0Hz, 1H),3.26-3.29 (m, 1H), 3.09-3.11 (m, 1H), 2.91 (d, 
J=12.4Hz, 1H), 2.38-2.41 (m, 2H), 2.12-2.18 (m, 1H). 
13C NMR (100 MHz, CDCl3): 36.1, 46.1, 58.1, 65.1, 88.1, 115.3, 128.5, 128.9, 129.2, 129.3, 
133.7, 134.5, 140.0. 
Anal. Calcd for C17H19ClFNO. 1/4H2O:  C, 65.38; H, 6.12; N, 4.54 Found: C, 65.46; H, 6.23; N, 
4.62. 
3-(4-Methylbenzyloxy)-3-phenylpyrrolidine hydrochloride (7ac, TAV-103) 
O
N
H
.HCl
CH3
 
General procedure C: This compound was obtained as a white solid (186 mg, 85%).  
1H NMR (400 MHz, CDCl3): 7.33-7.40 (m, 5H), 7.12-7.25 (m, 4H), 4.05-4.15 (m, 2H), 3.41 (d, 
J=12.0Hz, 1H), 3.24-3.31 (m, 1H), 3.05-3.11 (m, 1H), 2.90 (d, J =12.4Hz, 1H), 2.35-2.42 (m, 
2H), 2.32 (s, 3H), 2.13-2.16 (m, 1H). 
13C NMR (100 MHz, CDCl3): 21.3, 36.1, 46.1, 58.1, 65.7, 87.9, 127.6, 128.5, 128.8, 129.3, 
133.6, 135.7, 137.4, 140.1. 
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Anal. Calcd for C18H22ClNO. 1/3H2O:  C, 69.79; H, 7.37; N, 4.52 Found: C, 69.43; H, 7.11; N, 
4.65. 
3-(3,4-Dichlorobenzyloxy)-3-phenylpyrrolidine hydrochloride (7ad, TAV-84) 
O
N
H
.HCl
Cl
Cl
 
General procedure C: This compound was obtained as a white solid (175mg, 80%).  
1H NMR (400 MHz, CDCl3): 7.33-7.35 (m, 6H), 7.03 (d, J=8.4Hz, 2H), 4.04-4.12 (m, 2H), 
3.43 (d, J=11.6Hz, 1H), 3.27 (brs, 1H), 2.97-3.12 (m, 2H), 2.35-2.38 (m, 1H), 2.13-2.19 (s, 1H). 
13C NMR (100 MHz, CDCl3): 35.9, 45.9, 57.7, 64.4, 88.2, 126.6, 128.4, 129.0, 129.2, 130.5, 
132.5, 133.6 134.0, 139.0, 139.4. 
Anal. Calcd for C17H18Cl3NO. 2H2O:  C, 56.92; H, 5.05; N, 3.90 Found: C, 51.72; H, 5.57; N, 
3.58. 
3-(2-Fluorobenzyloxy)-3-phenylpyrrolidine hydrochloride (7ae, TAV-130) 
O
N
H
.HCl
F
 
General procedure C: This compound was obtained as a white solid (190 mg, 89%).  
1H NMR (400 MHz, CDCl3): 7.35-7.39 (m, 4H), 7.10 (t, J=7.6Hz, 2H), 6.96-7.00 (t, J=9.2Hz, 
1H), 4.14-4.23 (m, 2H), 3.43-3.46 (d, J=12.4Hz, 1H), 3.24-3.31 (m, 1H), 3.05-3.11 (m, 1H), 
2.90-2.93 (d, J=12.0Hz, 1H), 2.37-2.43 (m, 2H), 2.10-2.17 (m, 1H). 
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13C NMR (100 MHz, CDCl3): 36.1, 46.1, 58.0, 59.7, 88.1, 115.3, 124.3, 128.5, 128.8, 129.4, 
129.9, 130.5, 133.7, 138.9 139.7. 
Anal. Calcd for C17H19ClFNO:  C, 66.34; H, 6.22; N, 4.55 Found: C, 66.05; H, 6.28; N, 4.72. 
3-(3,5-Difluorobenzyloxy)-3-phenylpyrrolidine hydrochloride (7af, TAV-104) 
O
N
H
.HCl
F
F
 
General procedure C: This compound was obtained as a white solid (182 mg, 79%).  
1H NMR (400 MHz, CDCl3): 7.32-7.39 (m, 4H), 7.21-7.25 (m, 1H), 7.10 (t, J=7.6Hz, 2H), 
6.96-7.00 (t, J=8.8Hz, 1H), 4.14-4.23 (m, 2H), 3.43-3.46 (d, J=12.4Hz, 1H), 3.24-3.31 (m, 1H), 
3.05-3.11 (m, 1H), 2.90-2.93 (d, J=12.0Hz, 1H), 2.37-2.43 (m, 2H), 2.10-2.17 (m, 1H). 
13C NMR (100 MHz, CDCl3): 36.1, 46.1, 58.0, 59.7, 88.1, 115.3, 124.3, 128.5, 128.8, 129.4, 
129.9, 133.7, 139.7. 
Anal. Calcd for C17H18ClF2NO:  C, 62.67; H, 5.57; N, 4.30 Found: C, 62.40; H, 5.53; N, 4.39. 
3-(4-Chlorobenzyloxy)-3-phenylpyrrolidine hydrochloride (7ag, TAV-87) 
O
N
H
.HCl
Cl
 
General procedure C: This compound was obtained as a white solid (174 mg, 78%).  
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1H NMR (400 MHz, CDCl3): 7.32-7.37 (m, 5H), 7.26 (d, J=8.4Hz, 2H), 7.15 (d, J=8.4Hz, 2H), 
4.05-4.15 (m, 2H),  3.41 (d, J=12.1Hz, 1H), 3.26-3.28 (m, 1H), 3.09 (brs, 1H), 2.91-2.93 (m, 
2H),  2.34-2.40 (m, 1H), 2.10-2.17 (m, 1H). 
13C NMR (100 MHz, CDCl3): 36.1, 46.1, 58.1, 65.0, 128.4, 128.7, 128.8, 128.9, 133.4, 133.8, 
137.3, 139.8. 
Anal. Calcd for C17H19Cl2NO. 3/4H2O:  C, 62.97; H, 5.91; N, 4.32 Found: C, 62.68; H, 6.00; N, 
4.37. 
3-(3-Chlorobenzyloxy)-3-phenylpyrrolidine hydrochloride (7ah, TAV-132) 
O
N
H
.HCl
Cl
 
General procedure C: This compound was obtained as a white solid (188mg, 83%).  
1H NMR (400 MHz, CDCl3): 7.35-7.39 (m, 5H), 7.25-7.27 (m, 2H), 7.20 (t, J=8.4Hz, 2H), 
4.05-4.15 (m, 2H), 3.42 (d, J=12.4Hz, 2H), 3.27 (m, 1H), 2.91-2.93 (m, 2H), 2.38-2.40 (m, 1H), 
2.10-2.17 (m, 1H). 
13C NMR (100 MHz, CDCl3): 36.1, 46.1, 58.1, 65.0, 88.1, 115.3, 128.4, 128.7, 128.8, 128.9, 
131.2, 133.4, 133.8, 137.3, 139.7. 
Anal. Calcd for C17H19Cl2NO:  C, 60.45; H, 6.12; N, 4.15 Found: C, 60.15; H, 5.38; N, 4.63. 
3-(Benzyloxy)-3-(4-fluorophenyl)-pyrrolidine hydrochloride (7ba, TAV-94) 
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O
N
H
.HCl
F
 
General procedure C: This compound was obtained as a white solid (180 mg, 83%).  
1H NMR (400 MHz, CDCl3): 7.23-7.41 (m, 5H), 7.17-7.20 (m, 2H), 6.96-7.00 (m, 2H), 4.10-
4.20 (m, 2H), 3.43 (d, J=12.0Hz, 1H), 3.26-3.30 (m, 1H), 3.10 (s, 1H), 2.91-2.94 (m, 1H), 2.37-
2.48 (m, 2H), 2.10-2.18 (m, 1H) 
13C NMR (100 MHz, CDCl3): 36.1, 46.2, 58.2, 65.8, 88.0, 127.5, 127.7, 128.5, 128.6, 128.8, 
133.6, 138.8, 140.1. 
Anal. Calcd for C17H19ClFNO. 3/4H2O:  C, 63.55; H, 6.43; N, 4.36 Found: C, 63.70; H, 6.37; N, 
4.66. 
3-(4-Fluorobenzyloxy)-3-(4-fluorophenyl)-pyrrolidine hydrochloride (7bb, TAV-100) 
O
N
H
F
.HCl
F
 
General procedure C: This compound was obtained as a white solid (176 mg, 80%).  
1H NMR (400 MHz, CDCl3): 7.33-7.39 (m, 4H), 7.20-7.24 (m, 2H), 6.96-7.00 (m, 2H), 4.05-
4.14 (m, 2H), 3.41 (dd, J=1.2Hz, 11.6Hz, 1H),3.26-3.29 (m, 1H), 3.09-3.11 (m, 1H), 2.91 (d, 
J=12.4Hz, 1H), 2.38-2.41 (m, 2H), 2.12-2.18 (m, 1H). 
13C NMR (100 MHz, CDCl3): 36.1, 46.1, 58.1, 65.1, 88.1, 115.3, 128.5, 128.9, 129.2, 129.3, 
133.7, 134.5, 140.0. 
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Anal. Calcd for C17H18ClF2 NO. 1/2H2O:  C, 60.99; H, 5.72; N, 4.18 Found: C, 61.11; H, 5.55; 
N, 4.34. 
3-(4-Methylbenzyloxy)-3-(4-fluorophenyl)-pyrrolidine hydrochloride (7bc, TAV-108) 
O
N
H
.HCl
CH3
F
 
General procedure C: This compound was obtained as a white solid (195 mg, 90%).  
1H NMR (400 MHz, CDCl3): 7.33-7.40 (m, 4H), 7.09-7.29 (m, 4H), 4.05-4.15 (m, 2H), 3.41 (d, 
J=12.0Hz, 1H), 3.24-3.31 (m, 1H), 3.05-3.11 (m, 1H), 2.90 (d, J =12.4Hz, 1H), 2.35-2.42 (m, 
2H), 2.32 (s, 3H), 2.13-2.16 (m, 1H). 
13C NMR (100 MHz, CDCl3): 21.3, 36.1, 46.1, 58.1, 65.7, 87.9, 127.6, 128.5, 128.8, 129.3, 
133.6, 135.7, 137.4, 140.1. 
Anal. Calcd for C17H21ClFNO.2/3H2O:  C, 64.79; H, 6.74; N, 4.20 Found: C, 64.48; H, 6.44; N, 
4.45. 
3-(3,4-Dichlorobenzyloxy)-3-(4-fluorophenyl)-pyrrolidine hydrochloride (7bd, TAV-106) 
O
N
H
.HCl
F
Cl
Cl
 
General procedure C: This compound was obtained as a white solid (185 mg, 81%).  
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1H NMR (400 MHz, CDCl3): 7.33-7.35 (m, 2H), 7.25-7.27 (m, 2H), 7.20 (t, J=8.4Hz, 2H), 7.03 
(d, J=8.4Hz, 1H), 4.04-4.12 (m, 2H), 3.43 (d, J=11.6Hz, 1H), 3.27 (brs, 1H), 2.97-3.12 (m, 2H), 
2.35-2.38 (m, 1H), 2.13-2.19 (s, 1H). 
13C NMR (100 MHz, CDCl3): 35.9, 45.9, 57.7, 64.4, 88.2, 126.6, 128.4, 129.0, 129.2, 130.5, 
132.5, 133.6 134.0, 139.0, 139.4. 
Anal. Calcd for C17H17Cl3FNO:  C, 54.21; H, 4.55; N, 3.72 Found: C, 53.95; H, 4.44; N, 3.71. 
3-(Benzyloxy)-3-(4-chlorophenyl)-pyrrolidine hydrochloride (7ca, TAV-114) 
O
N
H
.HCl
Cl
 
General procedure C: This compound was obtained as a white solid (172 mg, 79%).  
1H NMR (400 MHz, CDCl3): 7.23-7.41 (m, 9H), 4.10-4.20 (m, 2H), 3.43 (d, J=12.0Hz, 1H), 
3.26-3.30 (m, 1H), 3.10 (s, 1H), 2.91-2.94 (m, 1H), 2.37-2.48 (m, 2H), 2.10-2.18 (m, 1H) 
13C NMR (100 MHz, CDCl3): 36.1, 46.2, 58.2, 65.8, 88.0, 127.5, 127.7, 128.5, 128.6, 128.8, 
133.6, 138.8, 140.1 
Anal. Calcd for C17H19Cl2NO:  C, 62.97; H, 5.91; N, 4.32 Found: C, 62.72; H, 5.74; N, 4.27. 
3-(4-Fluorobenzyloxy)-3-(4-chlorophenyl)-pyrrolidine hydrochloride (7cb, TAV-124) 
O
N
H
Cl
F
.HCl
 
General procedure C: This compound was obtained as a white solid (190 mg, 87%).  
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1H NMR (400 MHz, CDCl3): 7.33-7.39 (m, 4H), 7.17-7.20 (m, 2H), 6.96-7.00 (m, 2H), 4.05-
4.14 (m, 2H), 3.41 (dd, J=1.2Hz, 12.0Hz, 1H),3.26-3.29 (m, 1H), 3.09-3.11 (m, 1H), 2.91 (d, 
J=12.4Hz, 1H), 2.38-2.41 (m, 2H), 2.12-2.18 (m, 1H). 
13C NMR (100 MHz, CDCl3): 36.1, 46.1, 58.1, 65.1, 88.1, 115.3, 128.5, 128.9, 129.2, 129.3, 
133.7, 134.5, 140.0. 
Anal. Calcd for C17H18Cl2FNO:  C, 59.66; H, 5.30; N, 4.09 Found: C, 59.38; H, 5.40; N, 4.06. 
3-(4-Methylbenzyloxy)-3-(4-chlorophenyl)-pyrrolidine hydrochloride (7cc, TAV-122) 
O
N
H
.HCl
Cl
CH3
 
General procedure C: This compound was obtained as a white solid (198 mg, 91%).  
1H NMR (400 MHz, CDCl3): 7.33-7.40 (m, 4H), 7.12-7.25 (m, 4H), 4.05-4.15 (m, 2H), 3.41 (d, 
J=12.0Hz, 1H), 3.24-3.31 (m, 1H), 3.05-3.11 (m, 1H), 2.90 (d, J =12.4Hz, 1H), 2.35-2.42 (m, 
2H), 2.32 (s, 3H), 2.13-2.16 (m, 1H). 
13C NMR (100 MHz, CDCl3): 21.3, 36.1, 46.1, 58.1, 65.7, 87.9, 127.6, 128.5, 128.8, 129.3, 
133.6, 135.7, 137.4, 140.1. 
Anal. Calcd for C18H21Cl2NO. H2O:  C, 60.88; H, 6.51; N, 3.93 Found: C, 59.58; H, 6.26; N, 
3.97. 
3-(3,4-Dichlorobenzyloxy)-3-(4-chlorophenyl)-pyrrolidine hydrochloride (7cd, TAV-120) 
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O
N
H
.HCl
Cl
Cl
Cl
 
General procedure C: This compound was obtained as a white solid (184mg, 81%).  
1H NMR (400 MHz, CDCl3): 7.33-7.35 (m, 6H), 7.03 (d, J=8.4Hz, 1H), 4.04-4.12 (m, 2H), 
3.43 (d, J=11.6Hz, 1H), 3.27 (brs, 1H), 2.97-3.12 (m, 2H), 2.35-2.38 (m, 1H), 2.13-2.19 (s, 1H). 
13C NMR (100 MHz, CDCl3): 35.9, 45.9, 57.7, 64.4, 88.2, 126.6, 128.4, 129.0, 129.2, 130.5, 
132.5, 133.6 134.0, 139.0, 139.4. 
Anal. Calcd for C17H17Cl4NO. 1/4H2O:  C, 51.35; H, 4.44; N, 3.52 Found: C, 51.68; H, 4.40; N, 
3.53. 
3-(3,5-Difluorobenzyloxy)-3-(4-chlorophenyl)-pyrrolidine hydrochloride (7cf, TAV-126) 
O
N
H
.HCl
Cl F
F
 
General procedure C: This compound was obtained as a white solid (188 mg, 84%).  
1H NMR (400 MHz, CDCl3): 7.32-7.39 (m, 4H), 7.21-7.25 (m, 1H), 7.10 (t, J=7.6Hz, 1H), 
6.96-7.00 (t, J=8.8Hz, 1H), 4.14-4.23 (m, 2H), 3.43-3.46 (d, J=12.4Hz, 1H), 3.24-3.31 (m, 1H), 
3.05-3.11 (m, 1H), 2.90-2.93 (d, J=12.0Hz, 1H), 2.37-2.43 (m, 2H), 2.10-2.17 (m, 1H). 
13C NMR (100 MHz, CDCl3): 36.1, 46.1, 58.0, 59.7, 88.1, 115.3, 124.3, 128.5, 128.8, 129.4, 
129.9, 133.7, 139.7. 
Anal. Calcd for C17H17Cl2F2NO:  C, 56.68; H,4.76; N, 3.89 Found: C, 56.38; H, 4.81; N, 3.89. 
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3-(4-Chlorobenzyloxy)-3-(4-chlorophenyl)-pyrrolidine hydrochloride (7cg, TAV-116) 
O
N
H
.HCl
Cl
Cl
 
General procedure C: This compound was obtained as a white solid (175 mg, 79%).  
1H NMR (400 MHz, CDCl3): 7.32-7.37 (m, 4H), 7.26 (d, J=8.4Hz, 2H), 7.15 (d, J=8.4Hz, 2H), 
4.05-4.15 (m, 2H),  3.41 (d, J=12.1Hz, 1H), 3.26-3.28 (m, 1H), 3.09 (brs, 1H), 2.91-2.93 (m, 
2H),  2.34-2.40 (m, 1H), 2.10-2.17 (m, 1H). 
13C NMR (100 MHz, CDCl3): 36.1, 46.1, 58.1, 65.0, 128.4, 128.7, 128.8, 128.9, 133.4, 133.8, 
137.3, 139.8. 
Anal. Calcd for C17H18Cl3NO:  C, 56.92; H, 5.05; N, 3.90 Found: C, 56.88; H, 5.21; N, 3.92. 
3-(3-Chlorobenzyloxy)-3-(4-chlorophenyl)-pyrrolidine hydrochloride (7ch, TAV-136) 
O
N
H
.HCl
Cl Cl
 
General procedure C: This compound was obtained as a white solid (190 mg, 87%).  
1H NMR (400 MHz, CDCl3): 7.32-7.37 (m, 4H), 7.25-7.27 (m, 2H), 7.15 (t, J=8.4Hz, 2H), 
4.05-4.15 (m, 2H), 3.42 (d, J=12.4Hz, 2H), 3.27 (m, 1H), 2.91-2.93 (m, 2H), 2.38-2.40 (m, 1H), 
2.10-2.17 (m, 1H). 
13C NMR (100 MHz, CDCl3): 36.1, 46.1, 58.1, 65.0, 88.1, 115.3, 128.4, 128.7, 128.8, 128.9, 
131.2, 133.4, 133.8, 137.3, 139.7. 
Anal. Calcd for C17H18Cl3NO:  C, 56.92; H, 5.06; N, 3.90 Found: C, 56.62; H, 5.09; N, 3.93. 
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Chapter 3. Application of Iridium catalyzed N-heterocyclization for 
synthesis of Natural products. 
3.1. Abstract 
The focus of these studies has been toward the development of new synthetic methods and 
procedures for the synthesis of novel compounds with unique biological properties. This research 
has led to the development of new synthetic strategy for the construction of pyridine alkaloids 
such as Nicotine and Anabasine. The developed method utilizes microwave condition and water 
as solvent for the reaction. The protocol is efficient, facile and short as compare to the previous 
methods reported for synthesis for these compounds. The key step involves the aqueous 
microwave-assisted, iridium-catalyzed N-heterocyclization reaction of pyridinylbutane-1, 4-diols 
and pyridinylpentane- 1, 5-diols with various amines. The microwave-assisted N-
heterocyclization furnishes derivatives of nicotine and anabasine in good yields (50–75%) with 
overall yields ranging from 30–50%. 
3.2. Introduction 
Our group has been working on iridium catalyzed N-alkylation reaction of amines with alcohols 
over last 5 years. We have been utilizing iridium catalyzed methods for the total synthesis of 
medicinally important natural products. 
In recent years many transition metals have been used for synthesis of substituted amines such as 
hydroamination of alkenes or alkynes, and amination of aryl halides have been developed. The 
traditional method of synthesis of substituted amines includes N-alkylation of amines with alkyl 
halides and reductive amination using carbonyl compounds. However, these conventional 
reaction conditions have some disadvantages from environmental point of view because they 
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generate equimolar amounts of wasteful salts as co-products. Moreover, the reaction with alkyl 
halides and reducing agent is undesirable. Similarly, the N-heterocyclization of amines has been 
performed for synthesis of nitrogen heterocycles such as pyrrolidine, piperidine, and morpholine 
using hydroamination and ring closing metathesis which requires drastic reaction conditions and 
generates harmful byproduct at the end of reaction.  
3.3. Pyridine alkaloids 
Nicotine and anabasine are pyridine alkloids commonly found in the solanaceae plant family 
such as Nicotina tabacum and Nicotina rustica.1 Nicotine alkloids modulate neuronal acetyl 
chlorine receptors, which affect the central nervous system (Figure 3.1).2 
N
N
 
Nicotine
 
(1)
N
N
Anabasine
 
(2)
N
N
 
Benzo-fused
 nicotine
 
(3)
N
N
SIB-1508Y
 
(4)  
Figure 3.1. Pyridine alkloids- Nicotine derivatives 
The pharmacological action of nicotine alkloids and related derivatives on the central nervous 
system has attracted considerable attention as potential therapeutic targets for the variety of 
disease states and pathological conditions mediated by nicotinic acetylcholine receptors.2-5 
However, toxicity and abuse potential has limited the use of nicotine related drugs for central 
nervous system disorders.2  Therefore, new analogues of nicotine with unique nicotinic 
acetylcholine receptor subtype selectivity remain important pharmacological targets for the 
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development of novel therapeutics with improved safety profiles. Nicotine has also been used for 
synthesis of Altinicline (SIB-1508Y), a preclinical drug candidate for Parkinson’s disease. 
Benzo-fused nicotine derivative has found to shown similar binding affinity as nicotine. To this 
end, considerable effort has been focused on the development of new synthetic methods for the 
construction nicotine derivatives.6-8 Although a variety of methods have been reported; there is 
still a need for versatile and practical methods for the synthesis of nicotine-related derivatives. 
In the past, we have described the application of the iridium catalyzed N-heterocyclization 
reaction for the synthesis of nicotine related compounds, and the first total synthesis of the 
alkloid, Noranabasamine.9, 10 Further studies by Zhao and co-workers showed that N-
heterocyclization of simple amine/alcohol systems proceeded under solvent free, base-free 
microwave-assisted conditions.11 Based on the past findings, it was of interest to explore the 
further application of these conditions for the green synthesis of nicotine and anabasine-related 
analogues. 
3.4. Application of iridium catalysis 
N-Alkylation or N-heterocyclization of amines with alcohols or diols has been attracted 
considerable attention because the product of the reaction can be obtained from easily available 
starting materials in one step without generation of any harmful by products (Scheme 3.1).12 
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Scheme 3.1.  N-alkylation of primary amines with primary alcohol in the presence of Iridium 
catalyst 
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Alcohols or diols are more readily available than corresponding halides or carbonyl compounds 
in many cases. The reaction also works efficiently by the employment of equimolar amounts of 
starting materials, generating high atom economical system. Although, variety of catalytic 
system for N-alkylation or N-heterocyclizaton have been utilized using ruthenium and other 
transition metal catalysts but the requirement of high temperature and excess of use of alcohols 
or diols preclude use of these catalyst system for practical synthesis of  nitrogen heterocycles and 
N-substituted amines.  
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Scheme 3.2. N-heterocyclization of amines with alcohols using iridium catalyst12 
Fujita and co-workers reported the use of (pentamethylcyclopentadienyl) iridium dichloride 
dimer ([Cp*IrCl2]) 2 for N-alkylation of amines with alcohols and N-heterocyclization of amines 
with diols by primary amines (Scheme 3.2).12 The method works by hydrogen borrowing 
concept, which involves catalytic transfer of hydrogen from alcohol to form in-situ aldehydes or 
ketones. A possible mechanism for the Cp* Ir-catalyzed N-heterocyclization of primary amines 
with primary and secondary alcohols is shown in Figure 3.2. 
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Figure 3.2.  Mechanism of iridium catalysis 
3.5. Results and discussion 
We utilized approach using methodology already developed in our laboratory for the synthesis of 
1-(3-pyridinyl) diols. 3-bromopyridine or 5-bromo-2-methoxypyridine was treated with n-
butyllithium at -78oC in diethyl ether. Butyrolactone or valerolactone was then added to the 
resulting lithiated pyridine derivatives to afford the corresponding hydroxyl ketones in high 
yields. Further, subsequent reduction with sodium borohydride in methanol afforded the required 
intermediate diols in good to excellent yields (Scheme 3.3).13 
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Scheme 3.3. Synthesis of 1,4 and 1,5- pyridine diols. 
Similarly, 3-bromoquninoline and butyrolactone was used for synthesis of 3-quinoline-1, 4-diol 
using a two  step synthesis procedure (Scheme 3.4).13 
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Scheme 3.4. Synthesis of quinoline butan-1, 4-diol 
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Initially, we decided to explore and optimize the reaction conditions for the synthesis of N-
benzylnornicotine. The reaction of the diol and benzyl amine was performed under reflux and 
microwave assisted conditions. When the reaction was performed in the absence of a base and 
solvent compound was formed in low yields. Even using a base and toluene as the solvent did 
not improve substantially the yields of product. The highly polar nature and poor solubility of the 
diols in toluene encouraged us to explore the use of water as solvent for this transformation. It 
was found that reaction yield was considerably improved when water was used as the solvent 
under reflux conditions (Scheme 3.5, Table 3.1). 
N
OH
OH
N
N
NH2
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*IrCl2]2
Base,
  
Solvent
8a 9a  
Scheme 3.5. Development of method for synthesis of N-benzyl nor-nicotine derivatives. 
Entry Solvent Base Conditions Yields (%) 
1 - - Reflux, 17h 10 
2 - - Microwave, 2h 15 
3 Toluene NaHCO3 Reflux, 17h 10 
4 Toluene NaHCO3 Microwave, 2h 20 
5 H2O NaHCO3 Reflux, 17h 50 
6 H2O NaHCO3 Microwave, 2h 60 
7 H2O NaOAc Microwave, 2h 65 
8 H2O Na2CO3 Microwave, 2h 75 
9 H2O K2CO3 Microwave, 2h 35 
Table. 3.1. Optimization of the N-Heterocyclization Reaction. 
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Further, optimization was base showed that sodium carbonate was superior base than sodium 
bicarbonate, sodium acetate and potassium carbonate. And let to an optimized yield of 75%.13 
To check scope and limitations of the developed method, we performed N-heterocyclization of 
1,4-butandiols and 1, 5-pentandiols under optimized aqueous conditions to prepare series of 
nicotine and anabasine derivatives (Table 3.2, Scheme 3.6).13 
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Scheme 3.6. Synthesis of N-substituted nor-nicotine derivatives 
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Table 3.2. Synthesis of nor-nicotine derivatives, *Yields of isolated product 
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To check scope and limitations of the developed method, we performed N-heterocyclization of 1, 
4-butandiols and 1, 5-pentandiols under optimized aqueous conditions to prepare series of 
nicotine and anabasine derivatives. As provided in Table 3.2, the reaction of 1, 4-butandiols with 
methylamine gave a modest yield of nicotine. The lower than expected yield is believed to be 
due to the high volatililty of methylamine in water at elevated temperatures of the microwave 
conditions. The reaction of benzyl amine and 4-methoxy amine with 1, 4-diol and 1, 5-diol 
provided good yields of the corresponding cyclization products.  
We also synthesized quinoline derivative in good yields using developed N-heterocyclization 
method from it corresponding diol (Figure 3.3).  
N
N
 
10h 
Figure 3.3. Quinoline analogue of Benzyl-nornicotine13 
Further, to demonstrate utility of this approach, we performed transformation of one of the 
benzyl nor-nicotine derivative to its debenzylated analogue. The hydrogenolysis was performed 
using palladium on carbon at 55oC afforded in 75% yield (Scheme 3.7).13 
NO
N
H2
 
(1
 atm)
Pd/C,
 
CH3OH
, 2h NO
N
H
75%
10c 11  
Scheme 3.7. Synthesis of Nicotine from its N-benzyl derivative 
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3.6 Conclusion 
 
To conclude this chapter, we have devised an efficient three step methodology for the synthesis 
of nicotine and anabasine derivatives from readily available starting materials. The key step 
involves the aqueous microwave assisted, iridium-catalyzed N-heterocyclization reaction of 1, 4-
diols and 1, 5-diols with various amines. 
3.7. Experimental 
 
All chemicals were purchased from Aldrich Chemical Company and used as received unless 
otherwise noted. Microwave-assisted N-heterocyclization reactions were carried out using a 
StartSYNTH  multicavity  instrument with start rotor from Milestone. The maximum microwave 
power was 1200 W and the reaction temperature was monitored by an internal infrared sensor. 
All the reactions were performed in glass reactor tubes with a maximum working pressure of 15 
bars and maximum temperature of 230 °C. Thin-layer chromatography (TLC) was performed on 
silica gel plates (250 mm) purchased from Sorbent Technologies. Compounds were made visual 
with UV light, iodine or phosphomolybdic acid. Chromatography was accomplished with silica 
gel 60 Å (230–400 mesh) purchased from Sorbent Technologies. 1H NMR (400 MHz) and 13C 
NMR (100 MHz) spectra were recorded on a Varian 400 MHz NMR spectrometer at ambient 
temperature in CDCl3. 1H NMR chemical shifts are reported as δ values (ppm) relative to 
tetramethylsilane. 13C NMR chemical shifts are reported as δ values (ppm) relative to CDCl3 
(77.0 ppm). Atlantic Microlab, Inc., Norcross, GA performed all CHN microanalyses. 
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Hydroxy Ketones: General Procedure 
Under an N2 atm, bromopyridine (5b) (1 equiv) was added to anhyd Et2O (20 mL) and cooled to 
–78 °C. A soln of n-BuLi (2.5 M in hexane, 1.2 equiv) was added dropwise, and the mixture was 
stirred for 15 min. A solution of gamma-butyrolactone (6a) or delta-valerolactone (6b) (1.1 
equiv) in Et2O (5 mL) was added and the mixture was stirred for 2 h. The mixture was allowed to 
warm to R.T. and brine (20 mL) was added. The mixture was extracted with Et2O (3 × 20 mL) 
and the combined organic layers dried over Na2SO4, filtered and concentrated under reduced 
pressure. The residue was purified by flash chromatography (CH2Cl2–MeOH, 92:8) to afford the 
hydroxy ketones as oils. 
4-Hydroxy-1-(pyridine-3-yl) butan-1-one (7a) 
O
N O
H
 
The title product was prepared from 3-bromopyridine (5b) (2 g, 12.5 mmol), gamma-
butyrolactone (6a) (1.2 g, 13.9 mmol) and n-BuLi (6 mL, 15 mmol, 2.5 M in hexane) in anhyd 
Et2O (30 mL). Purification by flash chromatography afforded the product as yellow oil; Yield: 
1.4 g (65%). The spectroscopic data were consistent with those reported previously for this 
compound.10 
1H NMR (400 MHz, CDCl3): δ = 9.03 (s, 1 H), 8.61 (d, J = 3.6 Hz, 1 H), 8.14 (d, J = 8.0 Hz, 1 
H), 7.34–7.30 (m, 1 H), 3.91 (br s, 1 H), 3.63 (t, J = 6.0 Hz, 2 H), 3.04 (t, J = 7.2 Hz, 2 H), 1.92–
1.89 (m, 2H). 
13C NMR (100 MHz, CDCl3): δ = 199.3, 153.3, 149.5, 135.8, 132.4, 124.0, 61.5, 35.6, 26.8. 
4-Hydroxy-1-(6-methoxypyridin-3-yl) butan-1-one (7b) 
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O
N
O
OH
 
The title product was prepared from 5-bromo-2-methoxypyridine (5a) (2g, 10.6 mmol), gamma-
butyrolactone (6a) (1g, 11.7 mmol) and n- BuLi (5.1 mL, 12.7 mmol, 2.5 M in hexane) in anhyd 
Et2O (30 mL). Purification by flash chromatography afforded the product as yellow oil; yield: 
1.5 g (70%). The spectroscopic data were consistent with those reported previously for this 
compound.10 
1H NMR (400 MHz, CDCl3): δ = 8.80 (d, J = 2.4 Hz, 1 H), 8.13 (dd, J = 8.8, 2.4 Hz, 1 H), 6.77 
(d, J = 8.8 Hz, 1 H), 3.99 (s, 3 H), 3.74– 3.73 (m, 2 H), 3.07 (t, J = 7.2 Hz, 2 H), 2.02–1.97 (m, 2 
H).  
13C NMR (100 MHz, CDCl3): δ = 198.4, 166.4, 149.1, 138.3, 126.7, 111.1, 61.7, 54.1, 35.0, 
27.0. 
5-Hydroxy-1-(pyridin-3-yl) pentan-1-one (7c) 
O
N OH
 
The title product was prepared from 3-bromopyridine (5b) (2g, 12.5 mmol), delta-valerolactone 
(6b) (1.4 g, 13.9 mmol) and n-BuLi (6 mL, 15 mmol, 2.5 M in hexane) in anhyd Et2O (30 mL). 
Purification by flash chromatography afforded the product as yellow oil; yield: 1.7 g (65%). The 
spectroscopic data were consistent with those reported previously for this compound.10 
1H NMR (400 MHz, CDCl3): δ = 9.14 (d, J = 4.0 Hz, 1 H), 8.73 (dd, J = 8.0, 4.0 Hz, 1 H), 8.22 
(dd, J = 8.0, 4.0 Hz, 1 H), 7.41–7.39 (m, 1 H), 3.67 (t, J = 4.8 Hz, 2 H), 3.05–3.01 (m, 2 H), 
1.87–1.82 (m, 2 H), 1.67–1.63 (m, 2 H).  
119 
 
13C NMR (100 MHz, CDCl3): δ = 199.2, 153.2, 149.4, 135.7, 132.3, 123.9, 61.9, 38.6, 32.1, 
20.3. 
Diols 6a, b and 7; General Procedure 
Powdered NaBH4 (1.5 equiv) was added to a well stirred soln of hydroxy ketone 7a, 7b or 7c (1 
equiv) in anhyd MeOH at 0 °C. After 2 h, NaHCO3 was added to the reaction mixture and the 
solvent was removed under reduced pressure. The residue was purified by flash chromatography 
to afford the diols 8a, 8b or 8c as viscous oils. 
1-(Pyridin-3-yl) butane-1, 4-diol (8a) 
OH
N O
H
 
The title product was prepared from (7a) (1g, 6.0 mmol) and NaBH4 (0.34 g, 9 mmol) in anhyd 
MeOH (20 mL). Purification by flash chromatography (CH2Cl2–MeOH, 92:8) afforded colorless 
oil; yield: 0.96 g (95%). The spectroscopic data were consistent with those reported previously 
for this compound.14 
 1H NMR (400 MHz, CDCl3): δ = 8.47 (d, J = 4.0 Hz, 1 H), 8.38 (dd, J = 8.0, 4.0 Hz, 1 H), 7.72 
(d, J = 8.0 Hz, 1 H), 7.24 (dd, J = 8.0, 4.0 Hz, 1 H), 4.95 (brs, 1 H), 4.73 (t, J = 6.4 Hz, 1 H), 
3.69 (br s, 1 H), 3.68–3.64 (m, 2 H), 1.87–1.82 (m, 2 H), 1.68–1.62 (m, 2 H).  
13C NMR (100 MHz, CDCl3): δ = 148.3, 147.6, 140.8, 134.2, 123.8, 71.8, 62.6, 36.7, 29.1 
1-(6-Methoxypyridin-3-yl) butane-1, 4-diol (8b) 
OH
N
O
OH
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The title product was prepared from (7b) (1g, 5.2 mmol) and NaBH4 (0.30 g, 7.77 mmol) in 
anhyd MeOH (20 mL). Purification by flash chromatography afforded colorless oil; yield: 0.9 g 
(90%). 
1H NMR (400 MHz, CDCl3): δ = 7.89 (s, 1 H), 7.46 (d, J = 0.8 Hz, 1 H), 6.59 (d, J = 8.4 Hz, 1 
H), 5.06 (br s, 1 H), 4.48 (t, J = 6.4 Hz, 1 H), 4.43 (br s, 1 H), 3.76 (s, 3 H), 3.47–3.43 (m, 2 H), 
1.70–1.61 (m, 2 H), 1.52–1.43 (m, 2 H). 
 13C NMR (100 MHz, CDCl3): δ = 163.7, 144.5, 137.1, 133.3, 110.8, 71.4, 62.2, 53.7, 36.0, 
29.0.  
Anal. Calcd for C10H15NO3: C, 60.90; H, 7.67; N, 7.10. Found: C, 60.75; H, 7.55; N, 6.99. 
1-(pyridine-3-yl) pentane-1, 5-diol (8c) 
OH
N OH
 
The title product was prepared from (7c) (1g, 5.2 mmol) and NaBH4 (0.3g, 7.8 mmol) in anhyd 
MeOH (20 mL). Purification by flash chromatography afforded colorless oil; yield: 0.9g (95%). 
1H NMR (400 MHz, CDCl3): δ = 8.44 (d, J = 1.6 Hz, 1 H), 8.38 (dd, J = 6.4, 1.2 Hz, 1 H), 
7.70–7.69 (m, 1 H), 7.26–7.23 (m, 1 H), 4.68 (t, J = 5.6 Hz, 1 H), 3.58 (t, J = 6.4 Hz, 2 H), 1.82–
1.70 (m, 2 H), 1.71–1.65 (m, 2 H), 1.45–1.36 (m, 2 H).  
13C NMR (100 MHz, CDCl3): δ = 148.3, 147.6, 141.0, 134.27, 123.8, 71.8, 62.6, 38.8, 32.4, 
22.1. 
Anal. Calcd for C10H15NO2: C, 66.27; H, 8.34; N, 7.73. Found: C, 66.22; H, 8.45; N, 7.67. 
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1-(Quinolin-3-yl) butane-1, 4-diol (8d) 
OH
N O
H
 
Under an N2 atm, 3-bromoquinoline (5c) (2.0 g, 9.6 mmol) was added to anhydrous Et2O (30 
mL) and the resulting soln cooled to –78 °C. A solution of n-BuLi (4.6 mL, 11.4 mmol, 2.5 M in 
hexane) was added dropwise and the mixture stirred for 15 min. A solution of gamma-
butyrolactone (6a) (0.95 g, 10.5 mmol) in Et2O (5 mL) was added and the mixture was stirred for 
2 h. The mixture was allowed to warm to RT and brine (20 mL) was added. The mixture was 
extracted with Et2O (3 × 20 mL) and the combined organic layers were dried over Na2SO4, 
filtered and concentrated under reduced pressure to furnish ketone (7d) as light yellow oil. The 
crude ketone 8 was dissolved in anhydrous MeOH (20 mL) and cooled to 0 °C. Powdered 
NaBH4 (0.52 g, 14.22 mmol) was added in one portion and the mixture was stirred for 2 h. 
Purification by flash chromatography (10% MeOH– CH2Cl2) afforded as yellow oil; overall 
yield over two steps: 1.1g (50%). 
1H NMR (400 MHz, CDCl3): δ = 8.77 (d, J = 2.0 Hz, 1 H), 8.06 (s, 1 H), 7.98 (d, J = 8.4 Hz, 1 
H), 7.70 (d, J = 8.0 Hz, 1 H), 7.63–7.57 (m, 1 H), 7.46 (t, J = 8.0 Hz, 1 H), 4.87 (t, J = 6.0 Hz, 1 
H), 3.69– 3.60 (m, 3 H), 1.92–1.87 (m, 2 H), 1.71–1.01 (m, 2 H).  
13C NMR (100 MHz, CDCl3): δ = 149.5, 147.2, 138.0, 133.1, 129.6, 128.7, 128.1, 127.1, 110.5, 
72.0, 62.5, 36.7, 29.2.  
Anal. Calcd for C13H15NO2: C, 71.87; H, 6.96; N, 6.45. Found: C, 71.59; H, 7.03; N, 6.11. 
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Microwave-Assisted N-Heterocyclization; General Procedure 
The diol (1 equiv) was added to a well stirred soln of [Cp*IrCl2]2 (5 mol%) and Na2CO3 (1.1 
equiv), in H2O (5 mL), in a microwave reactor tube under an N2 atm. The amine (1 equiv) was 
added to the soln and the mixture was irradiated at 110 °C for 2 h. The mixture was extracted 
with EtOAc (3 × 10 mL) and the combined organic layers were dried over Na2SO4, filtered and 
concentrated under reduced pressure. The residue was purified by flash chromatography (3% 
MeOH–CH2Cl2) to afford the cyclic amine. 
 
(±)-Nicotine (10a) 
N
N
 
The title product was prepared from 6a (100 mg, 0.6 mmol), [Cp*IrCl2]2 (12 mg, 0.015 mmol), 
Na2CO3 (1.3 mg, 0.015 mmol) and 40% aq. MeNH2 soln (9a) (0.050 mL, 0.6 mmol). 
Purification by flash chromatography afforded brown oil; yield: 48 mg (50%). The spectroscopic 
data were consistent with a commercial sample and those reported previously for this 
compound.15 
 1H NMR (400 MHz, CDCl3): δ = 8.52 (d, J = 2.0 Hz, 1 H), 8.49 (dd, J = 4.8, 1.6 Hz, 1 H), 7.69 
(d, J = 8.0 Hz, 1 H), 7.26 (t, J = 6.8 Hz, 1 H), 3.25 (t, J = 7.6 Hz, 1 H), 3.09 (t, J = 8.0 Hz, 1 H), 
2.35–2.29 (m, 1 H), 2.24–2.16 (m, 4 H), 2.00–1.74 (m, 3 H). 
 13C NMR (100 MHz, CDCl3): δ = 153.5, 149.7, 135.8, 124.0, 75.8, 61.9, 35.7, 29.9, 26.8. 
3-(1-Benzylpyrrolidin-2-yl) pyridine (10b) 
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N
N
 
The title product was prepared from 8a (100 mg, 0.6 mmol), [Cp*IrCl2]2 (12 mg, 0.015 mmol), 
Na2CO3 (1.3 mg, 0.015 mmol) and BnNH2 (64 mg, 0.60 mmol) (9b) in H2O (5 mL). Purification 
by Flash chromatography afforded colorless oil; yield: 105 mg, (75%). The spectroscopic data 
were consistent with those reported previously for this compound.16 
1H NMR (400 MHz, CDCl3): δ = 8.63 (s, 1 H), 8.48 (d, J = 3.6 Hz, 1 H), 7.83 (d, J = 8.0 Hz, 1 
H), 7.33–7.18 (m, 6 H), 3.81 (d, J = 13.2 Hz, 1 H), 3.44–3.40 (m, 1 H), 3.13–3.09 (m, 2 H), 
2.28–2.18 (m, 2 H), 1.89–1.68 (m, 3 H).  
13C NMR (100 MHz, CDCl3): δ = 149.9, 148.8, 135.2, 128.8, 128.7, 128.4, 127.2, 123.9, 67.2, 
58.3, 53.7, 35.5, 22.7. 
 
5-(1-Benzylpyrrolidin-2-yl)-2-methoxypyridine (10c) 
N O
N
 
The title product was prepared from (8b) (100 mg, 0.5 mmol), [Cp*IrCl2]2 (12 mg, 0.012 mmol), 
Na2CO3 (1.1 mg, 0.012 mmol) and BnNH2 (9b) (0.053 g, 0.5 mmol). Purification by flash 
chromatography afforded colorless oil; yield: 100 mg (78%). 
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1H NMR (400 MHz, CDCl3): δ = 8.15–8.14 (d, J = 2.4 Hz, 1 H), 7.75 (dd, J = 8.8, 2.4 Hz, 1 
H), 7.29–7.20 (m, 5 H), 6.76 (d, J = 8.8 Hz, 1 H), 3.94 (s, 3 H), 3.80 (d, J = 12.0 Hz, 1 H), 3.33–
3.31 (m, 1 H), 3.08–3.06 (m, 2 H), 2.19–2.14 (m, 2 H), 1.89–1.86 (m, 1 H), 1.80–1.69 (m, 2 H). 
13C NMR (100 MHz, CDCl3): δ = 163.9, 146.3, 139.7, 138.2, 132.0, 128.4, 127.0, 111.3, 66.6, 
58.1, 53.5, 35.1, 22.5.  
Anal. Calcd for C17H20N2O: C, 76.09; H, 7.51; N, 10.44. Found: C, 76.00; H, 7.73; N, 10.28. 
 
3-[1-(4-Methoxybenzyl) pyrrolidin-2-yl] pyridine (10d) 
N
N
O
 
The title product was prepared from (8a) (100 mg, 0.6 mmol), [Cp*IrCl2]2 (12 mg, 0.015 mmol), 
Na2CO3 (1.3 mg, 0.015 mmol) and 4-methoxybenzylamine (9c) (82 mg, 0.6 mmol). Purification 
by flash chromatography afforded colorless oil; yield: 110 mg (73%). 
The spectroscopic data were consistent with those reported previously for this compound.16 
1H NMR (400 MHz, CDCl3): δ = 8.63 (d, J = 1.6 Hz, 1 H), 8.49 (dd, J = 4.4, 1.6 Hz, 1 H), 7.81 
(d, J = 8.0 Hz, 1 H), 7.25 (dd, J = 8.0 Hz, 1 H), 7.25 (dd, J = 8.0, 4.4 Hz, 1 H), 7.14 (d, J = 8.0 
Hz, 2 H), 6.81 (d, J = 8.0 Hz, 2 H), 3.78 (s, 3 H), 3.73 (d, J = 12.8 Hz, 2 H), 3.38 (t, J = 8.0 Hz, 
1 H), 3.10–3.02 (m, 2 H), 2.64–2.19 (m, 2 H), 1.77–1.67 (m, 3 H). 
13C NMR (100 MHz, CDCl3): δ = 158.8, 149.8, 148.8, 139.7, 135.2, 129.6, 123.8, 114.0, 113.8, 
67.0, 57.6, 55.4, 53.5, 35.5, 22.7. 
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2-Methoxy-5–[1-(4-methoxybenzyl) pyrrolidin-2-yl] pyridine (10e) 
N
N
O
O
 
The title product was prepared from (8b) (100 mg, 0.5 mmol), [Cp*IrCl2]2 (12 mg, 0.012 mmol), 
Na2CO3 (1.1 mg, 0.012 mmol) and 4-methoxybenzylamine (9c) (69 mg, 0.5 mmol). Purification 
by flash chromatography afforded colorless oil; yield: 110 mg (75%).  
1H NMR (400 MHz, CDCl3): δ = 8.13 (d, J = 1.6 Hz, 1 H), 7.72 (dd, J = 8.0, 1.6 Hz, 1 H), 7.15 
(d, J = 8.0 Hz, 2 H), 6.82 (d, J = 8.0 Hz, 2 H), 6.76 (d, J = 8.4 Hz, 1 H), 3.93 (s, 3 H), 3.77 (s, 3 
H), 3.73 (d, J = 12.8 Hz, 1 H), 3.28 (t, J = 8.0 Hz, 1 H), 3.05 (t, J = 8.0 Hz, 1 H), 2.98 (d, J = 
12.8 Hz, 1 H), 2.22–2.10 (m, 2 H), 1.89–1.65 (m, 3 H).  
13C NMR (100 MHz, CDCl3): δ = 163.9, 158.7, 146.2, 138.2, 132.0, 131.7, 130.0, 113.7, 111.3, 
66.4, 57.3, 55.4, 53.6, 53.4, 35.1, 22.4. 
Anal. Calcd for C18H22N2O2: C, 72.46; H, 7.43; N, 9.39. Found: C, 72.40; H, 7.52; N, 9.11. 
 
3-(1-Benzylpiperidin-2-yl) pyridine (10f)17 
N
N
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The title product was prepared from (8c) (100 mg, 0.55 mmol), [Cp*IrCl2]2 (14 mg, 0.013 
mmol), Na2CO3 (1.2 mg, 0.013 mmol) and BnNH2 (5b) (55 mg, 0.55 mmol). Purification by 
flash chromatography afforded colorless oil; yield: 100 mg, (70%).  
1H NMR (400 MHz, CDCl3): δ = 8.65 (d, J = 1.6 Hz, 1 H), 8.48 (dd, J = 4.8, 1.6 Hz, 1 H), 7.83 
(d, J = 8.0 Hz, 1 H), 7.34–7.18 (m, 6 H), 3.70 (d, J = 13.6 Hz, 1 H), 3.16 (dd, J = 11.2, 2.8 Hz, 1 
H), 2.99 (d, J = 11.6 Hz, 1 H), 2.85 (d, J = 13.6 Hz, 1 H), 1.99–1.92 (m, 2 H), 1.81–1.75 (m, 2 
H), 1.65–1.42 (m, 2 H), 1.42–1.37 (m, 1 H).  
13C NMR (100 MHz, CDCl3): δ = 149.7, 148.9, 141.2, 139.5, 135.1, 128.8, 128.4, 127.1, 124.0, 
66.7, 60.3, 53.5, 37.2, 26.0, 25.2.  
Anal. Calcd for C17H20N2: C, 80.91; H, 7.99; N, 11.10. Found: C, 80.77; H, 8.21; N, 11.00. 
3-[1-(4-Methoxybenzyl) piperidin-2-yl) pyridine (12b) 
N
N
O
 
The title product was prepared from (8c) (100 mg, 0.55 mmol), [Cp*IrCl2]2 (14 mg, 0.013 
mmol), Na2CO3 (1.2 mg, 0.013 mmol) and 4-methoxybenzylamine (5c) (75 mg, 0.55 mmol). 
Purification by flash chromatography afforded colorless oil; yield: 129 mg (75%). 
 1H NMR (400 MHz, CDCl3): δ = 8.63 (s, 1 H), 8.48 (dd, J = 4.8, 1.6 Hz, 1 H), 7.80 (d, J = 7.6 
Hz, 1 H), 7.26–7.24 (m, 1 H), 7.12 (d, J = 8.4 Hz, 2 H), 6.81 (d, J = 8.4 Hz, 2 H), 3.78 (s, 3 H), 
3.61 (d, J = 13.6 Hz, 1 H), 3.15 (dd, J = 7.2, 2.4 Hz, 1 H), 2.98 (d, J = 11.6 Hz, 1 H), 2.79 (d, J = 
13.6 Hz, 1 H), 1.96 1.89 (m, 1 H), 1.80–1.72 (m, 2 H), 1.63–1.50 (m, 3 H), 1.41–1.30 (m, 1 H). 
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13C NMR (100 MHz, CDCl3): δ = 158.7, 149.7, 148.8, 141.3, 135.1, 131.3, 130.0, 123.9, 113.7, 
66.6, 59.3, 55.4, 53.3, 37.3, 26.0, 25.2. 
 Anal. Calcd for C18H22N2O: C, 76.56; H, 7.85; N, 9.92. Found: C, 76.50; H, 7.91; N, 9.78. 
3-(1-Benzylpyrrolidin-2-yl) quinoline (13) 
N
N
 
The title product was prepared from (8d) (100 mg, 0.5 mmol), [Cp*IrCl2]2 (12 mg, 0.012 mmol), 
Na2CO3 (1.1 mg, 0.012 mmol) and BnNH2 (5b) (53 mg, 0.5 mmol). Purification by flash 
chromatography afforded colorless oil; yield: 100 mg (78%). 
1H NMR (400 MHz, CDCl3): δ = 9.05 (s, 1 H), 8.17 (s, 1 H), 8.12 (d, J = 8.8 Hz, 1 H), 7.83 (d, 
J = 8.0 Hz, 1 H), 7.67 (t, J = 7.2 Hz, 1 H), 7.56 (t, J = 7.2 Hz, 1 H), 7.34–7.19 (m, 5 H), 3.85 (d, 
J = 12.8 Hz, 1 H), 3.59 (t, J = 7.6 Hz, 1 H), 3.15 (d, J = 12.8 Hz, 1 H), 2.34– 2.27 (m, 2 H), 
2.01–1.81 (m, 4 H).  
13C NMR (100 MHz, CDCl3): δ = 151.6, 148.1, 139.5, 137.0, 134.4, 129.5, 129.2, 129.0, 128.6, 
128.4, 127.8, 127.1, 126.8, 67.5, 58.5, 53.7, 35.5, 22.9. 
Anal. Calcd for C20H20N2: C, 83.30; H, 6.99; N, 9.71. Found: C, 83.29; H, 7.08; N, 9.53. 
 
2-Methoxy-5-(pyrrolidin-2-yl) pyridine (11)  
N
H
N
O
 
5-(1-Benzylpyrrolidin-2-yl)-2-methoxypyridine (10c) (100 mg, 0.37 mmol),) and 10% Pd/C (10 
mg) were stirred in EtOH under H2 (1 atm) for 2 h at 55 °C. After the reaction was complete 
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(TLC), the mixture was filtered through Celite. The solvent was removed under reduced pressure 
to afford the nornicotine derivative as a light yellow oil; yield: 51 mg (75%). 
1H NMR (400 MHz, CDCl3): δ = 8.19 (d, J = 4.0 Hz, 1 H), 7.79 (dd, J = 4.8, 2.4 Hz, 1 H), 6.72 
(d, J = 4.8 Hz, 1 H), 5.73 (br s, 1 H, NH), 4.37 (t, J = 6.8 Hz, 1 H), 3.88 (s, 3 H), 3.36–3.34 (m, 
1 H), 3.21– 3.16 (m, 1 H), 2.16–2.14 (m, 1 H), 2.10–2.01 (m, 3 H). 
13C NMR (100 MHz, CDCl3): δ = 164.8, 147.0, 138.4, 123.8, 111.5, 60.8, 53.8, 45.1, 31.6, 
24.0.  
Anal. Calcd for C10H14N2O: C, 67.39; H, 7.92; N, 15.72. Found: C, 67.12; H, 8.15; N, 15.67. 
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Chapter 4: Solvent free, base free microwave mediated iridium catalyzed N-alkylation of 
amides with alcohols 
4.1. Abstract 
 
 Solvent-free, base-free microwave mediated (Cp*IrCl2)2 catalyzed conditions for the N-
alkylation of amides with alcohols have been developed. A series of primary and secondary 
alcohols have been shown to produce high yields of N-alkyl arylamides and N-alkyl alkylamides. 
4.2. Introduction 
Importance of N-substituted amides  
The N-substituted amide is an important functional group found in natural products as well as 
non-natural compounds and materials. The N-substituted amide also plays important role in 
synthetic chemistry as a protecting group for amines and carboxylic acid derivatives.1 There has 
been variety of reports that describe methods for the preparation of N-substituted amides.2, 3  
Recently, transition metals have been used to catalyze the formation of C-N bonds using alcohols 
as environmentally benign equivalents of alkyl halides.4-7 These reactions work on the hydrogen 
borrowing concept which involves generation of only water as a by-product. Previous reports on 
N-alkylation of amides with alcohols have been shown that high reaction temperatures (>180 °C) 
are required.8,9. 
Literature report of N-alkylation of primary amide 
The first example of N-alkylation of amides with alcohols using an iridium complex was 
reported by Fujita coworkers.10 This process required refluxing toluene for 17 h in the presence 
of base (Scheme 4.1).  
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Scheme 4.1.  N-alkylation of primary amides with primary alcohol using iridium catalysis 
Subsequent studies by Xu and co-workers had demonstrated that solvent-free conditions could be 
employed for N-alkylation of amides with primary alcohols using a variety of transition metal 
catalyst systems (Rh, Ru, Ir).11 However, these systems typically required long reaction times 
and high reaction temperatures. Williams and coworkers reported the use of ruthenium catalysis 
under solvent-free microwave mediated conditions to affect N-alkylation of amides with 
alcohols(Scheme 4.2).12 
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Scheme 4.2. N-alkylation of primary amides using primary alcohol with Ruthenium catalysis 
However, despite the success of the metal catalyzed N-alkylation of amides, these reports were 
limited to use of only primary alcohols as alkylation agents.  
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Figure 4.3. N-alkylation of primary amides using primary alcohol with copper catalysis 
 
Consequently, there has remained a need for the development of a suitable method with wide 
substrate tolerance that exploited solvent-free microwave mediated conditions. Our interest in 
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iridium-based catalytic systems for the formation of C-N bonds prompted us to investigate the 
potential application of iridium catalyzed amide alkylation under solvent-free and microwave 
conditions.13 Herein we wish to report the first solvent-free, base-free microwave mediated 
iridium catalyzed N-alkylation of amides with both primary and secondary alcohols. 
The developed method under microwave condition for synthesis of nicotine and anabasine 
derivatives prompted us to investigate the use of iridium catalyzed N-alkylation of amides under 
microwave conditions. 14The microwave approach would provide N-alkylated product in shorter 
time period than the conventional reflux times for these reactions. 
4.3. Result and discussion 
 Optimization of conditions 
Initially, we examined the conditions for N-alkylation of benzyl alcohol with benzamide with 
microwave irradiation to heat the reaction mixture. We found that the solvent free system using 1 
equiv. of alcohol and sodium acetate afforded a modest yield of N-benzylbenzamide (Table 1, 
Entry1). Further, we found that use of potassium carbonate showed slight improvement of yield, 
while switching to stronger base diminished the yield to only trace amount of product (Table 1, 
entry 2).15 
Serendipitously, it was discovered that if the base was omitted from the reactant mixture, the 
reaction still gave N-alkylation products, albeit in low yield (Table 1, entry 4). However, this 
result was encouraging since it revealed that a base was not essential to the catalytic cycle in 
order to affect the N-alkylation of amides. It was subsequently determined that by increasing the 
quantity of the alcohol 2a to three equivalents (Table 1, entry 6) and raising the reaction 
temperature to 160 °C (Table 1, entry 8) the yield of 3aa (85%) under base-free conditions could 
be significantly improved. It was determined that the solvent-free, base-free microwave mediated 
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conditions furnished amide yields equivalent to yields reported using conventional methods 
(Scheme 4.4, Table 4.1).10 
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Scheme 4.4. Development of methodology for N-alkylation of amides using microwave 
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Entry 2a (equiv) 
(Cp*IrCl2)2 
(mol %) 
 
Base T (°C) 
Yield 
[%] 
1 1 5 NaOAc 160 40 
2 1 5 K2CO3 160 51 
3 1 5 KOtBu 160 <10 
4 1 5 - 140 10 
5 2 5 - 140 25 
6 3 5 - 140 50 
7 3 5 - 150 80 
8 3 5 - 160 85 
9 3 5 - 165 84 
10 3 2.5 - 160 60 
11 3 1.25 - 160 35 
 
Table 4.1. Reaction optimization for N-alkylation of benzamide with benzyl alcohol 
 
135 
 
Further evaluation of the solvent-free base-free microwave mediated conditions revealed that 
there was no improvement in yields with an increase of reaction temperature above 160 °C 
(Table 4.1, entry 9), while a decrease in yield was observed with a reduction in catalyst loading 
below 5 mol% (Table 4.1, entries 10-11). Having established optimized conditions for the N-
alkylation of benzamide (1a, Table 4.1, entry 8) it was of interest to explore the scope and 
limitations of the method.15 
Examination of scope of developed method 
As summarized in Table 4.2, substituted benzyl alcohols afforded good yields of the 
corresponding N-substituted benzyl amides (3aa–3ai). Benzyl alcohols substituted with electron-
donating groups, electron-withdrawing groups and halogen were equally tolerant of the solvent-
free, base-free reaction conditions. Only the 4-nitrobenzyl alcohol (2f) failed to give a good yield 
of the amide 3f, affording only an intractable mixture of material.  In addition to benzyl alcohols, 
the primary alkanols, 1- pentanol (2j) and 1-hexanol (2k) furnished the N-alkyl amides 3aj and 
3ak in 70% yield and 72% yield, respectively. Acetamide (1b) and the substituted benzamides 
(1c-1f) also gave good yields of the corresponding N-benzyl benzamide derivatives (3ba-3fa) 
under the solvent-free, base-free conditions. 
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Entrya Amide Alcohol 
 
Product, Yield 
3 (%)b 
1 
NH2
O
 
1a 
OH
 
2a 
3aa, 85 
2 
NH2
O
 
1a 
OH
 
2b 
3ab, 85 
3 
NH2
O
 
1a 
OH
O  
2c 
3ac, 72 
4 
NH2
O
 
1a 
OH
S 2d 
3ad, 75 
5 
NH2
O
 
1a 
OH
F3C  
2e 
 
 
 
3ae, 77 
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Entrya Amide Alcohol 
 
Product, Yield 
3 (%)b 
6 
NH2
O
 
1a 
OH
O2N  
2f 
3af,  IM[c] 
7 
NH2
O
 
1a 
OH
Cl  
2g 
3ag, 65 
8 
NH2
O
 
1a 
OH
Br  
2h 
3ah, 68 
9 
NH2
O
 
1a 
OH
 
2i 
3ai, 60 
10 
NH2
O
 
1a 
CH3(CH2)4-OH 
2j 
3aj, 72 
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Entrya Amide Alcohol 
 
Product, Yield 
3 (%)b 
11 
NH2
O
 
1a 
CH3(CH2)5-OH 
2k 
3ak, 70 
12 
 CH3-NH2 
               1b  
OH
 2a 
3ba, 68 
13 
NH2
O
1c 
OH
  
2a 
3ca, 76 
14 
NH2
O
O 1d 
OH
  
2a 
3da, 75 
15 
NH2
O
Cl  
1e 
OH
  
2a 
3ea 70 
16 
NH2
O
O
O
 
1f 
OH
  
2a 
3fa, 78 
 
Table 4.2. Reaction of variety of amides with various substituted primary alcohols 
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As summarized in Table 4.2, substituted benzyl alcohols afforded good yields of the 
corresponding N-substituted benzyl amides 3aa – 3fa. Benzyl alcohols substituted with electron-
donating groups, electron-withdrawing groups and halogen were equally tolerant of the solvent-
free, base-free reaction conditions. Only the 4-nitrobenzyl alcohol (2f, entry 6) failed to give a 
good yield of the amide 3af, affording only an intractable mixture of material. However, the poor 
yield obtained with 2f was consistent with the sluggish reactivity previously reported for the 
nitro derivative in other systems.16, 17 
In addition to benzyl alcohols, the primary alkanols, 1- pentanol (2j, Table 4.2, entry 10) and 1-
hexanol (2k, Table 4.3, entry 11) furnished the N-alkyl amides 3aj and 3ak in 70% yield and 
72% yield, respectively. Acetamide (1b, entry 12) and the substituted benzamides (1c-1f, entries 
13-16) also gave good yields of the corresponding N-benzyl benzamide derivatives (3ba-3fa) 
under the solvent-free, base-free conditions.15 
The success of the solvent-free, base-free microwave mediated conditions with primary alcohols 
prompted a further investigation of the suitability of the reaction conditions for the N-alkylation 
of benzamide (1a) with secondary alcohols. A variety of acyclic and cyclic secondary alcohols 
(4) were investigated as substrates for the N-alkylation reaction.15 
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Scheme 4.6. Reaction of benzamide with secondary alcohols 
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Entry Alcohol  Product, Yield (%)  
1 HO  
2l 
O
N
H
 
3al, 68% 
2 HO  
2m 
O
N
H
 
3am, 72% 
3 
HO
 
2n 
O
N
H
 
3an, 65% 
4 HO  
2o 
O
N
H
 
3ao, 78% 
5 HO  
2p 
O
N
H
 
3ap, 76% 
6 HO
Cl  
2q 
O
N
H
Cl  
3aq, 65% 
7 
HO
F
F  
2r 
O
N
H
F
F  
3ar, 65% 
Table 4.3. Reaction of benzamide with secondary alcohols 
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It was satisfying to observe that the solvent free, base-free microwave mediated reaction 
conditions developed for the primary alcohols were applicable to secondary alcohols as well. The 
acyclic alcohols (entries 1-3) and cyclic alcohols (entries 4-5) coupled with benzamide to furnish 
the N-alkyated products in 65-78% yield. Even the sterically hindered benzhydrol derivatives 
(entry 6 and 7) afforded the N-benzhydryl amides 3aq and 3ar in good yield.15 
4.4. Conclusion 
 
In summary, we have devised a solvent-free, base free, micro-wave mediated process for the 
iridium-catalyzed alkylation of amides with alcohols. This environmentally benign method 
furnished a variety of structurally diverse N-alkyl and N-arylalkyl amides from both primary and 
secondary alcohols. The reaction conditions were tolerant of a variety of functional groups, 
employed short reaction times and provided good to high yields of the corresponding highly 
functionalized N-alkylated amides.15 
4.5. Experimental 
 
All chemicals were purchased from Aldrich Chemical Company and used as received unless 
otherwise noted. Microwave-assisted N-alkylation of amides were carried out using a 
StartSYNTH multicavity instrument with start rotor from Milestone. The maximum microwave 
power was 1200 W and the reaction temperature was monitored by an internal infrared sensor. 
Thin layer chromatography (TLC): silica gel (250 m). Visualization with UV light, iodine or 
phosphomolybdic acid, Chromatography: silica gel 60 Å (230-400 mesh). 1H NMR (400 MHz) 
and 13C NMR (100 MHz) were recorded on a Varian-400 MHz nuclear magnetic resonance 
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spectrometer at ambient temperature in CDCl3. 1H NMR chemical shifts are reported as δ values 
(ppm) relative to tetramethylsilane. 13C NMR chemical shifts are reported as δ values (ppm) 
relative to chloroform-d (77.0 ppm). Atlantic Microlab, Inc., Norcross, GA performed all CHN 
microanalyses.  
 
N-Alkylation of Amides with Alcohols 
General Procedure The amide (100 mg, 1 equiv), alcohol (3 equiv.) and (Cp*IrCl2)2 (2.5 mol 
%) were added to a microwave reactor tube. The reaction mixture was microwaved at 160ºC for 
3h. The reaction mixture was allowed to cool to room temperature and water (10 mL) was added. 
The mixture was extracted with EtOAc (3×10 mL). The combined organic layers were dried over 
Na2SO4 and filtered. The solvent was removed under reduced pressure and the residue was 
purified using flash silica gel chromatography with DCM: CH3OH (95:5) to furnish the N-alkyl 
amide.  
N-Benzylbenzamide (3aa) 18 
H
N
O
 
The title product was prepared according to the general method using 1a (100 mg, 0.83 mmol), 
(Cp*IrCl2)2 (16 mg, 0.021 mmol) and benzyl alcohol (270 mg, 2.5 mmol). Purification by flash 
chromatography afforded a white solid; yield: 149 mg (85%); mp 105-106ºC [Lit. 103-104ºC].  
1H NMR (400 MHz, CDCl3): δ 7.79 (d, J = 7.2 Hz, 2H), 7.52-7.30 (m, 8H), 6.39 (brs, 1H), 4.65 
(d, J = 5.6 Hz, 2H). 
13C NMR (100 MHz, CDCl3): δ 44.3, 127.2, 127.8, 128.1, 128.8, 129.0, 131.7, 134.6, 138.4, 
167.6.  
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N-(4-Methylbenzyl) benzamide (3ab) 19 
O
N
H
 
The final compound was prepared according to the general method using 1a (100 mg, 0.83 
mmol), (Cp*IrCl2)2 (16 mg, 0.021 mmol) and 2b (305 mg, 2.5 mmol). Purification by flash 
chromatography afforded a white solid; yield: 159 mg (85%); mp 138-140 °C [Lit. 137 °C]. 
1H NMR (400 MHz, CDCl3): δ 7.80 (d, J = 7.6 Hz, 2H), 7.49 (t, J = 7.2 Hz, 1H), 7.41 (t, J = 7.6 
Hz, 2H), 7.24 (d, J = 8.0 Hz, 2H), 7.16 (d, J = 7.6 Hz, 2H), 6.41 (brs, 1H), 4.59 (d, J = 5.6 Hz, 
2H), 2.34 (s, 3H).  
13C NMR (100 MHz, CDCl3): δ 21.3, 44.1, 127.3, 128.2, 128.8, 129.7, 131.7, 134.6, 135.3, 
137.6, 167.5. 
 
 
N-(4-Methoxybenzyl) benzamide (3ac) 18 
O
N
H
O  
The final compound was prepared according to the general method using 1d (100 mg, 0.83 
mmol), (Cp*IrCl2)2 (16 mg, 0.021 mmol) and 2c (350 mg, 2.5 mmol). Purification by flash 
chromatography afforded a white solid; yield: 144 mg (72%); mp 94-96 °C [Lit. 97-98 °C].  
1H NMR (400 MHz, CDCl3): δ  7.76 (d, J = 8.4 Hz, 2H), 7.48 (t, J = 7.2 Hz, 1H), 7.41 (t, J = 
7.6 Hz, 2H), 7.27 (d, J = 8.4 Hz, 2H), 6.87 (d, J = 8.4, 2H), 6.40 (brs, 1H), 4.57 (d, J = 5.2 Hz, 
2H), 3.79 (s, 3H).  
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13C NMR (100 MHz, CDCl3): δ 43.8, 55.5, 114.3, 127.1, 128.8, 129.5, 130.4, 131.7, 134.6, 
159.3, 167.4.  
N-4-Methylthiobenzyl benzamide (3ad) 
O
N
H
S  
The final compound was Prepared according to the general method using 1a (100 mg, 0.83 
mmol), (Cp*IrCl2)2 (16 mg, 0.021 mmol) and 2d (390 mg, 2.5 mmol). Purification by flash 
chromatography afforded a white solid; yield: 160 mg (75%); mp 109-110 °C. 
1H NMR (400 MHz, CDCl3): δ 7.77 (d, J = 7.6 Hz, 2H), 7.49 (t, J = 7.2 Hz, 1H), 7.40 (t, J = 7.2 
Hz, 2H), 7.21-7.28 (m, J = 7.2 Hz, 2H), 6.47 (brs, 1H), 4.58 (d, J = 5.6 Hz, 2H), 2.46 (s, 3H). 
13C NMR (100 MHz, CDCl3): δ 16.1, 43.8, 127.1, 127.2, 128.7, 128.8, 131.8, 134.5, 135.2, 
128.0, 167.6. 
Anal. Calcd. for C15H15NOS: C, 70.01; H, 5.87; N, 5.44. Found: 69.88; H, 5.71; 5.20.  
 
 
N-4-Trifluoromethylbenzyl benzamide (3ae).20 
O
N
H
CF3  
The final compound was prepared according to the general method using 1a (100 mg, 0.83 
mmol), (Cp*IrCl2)2 (16 mg, 0.021 mmol) and 2e (440 mg, 2.5 mmol). Purification by flash 
chromatography afforded a white solid 179 mg (77%); mp 134-135 °C [Lit.131-134 °C].  
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1H NMR (400 MHz, CDCl3): δ 7.79 (d, J = 7.2 Hz, 2H), 7.55 (d, J = 8.4 Hz, 2H), 7.48-7.52 (m, 
1H), 7.41 (d, J = 6.4 Hz, 2H), 7.37-7.38 (m, 2H), 6.91 (brs, 1H), 4.64 (d, J = 5.6 Hz, 2H).  
13C NMR (100 MHz, CDCl3): δ 43.6, 125.8, 125.9, 127.2, 128.1, 128.8, 132.0, 134.2, 142.6, 
167.9.  
N-4-Chlorobenzyl benzamide (3ag) 13 
O
N
H
Cl  
The final compound was prepared according to the general method using 1a (100 mg, 0.83 
mmol), (Cp*IrCl2)2 (16 mg, 0.021 mmol) and 2g (350 mg, 2.5 mmol). Purification by flash 
chromatography afforded a white solid; yield: 132 mg, (65%); mp 140-142 °C [Lit. 140-143 °C];  
1H NMR (400 MHz, CDCl3): δ 7.77 (d, J = 7.6 Hz, 2H), 7.49 (t, J = 7.2 Hz, 1H), 7.39 (t, J = 7.6 
Hz, 2H), 7.22-7.28 (m, 4H), 6.78 (brs, 1H), 4.55 (d, J = 6.0 Hz, 2H). 
13C NMR (100 MHz, CDCl3): δ 43.5, 127.2, 128.8, 129.0, 129.3, 131.9, 133.5, 134.3, 137.0, 
167.7. 
N-(4-Bromobenzyl) benzamide (3ah) 21 
NH
O
Br  
 The final compound was prepared according to the general method using 1a (100 mg, 0.83 
mmol), (Cp*IrCl2)2 (16 mg, 0.021 mmol) and 2h (470 mg, 2.5 mmol). Purification by flash 
chromatography afforded a white solid; yield: 163 mg (68%); mp 140-142 °C [Lit. 144-145 °C]. 
1H NMR (400 MHz, CDCl3): δ 7.76 (d, J = 7.2 Hz, 2H), 7.49 (t, J = 6.8 Hz, 1H), 7.36-7.42 (m, 
4H), 7.16 (d, J = 8.0 Hz, 2H), 6.88 (brs, 1H), 4.51 (d, J = 6.0 Hz, 2H). 
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13C NMR (400 MHz, CDCl3): δ 43.5, 115.5, 121.5, 127.2, 128.8, 129.6, 131.9, 134.3, 137.6, 
167.8 
N-(4-Phenylbenzyl) benzamide (3ai) 22 
NH
O
 
The final compound was prepared according to the general method using 1a (100 mg, 0.83 
mmol), (Cp*IrCl2)2 (16 mg, 0.021 mmol) and 2i (220 mg, 2.5 mmol). Purification by flash 
chromatography afforded a white solid; yield: 143 mg (60%); mp 166-167 °C [Lit. 166.9 – 168.3 
°C].  
1H NMR (400 MHz, CDCl3): δ 7.82 (d, J = 6.8 Hz, 2H), 7.59 – 7.52 (m, 4H), 7.49 – 7.35 (m, 
6H), 7.33 (d, J = 7.2 Hz, 2H), 6.57 (s, 1H), 4.68 (d, J = 5.6 Hz, 2H).  
13C NMR (100 MHz, CDCl3): δ 44.1, 127.2, 127.3, 127.6, 127.8, 128.6, 128.8, 129.1, 131.8, 
134.6, 137.5, 140.9, 141.0, 167.7.  
N-Pentylbenzamide (3aj) 21 
NH
O
 
The final compound was prepared according to the general method using 1a (100 mg, 0.83 
mmol), (Cp*IrCl2)2 (16 mg, 0.021 mmol) and 2j (220 mg, 2.5 mmol). Purification by flash 
chromatography afforded a colorless liquid; yield: 114 mg (72%).  
1H NMR (400 MHz, CDCl3): δ 7.74 (d, J = 7.6 Hz, 2H), 7.44 (t, J = 7.2 Hz, 1H), 7.35 (t, J = 7.6 
Hz, 2H), 6.64 (brs, 1H), 3.35-3.40 (m, 2H), 1.53-1.60 (m, 2H), 1.26-1.31 (m, 4H), 0.86 (t, J = 6.8 
Hz, 3H).  
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13C NMR (100 MHz, CDCl3): δ 14.2, 22.6, 29.3, 29.5, 40.3, 127.1, 128.6, 131.4, 135.0, 167.8.  
N-Hexylbenzamide (3ak) 23 
NH
O
 
The final compound was prepared according to the general method using 1a (100 mg, 0.83 
mmol), (Cp*IrCl2)2 (16 mg, 0.021 mmol) and 2k (260 mg, 2.5 mmol). Purification by flash 
chromatography afforded a white solid; yield: 119 mg (70%); mp 44-45 °C.  
1H NMR (400 MHz, CDCl3): δ 7.74 (d, J = 8.0 Hz, 2H), 7.43 (t, J = 6.0 Hz, 1H), 7.33-7.41 (m, 
2H), 6.64 (brs, 1H), 3.35-3.40 (m, 2H), 1.52-1.59 (m, 2H), 1.26-1.33 (m, 6H), 0.83 (t, J = 6.8 Hz, 
3H).  
13C NMR (100 MHz, CDCl3): δ 14.2, 22.7, 26.9, 29.8, 31.7, 40.3, 127.1, 128.6, 131.4, 135.0, 
167.8. 
 
N-Benzylacetamide (3ba) 24 
NH
O
 
The final compound was prepared according to the general method using 1b (100 mg, 1.7 
mmol), (Cp*IrCl2)2 (32 mg, 0.041 mmol) and 2a (550 mg, 5.1 mmol). Purification by flash 
chroma-tography afforded a white solid; yield: 172 mg (68%); mp 58-60 °C [Lit. 61°C].  
1 H NMR (400 MHz, CDCl3): δ 7.23-7.32 (m, 5H), 6.27 (brs, 1H), 4.35 (d, J = 5.6 Hz, 2H), 
1.95 (s, 3H).  
13C NMR (100 MHz, CDCl3): δ 23.3, 43.8, 127.6, 128.0, 128.8, 138.5, 170.4.  
N-Benzyl 4-methylbenzamide (3ca) 25 
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NH
O
 
The final compound was prepared according to the general method using 1c (100 mg, 0.74 
mmol), (Cp*IrCl2)2 (14 mg, 0.019 mmol) and 2a (240 mg, 2.2 mmol). Purification by flash 
chromatography afforded a white solid; yield: 133 mg (80%); mp 133-135 °C [Lit. 133-135 °C].  
1H NMR (400 MHz, CDCl3): δ 7.68 (d, J = 8.0 Hz, 2H), 7.25-7.35 (m, 5H), 7.18 (d, J = 7.6 Hz, 
2H), 6.71 (brs, 1H), 4.58 (d, J = 5.6 Hz, 2H), 2.37 (s, 3H).  
13C NMR (100 MHz, CDCl3): δ 21.6, 44.21, 127.2, 127.7, 128.0, 128.9, 129.4, 131.7, 138.6, 
142.1, 167.6.  
N-Benzyl 4-methoxybenzamide (3da) 26 
NH
O
O  
The final compound was prepared according to the general method using 1d (100 mg, 0.66 
mmol), (Cp*IrCl2)2 (13 mg, 0.017 mmol) and 2a (216 mg, 2.0 mmol). Purification by flash 
chromatography afforded a white solid; yield: 119 mg (75%); mp 126-128 °C [Lit. 126-128 °C].  
1H NMR (400 MHz, CDCl3): δ 7.75 (d, J = 8.8 Hz, 2H), 7.25-7.33 (m, 5H), 7.88 (d, J = 8.8 Hz, 
2H), 6.52 (brs, 1H), 4.59 (d, J = 5.6 Hz, 2H), 3.82 (s, 3H).  
13C NMR (100 MHz, CDCl3): δ 44.2, 55.6, 113.9, 126.8, 127.7, 128.1, 128.9, 129.0, 138.6, 
162.4, 167.1.  
N-Benzyl-4-chlorobenzamide (3ea) 25 
NH
O
Cl  
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The final compound was prepared according to the general method using 1e (100 mg, 0.65 
mmol), (Cp*IrCl2)2 (12 mg, 0.016 mmol) and 2a (216 mg, 2.0 mmol). Purification by flash 
chromatography afforded a white solid; yield: 121 mg (76%); mp 162-164 °C [Lit. 162 °C].  
1H NMR (400 MHz, CDCl3): δ 7.72 (dd, J = 6.4 Hz, J = 2.0 Hz, 2H), 7.27-7.40 (m, 7H), 6.47 
(brs, 1H), 4.62 (d, J = 5.6 Hz, 2H).  
13C NMR (100 MHz, CDCl3): δ 44.5, 127.9, 128.6, 129.0, 132.9, 138.0, 138.1, 166.5. 
N-Benzyl-3, 5-dimethoxybenzamide (3fa) 26 
NH
O
O
O  
The final compound was prepared according to the general method using 1f (100 mg, 0.55 
mmol), (Cp*IrCl2)2 (11 mg, 0.014 mmol) and 2a (180 mg, 2.5 mmol). Purification by flash 
chromatography afforded a white solid; yield: 117 mg (78%); mp 125-126 °C.  
1H NMR (400 MHz, CDCl3): δ 7.25-7.33 (m, 5H), 6.91 (d, J = 2.0 Hz, 2H) 6.59 (brs, 1H), 6.55 
(t, J = 2.0 Hz, 1H), 4.59 (d, J = 6.0 Hz, 2H), 3.78 (s, 6H).  
13C NMR (100 MHz, CDCl3): δ 44.3, 55.7, 103.8, 105.1, 127.8, 128.1, 132.8, 136.8, 138.3, 
161.1, 167.4. 
N-(Pentan-2-yl) benzamide (3al) 27 
NH
O
 
The final compound was prepared according to the general method using 1a (100 mg, 0.83 
mmol), (Cp*IrCl2)2 (16 mg, 0.021 mmol) and 2l (220 mg, 2.5 mmol). Purification by flash 
chromatography afforded a colorless liquid; yield: 108 mg (68%).  
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1H NMR (400 MHz, CDCl3): δ 7.74 (d, J = 7.2 Hz, 2H), 7.42 (t, J = 7.2 Hz, 1H), 7.35 (t, J = 7.2 
Hz, 2H), 6.58 (brs, 1H), 3.42 (q, J = 6.0 Hz, 2H), 1.59-1.64 (m, 1H), 1.45 (q, J = 6.4 Hz, 2H), 
0.88-0.90 (m, 6H).  
1H NMR (100 MHz, CDCl3): δ 22.7, 26.1, 38.6, 38.6, 127.1, 128.6, 131.4, 135.0, 167.8 
N-(1-Phenylpropan-2-yl) benzamide (3am) 29 
O
N
H
 
The final compound was prepared according to the general method using 1a (100 mg, 0.83 
mmol), (Cp*IrCl2)2 (16 mg, 0.021 mmol) and 2m (340 mg, 2.5 mmol) Purification by flash 
chromatography afforded a white solid; yield: 143 mg (72%); mp 127-129 °C. 
1H NMR (400 MHz, CDCl3): δ 7.68 (d, J = 8.0 Hz, 2H), 7.48 (d, J = 7.2 Hz, 1H), 7.40 (d, J = 
7.6 Hz, 2H), 7.31 (t, J = 7.2 Hz, 2H), 7.24 (t, J = 7.6 Hz, 3H), 5.91 (brs, 1H), 4.46-4.49 (m, 1H), 
2.83-2.97 (m, 2H), 1.21 (d, J = 6.8 Hz, 3H).  
13C NMR (100 MHz, CDCl3): δ 20.2, 42.5, 46.6, 126.7, 126.9, 128.6, 128.7, 129.7, 131.5, 
135.0, 138.0, 166.9.  
N-(1-Phenylbutan-3-yl) benzamide (3an) 31  
O
N
H
 
The final compound was prepared according to the general method using 1a (100 mg, 0.83 
mmol), (Cp*IrCl2)2 (16 mg, 0.021 mmol) and 2n (375 mg, 2.5 mmol). Purification by flash 
chromatography afforded a white solid; yield: 136 mg (65%); mp 117-119 °C.  
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1H NMR (400 MHz, CDCl3): δ 7.68 (d, J = 7.6 Hz, 2H), 7.46-7.49 (t, J = 8.0 Hz, 1H), 7.40 (t, J 
= 7.6 Hz, 2H), 7.27 (t, J = 7.6 Hz, 2H), 7.18 (t, J = 6.8 Hz, 3H), 5.93 (brs, 1H), 4.26-4.30 (m, 
1H), 2.70-2.74 (m, 2H), 1.86-1.92 (m, 2H), 1.28 (d, J = 6.8 Hz, 3H).  
13C NMR (100 MHz, CDCl3): δ 21.3, 32.7, 38.8, 45.9, 126.2, 127.0, 128.6, 128.7, 131.5, 135.1, 
141.9, 167.0.  
 
N-(Cyclopentyl) benzamide (3ao) 28 
O
N
H
 
The final compound was prepared according to the general method using 1a (100 mg, 0.83 
mmol), (Cp*IrCl2)2 (16 mg, 0.021 mmol) and 2o (215 mg, 2.5 mmol). Purification by flash 
chromatography afforded a white solid; yield: 122 mg (78%); mp 158-160°C [Lit. 160-162 °C].  
1H NMR (400 MHz, CDCl3): δ 7.73 (d, J = 7.2 Hz, 2H), 7.46 (t, J = 8.0 Hz, 1H), 7.40 (d, J = 
8.0 Hz, 2H), 6.53 (brs, 1H), 4.37-4.41 (m, 1H), 2.06-2.10 (m, 2H), 1.63-1.77 (m, 4H), 1.47-1.64 
(m, 2H).  
13C NMR (100 MHz, CDCl3): δ 24.0, 33.4, 51.9, 127.0, 128.7, 131.4, 135.1, 167.4.  
N-Cyclohexylbenzamide (5ap) 33 
O
N
H
 
The final compound was prepared according to the general method using 1a (100 mg, 0.83 
mmol), (Cp*IrCl2)2 (16 mg, 0.021 mmol) and 2p (250 mg, 2.5 mmol). Purification by flash 
chromatography afforded a white solid; yield: 128 mg (76%); mp 152-154 °C [Lit. 152-154 °C].  
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1H NMR (400 MHz, CDCl3): δ = 7.74 (d, J = 7.2 Hz, 2H), 7.47 (t, J = 7.2 Hz, 1H), 7.40 (t, J = 
7.2 Hz, 2H), 5.98 (brs, 1H), 3.95-3.99 (m, 1H), 2.05-2.04 (m, 2H), 1.63-1.77 (m, 4H), 1.18-1.47 
(m, 5H).  
13C NMR (100 MHz, CDCl3): δ = 25.1, 25.7, 33.4, 48.9, 127.0, 128.7, 131.4, 135.3, 166.8.  
N-[(4-Chlorophenyl) (phenyl) methyl]-benzamide (3aq) 34 
O
N
H
Cl  
The final compound was prepared according to the general method using 1a (100 mg, 0.83 
mmol), (Cp*IrCl2)2 (16 mg, 0.021 mmol) and 2q (545 mg, 2.5 mmol). Purification by flash 
chromatography afforded a white solid; yield: 173 mg (65%) 
1H NMR (400 MHz, CDCl3): δ 7.78 (d, J = 7.6 Hz, 2H), 7.50 (t, J = 7.6 Hz, 1H), 7.41 (t, J = 8.0 
Hz, 2H), 7.21-7.35 (m, 8H), 6.80 (d, J = 7.6 Hz, 1H), 6.38 (d, J = 7.6 Hz, 1H). 
13C NMR (100 MHz, CDCl3): δ 57.1, 115.5, 127.3, 127.8, 128.0, 128.8, 129.0, 129.0, 129.1, 
132.0, 134.2, 140.2, 141.1, 166.8.  
N-Bis (4-fluorophenyl) methylbenzamide (3ar) 25 
O
NH
F
F
 
The final compound was prepared according to the general method using 1a (100 mg, 0.83 
mmol), (Cp*IrCl2)2 (16 mg, 0.021 mmol) and 2r (550 mg, 2.5 mmol). Purification by flash 
chromatography afforded a white solid; yield: 174 mg (65%); mp 177-179 °C.  
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1H NMR (400 MHz, CDCl3): δ 7.79 (d, J = 8.0 Hz, 2H), 7.52 (t, J = 8.0 Hz, 1H), 7.42 (t, J = 7.6 
Hz, 2H), 7.22-7.05 (m, 4H), 7.02 (t, J = 8.4 Hz, 4H), 6.65 (brs, 1H), 6.39 (d, J = 7.6 Hz, 2H). 13C 
NMR (100 MHz, CDCl3): δ 56.4, 115.8, 116.0, 127.2, 128.9, 129.3, 129.3, 132.1, 134.1, 137.2, 
137.2, 163.6 
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